,i #aahth ,,congress #ast ,session ,h4 ,r4 #bcfi ,,in ,,the ,,house ,,of ,,representatives ,march #bi1 #bjbc,mr4 ,bucshon 7for himself and ,ms4 ,de,gette7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act with respect to in vitro clinical tests1 and for other purposes4 #a4 ,short title 7a7 ,short title ,this ,act may be cited as the ,verifying ,accurate ,leading-edge ,,ivct ,development ,act of #bjbc or the ,,valid ,act of #bjbc4 #b4 ,definitions 7a7 ,in general ,section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7 is amended-- 7#a7 by adding at the end the following3 7ss7 7#a7 ,the term in vitro clinical test means an article specified in subparagraph 7#b7 that is intended to be used in the collection1 preparation1 analysis1 or in vitro clinical examination of specimens taken or derived from the human body for the purpose of-- 7,a7 identifying or diagnosing a disease or condition2 7,b7 providing information for diagnosing1 screening1 measuring1 detecting1 predicting1 prognosing1 analyzing1 or monitoring a disease or condition1 including by making a determination of an individual's state of health2 or 7,c7 selecting1 monitoring1 or informing therapy or treatment for a disease or condition4 7#b7 ,an article specified in this subparagraph is-- 7,a7 a test kit2 7,b7 a test system2 7,c7 a test protocol or laboratory test protocol2 7,d7 an instrument 7as defined in section #ehg7aa772 7,e7 a specimen receptacle 7as defined in section #ehg7ag772 7,f7 software1 excluding software that is excluded by section #ebj7o7 from the definition of a device under section #bja7;h71 that-- 7i7 is a component or part of another in vitro clinical test or analyzes1 processes1 or interprets a signal or pattern from another in vitro clinical test2 and 7ii7 does not analyze1 process1 or interpret a signal1 pattern1 or medical image from a device2 and 7,g7 subject to subparagraph 7#c71 a component or part of a test kit1 a test system1 a test protocol or laboratory test protocol1 an instrument1 a specimen receptacle1 or software described in subparagraph 7,f71 whether alone or in combination1 including reagents1 calibrators1 and controls4 7#c7 ,notwithstanding subparagraph 7#b77;,g71 an article intended to be used as a component or part of an in vitro clinical test described in subparagraph 7#a7 is excluded from the definition in subparagraph 7#a7 if the article consists of any of the following3 7,a7 ,blood1 blood components1 or human cells or tissues1 from the time of acquisition1 donation1 or recovery of such article1 including determination of donor eligibility1 as applicable1 until such time as the article is released as a component or part of an in vitro clinical test by the establishment that collected such article4 7,b7 ,an article used for invasive sampling1 a needle1 or a lancet1 except to the extent such article1 needle1 or lancet is an integral component of an article for holding1 storing1 or transporting a specimen4 7,c7 ,general purpose laboratory equipment4 2 7#b7 by adding at the end of paragraph 7g7 the following3 7#c7 ,the term drug does not include an in vitro clinical test4 2 and 7#c7 in paragraph 7h77#a71 in the matter following clause 7,c71 by striking section #ebj7o7 and inserting section #ebj7o7 or an in vitro clinical test4 7b7 ,exclusion from definition of biological product ,section #cea7;i77#a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i77#a77 is amended-- 7#a7 by striking 7#a7 ,the term biological product means and inserting 7#a77;,a7 ,the term biological product means2 and 7#b7 by adding at the end the following3 7,b7 ,the term biological product does not include an in vitro clinical test as defined in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 4 7c7 ,in vitro clinical test definition ,in this ,act1 the term in vitro clinical test has the meaning given such term in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a74 #c4 ,regulation of in vitro clinical tests ,the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 is amended-- 7#a7 by amending the heading of chapter ,v to read as follows3 ,drugs1 ,devices1 and ,in ,vitro ,clinical ,tests2 and 7#b7 by adding at the end of chapter ,v the following3 ,j ,in ,vitro ,clinical ,tests #ehg4 ,definitions ,in this subchapter3 7#a7 ,analytical validity ,the term analytical validity means1 with respect to an in vitro clinical test1 the ability of the in vitro clinical test1 to identify1 measure1 detect1 calculate1 or analyze 7or assist in such identification1 measurement1 detection1 calculation1 or analysis of7 one or more analytes1 biomarkers1 substances1 or other targets intended to be identified1 measured1 detected1 calculated1 or analyzed by the test4 7#b7 ,applicable standard ,the term applicable standard1 with respect to an in vitro clinical test1 means a reasonable assurance of analytical and clinical validity for its indications for use1 and a reasonable assurance of safety for individuals who come into contact with such in vitro clinical test1 except that such term1 with respect to specimen receptacles and test instruments1 means a reasonable assurance of analytical validity for its indications for use and safety for individuals who come into contact with such specimen receptacle or test instrument4 7#c7 ,clinical use ,the term clinical use means the operation1 application1 or functioning of an in vitro clinical test for the purpose for which it is intended as described in section #bja7ss77#a74 7#d7 ,clinical validity ,the term clinical validity means the ability of an in vitro clinical test to achieve the purpose for which it is intended as described in section #bja7ss77#a74 7#e7 ,component or part ,the term component or part means a substance1 piece1 part1 raw material1 software1 firmware1 labeling1 or assembly1 including reagents1 that is intended to be included as an aspect of an in vitro clinical test described in section #bja7ss77#a74 7#f7 ,develop ,the term develop1 with respect to an in vitro clinical test1 means-- 7,a7 designing1 validating1 producing1 manufacturing1 remanufacturing1 labeling1 advertising1 propagating1 importing1 or assembling an in vitro clinical test2 7,b7 modifying an in vitro clinical test1 including modifying the indications for use of the in vitro clinical test1 or modifying an article to be an in vitro clinical test2 or 7,c7 establishing a test system as described or included in a test protocol developed by another entity unless such test protocol is listed as an in vitro clinical test in the comprehensive test information system established under section #ehg,t by that other entity4 7#g7 ,developer ,the term developer means a person who engages in development as described in paragraph 7#f71 except the term does not include a laboratory that-- 7,a7 is certified by the ,secretary under section #cec of the ,public ,health ,service ,act2 and 7,b7 assembles for use solely within that laboratory1 without otherwise developing1 an in vitro clinical test appropriately listed in the comprehensive test information system established under section #ehg,t by a different person4 7#h7 ,first-of-a-kind ,the term first-of-a-kind1 with respect to an in vitro clinical test1 means that such test has any novel combination of the elements specified in paragraph 7#aj7 that differs from in vitro clinical tests that already are legally available in the ,united ,states1 except for such tests offered under section #ehg;,c7a77#c71 #ehg;,c7a77#d71 or #ehg;,g4 7#i7 ,high-risk ,the term high-risk1 with respect to an in vitro clinical test or category of in vitro clinical tests1 means that an undetected inaccurate result from such test1 or such category of tests1 when used as intended-- 7,a7 7i7 is reasonably likely to result in serious or irreversible harm or death to a patient or patients1 or would otherwise cause serious harm to the public health2 or 7ii7 is reasonably likely to result in the absence1 significant delay1 or discontinuation of life-supporting or life-sustaining medical treatment2 and 7,b7 mitigating measures are not able to be established and applied to prevent1 mitigate1 or detect the inaccurate result1 or otherwise sufficiently mitigate the risk resulting from an undetected inaccurate result described in subparagraph 7,a71 such that the test would be moderate-risk or low-risk4 7#aj7 ,indications for use ,the term indications for use1 with respect to an in vitro clinical test1 means the following elements3 7,a7 ,substance or substances measured by the in vitro clinical test1 such as an analyte1 protein1 or pathogen4 7,b7 ,test method4 7,c7 ,test purpose or purposes1 as described in section #bja7ss77#a74 7,d7 ,diseases or conditions for which the in vitro clinical test is intended for use1 including intended patient populations4 7,e7 ,context of use1 such as in a clinical laboratory1 in a health care facility1 prescription home use1 over-the-counter use1 or direct-to-consumer testing4 7#aa7 ,instrument 7,a7 ,in general ,the term instrument means an analytical or pre-analytical instrument4 7,b7 ,analytic instrument ,the term analytic instrument means an in vitro clinical test that is hardware intended by the developer to be used with one or more other in vitro clinical tests to generate a clinical test result1 including software used to effectuate the functionality of the hardware4 7,c7 ,pre-analytical instrument ,the term pre-analytical instrument means an in vitro clinical test that is hardware intended by the developer solely to generate an output for use exclusively with one or more analytical instruments as defined in subparagraph 7,b7 and which does not itself generate a clinical test result4 ,such term may include software used to effectuate the hardware's functionality4 7#ab7 ,instrument family ,the term instrument family means more than one instrument developed by the same developer for which the developer demonstrates and documents1 with respect to all such instruments1 that all-- 7,a7 have the same basic architecture1 design1 and performance characteristics2 7,b7 have the same indications for use and capabilities2 7,c7 share the same measurement principles1 detection methods1 and reaction conditions1 as applicable2 and 7,d7 produce the same or similar analytical results from samples of the same specimen type or types4 7#ac7 ,laboratory operations ,the term laboratory operations-- 7,a7 means the conduct of a laboratory examination or other laboratory procedure on materials derived from the human body1 including the conduct of an in vitro clinical test and associated activities1 that is-- 7i7 regulated under section #cec of the ,public ,health ,service ,act2 and 7ii7 not related to the design1 analytical validation1 or clinical validation of an in vitro clinical test2 and 7,b7 includes-- 7i7 performing pre-analytical and post-analytical processes for an in vitro clinical test2 7ii7 standard operating procedures and the conduct thereof2 and 7iii7 preparing reagents or other test materials that do not meet the criteria for being an in vitro clinical test for clinical use4 7#ad7 ,low-risk ,the term low-risk1 with respect to an in vitro clinical test or category of in vitro clinical tests1 means that an undetected inaccurate result from such in vitro clinical test1 or such category of in vitro clinical tests1 when used as intended-- 7,a7 would cause only minimal or immediately reversible harm1 and would lead to only a remote risk of adverse patient impact or adverse public health impact2 or 7,b7 sufficient mitigating measures are able to be established and applied such that the in vitro clinical test meets the standard described in subparagraph 7,a74 7#ae7 ,mitigating measures ,the term mitigating measures-- 7,a7 means controls1 standards1 and other requirements that the ,secretary determines1 based on evidence1 are necessary-- 7i7 for an in vitro clinical test1 or a category of in vitro clinical tests1 to meet the applicable standard2 or 7ii7 to mitigate the risk of harm ensuing from an undetected inaccurate result or misinterpretation of a result2 and 7,b7 may include1 as required by the ,secretary1 as appropriate1 applicable requirements regarding labeling1 conformance to performance standards and consensus standards1 performance testing1 submission of clinical data1 advertising1 website posting of information1 clinical studies1 postmarket surveillance1 user comprehension studies1 training1 and confirmatory laboratory1 clinical findings1 the history of the developer1 the role of a health professional in the testing process1 such as integration of the testing laboratory into the direct medical care of the patient1 including direct interaction between the testing laboratory and treating physician1 or testing4 7#af7 ,moderate-risk ,the term moderate-risk1 with respect to an in vitro clinical test or category of in vitro clinical tests-- 7,a7 means a test or category of tests that is not high-risk under the criteria under paragraph 7#i7 or low-risk under the criteria under paragraph 7#ad72 and 7,b7 may include a test or category of tests that1 when used as intended1 meet the criteria specified in paragraph 7#i77;,a7 for high-risk1 but for which one or more mitigating measures are able to be established and applied to prevent1 mitigate1 or detect an inaccurate result or otherwise sufficiently mitigate the risk resulting from an undetected inaccurate result1 but are not sufficient such that the test is low-risk under the criteria in paragraph 7#ad74 7#ag7 ,specimen receptacle ,the term specimen receptacle means an in vitro clinical test intended for taking1 collecting1 holding1 storing1 or transporting of specimens derived from the human body or for preparation1 analysis1 or in vitro clinical examination for purposes described in section #bja7ss77#a74 7#ah7 ,technology ,the term technology-- 7,a7 means a set of control mechanisms1 energy sources1 or operating principles-- 7i7 that do not differ significantly among multiple in vitro clinical tests2 and 7ii7 for which design and development 7including analytical and clinical validation1 as applicable7 of the tests would be addressed in a similar manner or through similar procedures2 and 7,b7 may include clot detection1 colorimetric 7non-immunoassay71 electrochemical 7non-immunoassay71 enzymatic 7non-immunoassay71 flow cytometry1 fluorometry 7non-immunoassay71 immunoassay1 mass spectrometry or chromatography1 microbial culture1 next generation sequencing1 nephlometric or turbidimetric 7non-immunoassay71 singleplex or multiplex non-,,ngs nucleic acid analysis1 slide-based technology1 spectroscopy1 and any other technology1 as the ,secretary determines appropriate4 7#ai7 ,test ,the term test1 unless otherwise provided1 means an in vitro clinical test4 7#bj7 ,valid scientific evidence ,the term valid scientific evidence-- 7,a7 means1 with respect to an in vitro clinical test1 evidence that-- 7i7 has been generated and evaluated by persons qualified by training or experience to do so1 using procedures generally accepted by other persons so qualified2 and 7ii7 forms an appropriate basis for concluding by qualified experts whether the applicable standard has been met by the in vitro clinical test2 and 7,b7 may include evidence described in subparagraph 7,a7 consisting of-- 7i7 peer-reviewed literature2 7ii7 clinical guidelines2 7iii7 reports of significant human experience with an in vitro clinical test2 7iv7 bench studies2 7v7 case studies or histories2 7vi7 clinical data2 7vii7 consensus standards2 7viii7 reference standards2 7ix7 data registries2 7x7 postmarket data2 7xi7 real world data2 7xii7 clinical trials2 and 7xiii7 data collected in countries other than the ,united ,states if such data are demonstrated to be appropriate for the purpose of making a regulatory determination under this subchapter4 #ehg;,a4 ,regulation of in vitro clinical tests 7a7 ,in general ,no person shall introduce or deliver for introduction into interstate commerce any in vitro clinical test1 unless-- 7#a7 an approval of an application filed pursuant to subsection 7a7 or 7b7 of section #ehg;,b is effective with respect to such in vitro clinical test2 7#b7 the in vitro clinical test is offered under a technology certification order under section #ehg;,d7b77#a72 or 7#c7 the test is exempt under sections #ehg;,c or #ehg;,g from the requirements of section #ehg;,b4 7b7 ,transfer or sale of ,in vitro clinical tests 7#a7 ,transfer and assumption of regulatory obligations ,if ownership of an in vitro clinical test is sold or transferred in such manner that the developer transfers the regulatory submissions and obligations applicable under this subchapter with respect to the test1 the transferee or purchaser becomes the developer of the test and shall have all regulatory obligations applicable to such a test under this subchapter4 ,the transferee or purchaser shall update the registration and listing information under section #ehg;,j for the in vitro clinical test4 7#b7 ,transfer or sale of premarket approval 7,a7 ,notice required ,if a developer of an in vitro clinical test transfers or sells the approval of the in vitro clinical test1 the transferor or seller shall-- 7i7 submit a notice of the transfer or sale to the ,secretary and update the registration and listing information under section #ehg;,j for the in vitro clinical test2 and 7ii7 submit a supplement to an application if required under section #ehg;,b7h74 7,b7 ,effective date of approval transfer ,a transfer or sale described in subparagraph 7,a7 shall become effective upon completion of a transfer or sale described in paragraph 7#a7 or the approval of a supplement to an application under section #ehg;,b7h7 if required1 whichever is later4 ,the transferee or purchaser shall update the registration and listing information under section #ehg;,j for the in vitro clinical test within #ae calendar days of the effective date of the transfer or sale4 7#c7 ,transfer or sale of technology certification 7,a7 ,requirements for transfer or sale of technology certification ,an unexpired technology certification can be transferred or sold if the transferee or purchaser-- 7i7 is an eligible person under section #ehg;,d7a77#b72 and 7ii7 maintains1 upon such transfer or sale1 test design and quality requirements1 processes and procedures under the scope of technology certification1 and scope of the technology certification identified in the applicable technology certification order4 7,b7 ,notice required ,if a developer of an in vitro clinical test transfers or sells a technology certification order that has not expired1 the transferor or seller shall submit a notice of the transfer or sale to the ,secretary and shall update the registration and listing information under section #ehg;,j for all in vitro clinical tests covered by the technology certification4 7,c7 ,effective date of technology certification transfer ,the transfer of a technology certification shall become effective upon completion of a transfer or sale described in subparagraph 7,a74 ,the transferee or purchaser shall update the registration and listing information under section #ehg;,j for the in vitro clinical test within #cj calendar days of the effective date of the technology certification transfer4 7,d7 ,new technology certification required ,if the requirements of subparagraph 7,a77ii7 are not met1 the technology certification order may not be transferred and the transferee or purchaser of an in vitro clinical test is required to submit an application for technology certification and obtain a technology certification order prior to offering the test for clinical use4 7c7 ,regulations ,the ,secretary may issue regulations to implement this subchapter4 #ehg;,b4 ,premarket review 7a7 ,application 7#a7 ,filing ,any developer may file with the ,secretary an application for premarket approval of an in vitro clinical test under this subsection4 7#b7 ,transparency and predictability ,if a developer files a premarket application under this section and provides any additional documentation required under section #ehg;,d1 the in vitro clinical test that is the subject of the premarket application may be utilized as the representative in vitro clinical test reviewed by the ,secretary to support a technology certification order under section #ehg;,d4 7#c7 ,application content ,an application submitted under paragraph 7#a7 shall include the following1 in such format as the ,secretary specifies3 7,a7 ,general information regarding the in vitro clinical test1 including-- 7i7 the name and address of the applicant2 7ii7 the table of contents for the application and the identification of the information the applicant claims as trade secret or confidential commercial or financial information2 7iii7 a description of the test's design and intended use1 including the indications for use2 and 7iv7 a description regarding test function and performance characteristics4 7,b7 ,a summary of the data and information in the application for the in vitro clinical test1 including-- 7i7 a brief description of the foreign and domestic marketing history of the test1 if any1 including a list of all countries in which the test has been marketed and a list of all countries in which the test has been withdrawn from the market for any reason related to the ability of the in vitro clinical test to meet the applicable standard1 if known by the applicant2 7ii7 a description of benefit and risk considerations related to the in vitro clinical test1 including a description of any applicable adverse effects of the test on health and how such adverse effects have been1 or will be1 mitigated2 7iii7 a risk assessment of the test2 and 7iv7 a description of how the data and information in the application constitute valid scientific evidence and support a showing that the test meets the applicable standard under section #ehg7b74 7,c7 ,the signature of the developer filing the premarket application or an authorized representative4 7,d7 ,a bibliography of applicable published reports and a description of any studies conducted1 including any unpublished studies related to such test1 that are known or that should reasonably be known to the applicant1 and a description of data and information relevant to the evaluation of whether the test meets the applicable standard4 7,e7 ,applicable information regarding the methods used in1 and the facilities or controls used for1 the development of the test to demonstrate compliance with the applicable quality requirements under section #ehg,k4 7,f7 ,information demonstrating compliance with any relevant and applicable-- 7i7 mitigating measures under section #ehg;,e2 and 7ii7 standards established or recognized under section #ead prior to the date of enactment of the ,,valid ,act of #bjbc1 or1 after applicable standards are established or recognized under section #ehg,r1 with such standards4 7,g7 ,valid scientific evidence to support that the test meets the applicable standard1 which shall include-- 7i7 summary information for all supporting validation studies performed1 including a description of the objective of the study1 a description of the experimental design of the study1 a description of any limitations of the study1 a brief description of how the data were collected and analyzed1 a brief description of the results of each study1 and conclusions drawn from each study2 7ii7 raw data for each study1 which may include1 as applicable1 tabulations of data and results2 and 7iii7 for nonclinical laboratory studies involving the test1 if applicable1 a statement that studies were conducted in compliance with applicable good laboratory practices4 7,h7 ,to the extent the application seeks authorization to make modifications to the test within the scope of the approval that are not otherwise permitted without premarket review under this subchapter1 a proposed change protocol that includes validation procedures and acceptance criteria for anticipated modifications that could be made to the test within the scope of the approval4 7,i7 ,proposed labeling1 in accordance with the requirements of section #ehg,l4 7,j7 ,such other data or information as the ,secretary may require in accordance with the least burdensome requirements under section #ehg;,,aa7c74 7#d7 ,regulation for premarket and abbreviated premarket applications ,not later than #c years after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall promulgate final regulations detailing the information to be provided in a premarket application and abbreviated premarket application under this section4 7#e7 ,refuse to file a premarket or abbreviated premarket application ,the ,secretary may refuse to file an application under this section only for lack of completeness or legibility of the application4 ,if1 after receipt of an application under this section1 the ,secretary refuses to file such an application1 the ,secretary shall provide to the developer1 within #de calendar days of receipt of such application submitted under this subsection or within #cj calendar days of receipt of an application submitted under subsection 7b71 a description of the reason for such refusal1 and identify the information required1 if any1 to allow for the filing of the application4 7#f7 ,substantive review for deficient application ,if1 after receipt of an application under this section1 the ,secretary determines that any portion of such application is materially deficient1 the ,secretary shall provide to the applicant a description of such material deficiencies and the information required to resolve such deficiencies4 7#g7 ,inspections ,with respect to an application under paragraph 7#a71 preapproval inspections authorized by an employee of the ,food and ,drug ,administration or a person accredited under section #ehg,q need not occur unless requested by the ,secretary4 7b7 ,abbreviated premarket review 7#a7 ,in general ,any developer may file with the ,secretary an application for abbreviated premarket approval for-- 7,a7 an instrument2 7,b7 a specimen receptacle2 7,c7 an in vitro clinical test that is moderate-risk2 or 7,d7 an in vitro clinical test that is determined by the ,secretary to be eligible for abbreviated premarket review under section #ehg;,f7a77#a77;,b74 7#b7 ,application content ,an application under paragraph 7#a7 shall include-- 7,a7 the information required for applications submitted under subsection 7a77#c71 except that applications under paragraph 7#a7 need not include-- 7i7 quality requirement information2 or 7ii7 raw data1 unless requested in writing by the ,secretary1 in accordance with the least burdensome requirements under section #ehg;,,aa7c71 and with supervisory review and concurrence prior to issuance of such request2 and 7,b7 data1 as applicable1 to support software validation1 electromagnetic compatibility1 and electrical safety1 and information demonstrating compliance with maintaining quality systems documentation4 7#c7 ,safety information ,the developer of an in vitro clinical test specimen receptacle reviewed under this subsection shall maintain safety information for such specimen receptacle4 7#d7 ,inspections ,with respect to an application under paragraph 7#a71 preapproval inspections shall not be required unless requested in writing by the ,secretary1 after supervisory review and concurrence1 because such inspection is considered necessary to complete the review4 7c7 ,instruments and instrument families 7#a7 ,in general ,a developer of an instrument family shall file with the ,secretary an application for premarket approval of one version of an instrument under this subsection4 ,any modified versions of the instrument that generate a new instrument within the same instrument family shall be exempt from premarket review requirements of this section1 provided that the developer of such instrument or instrument family-- 7,a7 maintains documentation that the new instrument is part of the instrument family1 as defined in section #ehg2 7,b7 performs1 documents1 and maintains a risk assessment 7as described in subsection 7a77#c77;,b77iii77 of the new instrument compared to the instrument approved under subsection 7b7 and no new risks are identified2 7,c7 performs1 documents1 and maintains validation and verification activities for the new instrument2 7,d7 makes such documentation available to the ,secretary upon request2 and 7,e7 registers and lists the new instrument in accordance with section #ehg;,j4 7#b7 ,test kits and test protocols ,with regard to a test kit or test protocol that is approved under this section for use on an approved instrument or an instrument exempt from premarket review1 including an instrument within an instrument family under this section1 a submission under this section shall not be required for such test kit or test protocol in order for it to be used on a new instrument within its instrument family1 provided that-- 7,a7 use of the test kit or test protocol with the new instrument does not-- 7i7 change the claims for the test kit or test protocol1 except as applicable1 claims regarding an instrument or instruments that can be used with such test kit or test protocol2 7ii7 adversely affect performance of the test kit or test protocol2 or 7iii7 cause the test kit or test protocol to no longer conform with performance standards required under section #ehg,r or comply with any applicable mitigating measures under section #ehg;,e1 conditions of approval under subsection 7e77#b77;,b71 or restrictions under section #ehg,o2 7,b7 the test developer does not identify any new risks for the test kit or test protocol when using the new instrument after conducting a risk assessment2 7,c7 the test developer validates the use of the new instrument with the test kit or test protocol and maintains validation documentation2 7,d7 the test kit or test protocol is not intended for use-- 7i7 in settings for which a certificate of waiver is in effect under section #cec of the ,public ,health ,service ,act2 7ii7 without a prescription2 7iii7 at home2 or 7iv7 in testing donors1 donations1 and recipients of blood1 blood components1 human cells1 tissues1 cellular-based products1 or tissue-based products2 7,e7 the test developer makes the documentation described under subparagraph 7,c7 available to the ,secretary upon request2 and 7,f7 the test developer updates the listing information for the test kit or test protocol1 as applicable4 7d7 ,amendments to an application ,an applicant shall amend an application submitted under subsection 7a71 7b71 or 7f7 if the applicant becomes aware of information that could reasonably affect an evaluation under subsection 7e7 of whether the approval standard has been met4 7e7 ,action on an application for premarket approval 7#a7 ,review 7,a7 ,disposition ,as promptly as possible1 but not later than #ij calendar days after an application under subsection 7a7 is accepted for submission 7unless the ,secretary determines that an extension is necessary to review one or more major amendments to the application71 or not later than #fj calendar days after an application under subsection 7b7 is accepted for submission or a supplemental application under subsection 7f7 is accepted for submission1 the ,secretary1 after considering any applicable report and recommendations pursuant to advisory committees under section #ehg;,h1 shall issue an order approving the application1 unless the ,secretary finds that the grounds for approval in paragraph 7#b7 are not met4 7,b7 ,reliance on proposed labeling ,in determining whether to approve or deny an application under paragraph 7#a71 the ,secretary shall rely on the indications for use included in the proposed labeling1 provided that such labeling is not false or misleading based on a fair evaluation of all material facts4 7#b7 ,approval of an application 7,a7 ,in general ,the ,secretary shall approve an application submitted under subsection 7a7 or 7b7 with respect to an in vitro clinical test if the ,secretary finds that the applicable standard is met1 and-- 7i7 the applicant is in compliance with applicable quality requirements in section #ehg,k2 7ii7 the application does not contain a false statement or misrepresentation of material fact2 7iii7 based on a fair evaluation of all material facts1 the proposed labeling is truthful and non-misleading and complies with the requirements of section #ehg,l2 7iv7 the applicant permits1 if requested1 authorized employees of the ,food and ,drug ,administration and persons accredited under section #ehg,q an opportunity to inspect pursuant to section #gjd2 7v7 the test conforms with any applicable performance standards required under section #ehg,r and any applicable mitigating measures under section #ehg;,e2 7vi7 all nonclinical laboratory studies and clinical investigations involving human subjects that are described in the application were conducted in a manner that meets the applicable requirements of this subchapter2 and 7vii7 other data and information the ,secretary may require under subsection 7a77#c77;,j7 support approval4 7,b7 ,conditions of approval ,an order approving an application pursuant to this section may require reasonable conditions of approval for the in vitro clinical test1 which may include conformance with applicable mitigating measures under section #ehg;,e1 restrictions under section #ehg,o1 and performance standards under section #ehg,r4 7,c7 ,publication ,the ,secretary shall publish an order for each application approved pursuant to this paragraph on the public website of the ,food and ,drug ,administration and make publicly available a summary of the data used to approve such application4 ,in making the order and summary publicly available1 the ,secretary shall not disclose any information that-- 7i7 is confidential commercial information or trade secret information subject to section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code2 or 7ii7 could compromise national security4 7#c7 ,review of denials ,an applicant whose application submitted under this section has been denied approval under this subsection may1 by petition filed not more than #fj calendar days after the date on which the applicant receives notice of such denial1 obtain review of the denial in accordance with section #ehg,p4 7f7 ,supplements to an approved application 7#a7 ,risk analysis ,prior to implementing any modification to an in vitro clinical test1 the holder of the application approved under subsection 7e7 for such test shall perform risk analyses in accordance with this subsection1 unless such modification is included in the change protocol submitted by the applicant and approved under this section or exempt under section #ehg;,c4 7#b7 ,supplement requirement 7,a7 ,in general ,if the holder of an application of an approved in vitro clinical test makes a modification to such in vitro clinical test1 except as provided in subparagraph 7,c71 or otherwise specified by the ,secretary1 the holder of the application approved under subsection 7e7 for an in vitro clinical test shall submit a supplemental application to the ,secretary4 ,the holder of the application may not implement such modification to the in vitro clinical test until such supplemental application is approved4 ,the information required in a supplemental application is limited to what is needed to support the change4 7,b7 ,change protocols ,the holder of an approved application may submit under this paragraph a supplemental application to modify the change protocol for a test or to request a change protocol for a test4 7,c7 ,exceptions ,notwithstanding subparagraphs 7,a7 and 7,b71 and so long as the holder of an approved application submitted under subsection 7a7 or 7b7 for an in vitro clinical test does not add a manufacturing site1 or change activities at an existing manufacturing site1 with respect to the test1 the holder of an approved application may1 without submission of a supplemental application1 implement the following modifications to the test3 7i7 ,modifications in accordance with an approved change protocol under subsection 7a77#c77;,h74 7ii7 ,modifications that are exempt under section #ehg;,c7a77#f74 7iii7 ,labeling changes that are appropriate to address a safety concern1 except such labeling changes that include any of the following remain subject to subparagraph 7,a73 7,i7 ,a change to the indications for use of the test4 7,,ii7 ,a change to the performance claims made with respect to the test4 7,,iii7 ,a change that adversely affects performance of the test4 7,d7 ,reporting for certain modifications made pursuant to a change protocol ,the holder of an application approved under subsection 7e71 with an approved change protocol under subsection 7a77#b77;,h7 for such in vitro clinical test shall-- 7i7 report any modification to such test made pursuant to such change protocol approved under subsection 7a77#c77;,h7 in a submission under section #ehg;,j7c77#b77;,b72 and 7ii7 include in such report-- 7,i7 a description of the modification2 7,,ii7 the rationale for implementing such modification2 and 7,,iii7 as applicable1 a summary of the evidence supporting that the test1 as modified1 meets the applicable standard1 complies with performance standards required under section #ehg,q1 and complies with any mitigating measures established under section #ehg;,e and any restrictions under section #ehg,o4 7,e7 ,reporting for certain safety related labeling changes ,the holder of the application for an in vitro clinical test approved under subsection 7e7 shall-- 7i7 report to the ,secretary any modification to the test described in subparagraph 7,c77iii7 not more than #cj days after the date on which the test1 with the modification1 is introduced into interstate commerce2 and 7ii7 include in the report-- 7,i7 a description of the change or changes2 7,,ii7 the rationale for implementing such change or changes2 and 7,,iii7 a description of how the change or changes were evaluated4 7#c7 ,contents of supplement ,unless otherwise specified by the ,secretary1 a supplement under this subsection shall include-- 7,a7 for modifications other than manufacturing site changes requiring a supplement-- 7i7 a description of the modification2 7ii7 data relevant to the modification to demonstrate that the applicable standard is met1 not to exceed data requirements for the original submission2 7iii7 acceptance criteria2 and 7iv7 any revised labeling2 and 7,b7 for manufacturing site changes-- 7i7 the information listed in subparagraph 7,a72 and 7ii7 information regarding the methods used in1 or the facilities or controls used for1 the development of the test to demonstrate compliance with the applicable quality requirements under section #ehg,k4 7#d7 ,additional data ,the ,secretary may require1 when necessary1 data to evaluate a modification to an in vitro clinical test that is in addition to the data otherwise required under the preceding paragraphs if the data request is in accordance with the least burdensome requirements under section #ehg;,,aa7c74 7#e7 ,conditions of approval ,in an order approving a supplement under this subsection1 the ,secretary may require conditions of approval for the in vitro clinical test1 including compliance with restrictions under section #ehg,o and conformance to performance standards under section #ehg,r4 7#f7 ,approval ,the ,secretary shall approve a supplement under this subsection if-- 7,a7 the data demonstrate that the modified in vitro clinical test meets the applicable standard2 and 7,b7 the holder of the application approved under subsection 7e7 for the test has demonstrated compliance with applicable quality and inspection requirements1 as applicable and appropriate4 7#g7 ,publication ,the ,secretary shall publish on the public website of the ,food and ,drug ,administration notice of any order approving a supplement under this subsection provided that doing so does not disclose any information that-- 7,a7 is trade secret or confidential commercial or financial information2 or 7,b7 could compromise national security4 7#h7 ,review of denial ,an applicant whose supplement under this subsection has been denied approval may1 by petition filed on or before the #fjth calendar day after the date upon which the applicant receives notice of such denial1 obtain review of the denial in accordance with section #ehg,p4 7g7 ,withdrawal and temporary suspension of approval 7#a7 ,order withdrawing approval 7,a7 ,in general ,the ,secretary may1 after providing due notice and an opportunity for an informal hearing to the holder of an approved application for an in vitro clinical test under this section1 issue an order withdrawing approval of the application if the ,secretary finds that-- 7i7 the grounds for approval under subsection 7e7 are no longer met2 7ii7 there is a reasonable likelihood that the test would cause death or serious adverse health consequences1 including by causing the absence1 significant delay1 or discontinuation of life-saving or life sustaining medical treatment2 7iii7 the holder of the approved application-- 7,i7 has failed to1 or repeatedly or deliberately failed to1 maintain records to make reports1 as required under section #ehg,m2 7,,ii7 has refused to permit access to1 or copying or verification of such records1 as required under section #gjd2 7,,iii7 has not complied with the requirements of section #ehg,k2 or 7,,iv7 has not complied with any mitigating measure required under section #ehg;,e or restriction under section #ehg,o2 or 7iv7 the labeling of such in vitro clinical test1 based on a fair evaluation of all material facts1 is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the ,secretary of such fact4 7,b7 ,content ,an order under subparagraph 7,a7 withdrawing approval of an application shall state each ground for withdrawal and shall notify the holder of such application #fj calendar days prior to issuing such order4 7,c7 ,publication ,the ,secretary shall publish any order under subparagraph 7,a7 on the public website of the ,food and ,drug ,administration provided that doing so does not disclose-- 7i7 any information that is trade secret or confidential commercial or financial information2 or 7ii7 any other information that the ,secretary determines1 if published1 could compromise national security4 7#b7 ,order of temporary suspension ,if1 after providing due notice and an opportunity for an informal hearing to the holder of an approved application for an in vitro clinical test under this section1 the ,secretary determines1 based on scientific evidence1 that there is a reasonable likelihood that the in vitro clinical test would cause death or serious adverse health consequences1 such as by causing the absence1 significant delay1 or discontinuation of life-saving or life-sustaining medical treatment1 the ,secretary shall1 by order1 temporarily suspend the approval of the application4 ,if the ,secretary issues such an order1 the ,secretary shall proceed expeditiously under paragraph 7#a7 to withdraw approval of such application4 7#c7 ,appeal withdrawing approval and orders of temporary suspensions ,an order of withdrawal or an order of temporary suspension may be appealed under #ehg,p4 #ehg;,c4 ,exemptions 7a7 ,in general ,the following in vitro clinical tests are exempt from premarket review under section #ehg;,b1 and may be lawfully offered subject to other applicable requirements of this ,act3 7#a7 ,tests exempt from section #eaj7k7 7,a7 ,exemption ,an in vitro clinical test is exempt from premarket review under section #ehg;,b and may be lawfully offered subject to the other applicable requirements of this ,act1 if the developer of the in vitro clinical test-- 7i7 maintains documentation demonstrating that the test meets and continues to meet the criteria set forth in subparagraph 7,b72 and 7ii7 makes such documentation available to the ,secretary upon request4 7,b7 ,criteria for exemption ,an in vitro clinical test is exempt as specified in subparagraph 7,a7 if such test-- 7i7 7,i7 7aa7 was offered for clinical use prior to the date of enactment of the ,,valid ,act of #bjbc2 and 7bb7 immediately prior to such date of enactment was exempt pursuant to subsection 7l7 or 7m77#b7 of section #eaj from the requirements for submission of a report under section #eaj7k72 or 7,,ii7 7aa7 was not offered for clinical use prior to such date of enactment2 7bb7 is not an instrument2 and 7cc7 falls within a category of tests that was exempt from the requirements for submission of a report under section #eaj7k7 as of such date of enactment 7including class ,,ii devices and excluding class ,i devices described in section #eaj7l772 7ii7 meets the applicable standard as described in section #ehg7b72 7iii7 is not offered with labeling and advertising that is false or misleading2 and 7iv7 is not likely to cause or contribute to serious adverse health consequences4 7,c7 ,effect on special controls ,for any in vitro clinical test1 or category of in vitro clinical tests1 that is exempt from premarket review based on the criteria in subparagraph 7,b71 any special control that applied to a device within a predecessor category immediately prior to the date of enactment of the ,,valid ,act of #bjbc shall be deemed a mitigating measure applicable under section #ehg;,e to an in vitro clinical test within the successor category1 except to the extent such mitigating measure is withdrawn or changed in accordance with section #ehg;,e4 7,d7 ,near-patient testing ,not later than #a year after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall issue draft guidance indicating categories of tests that shall be exempt from premarket review under section #ehg;,b when offered for near-patient testing 7point of care71 which were not exempt from submission of a report under section #eaj7k7 pursuant to subsection 7l7 or 7m77#b7 of section #eaj and regulations imposing limitations on exemption for in vitro devices intended for near-patient testing 7point of care74 7#b7 ,low-risk tests 7,a7 ,exemption ,an in vitro clinical test is exempt from premarket review under section #ehg;,b and may be lawfully offered subject to the other applicable requirements of this ,act1 including section #ehg;,j7b71 if such test meets the definition of low-risk under section #ehg and if the developer of the test-- 7i7 maintains documentation demonstrating that the in vitro clinical test meets and continues to meet the criteria set forth in subparagraph 7,b72 and 7ii7 makes such documentation available to the ,secretary upon request4 7,b7 ,criteria for exemption ,an in vitro clinical test is exempt as specified in subparagraph 7,a7 if-- 7i7 the in vitro clinical test meets the applicable standard as described in #ehg7b72 7ii7 the labeling and advertising are not false or misleading2 7iii7 the in vitro clinical test is not likely to cause or contribute to serious adverse health consequences2 and 7iv7 the in vitro clinical test falls within a category of tests listed as described in subparagraph 7,c74 7,c7 ,list of low-risk tests 7i7 ,in general ,the ,secretary shall maintain1 and make publicly available on the website of the ,food and ,drug ,administration1 a list of in vitro clinical tests1 and categories of in vitro clinical tests1 that are low-risk in vitro clinical tests for purposes of the exemption under this paragraph4 7ii7 ,inclusion ,the list under clause 7i7 shall consist of-- 7,i7 all in vitro clinical tests and categories of in vitro clinical tests that are exempt from premarket review pursuant to paragraph 7#a7 or this paragraph2 and 7,,ii7 all in vitro clinical tests and categories of in vitro clinical tests that are designated by the ,secretary pursuant to subparagraph 7,d7 as low-risk for purposes of this paragraph4 7,d7 ,designation of tests and categories ,without regard to subchapter ,,ii of chapter #e of title #e1 ,united ,states ,code1 the ,secretary may designate1 in addition to the tests and categories described in subparagraph 7,c77i71 additional in vitro clinical tests1 and categories of in vitro clinical tests1 as low-risk in vitro clinical tests for purposes of the exemption under this paragraph4 ,the ,secretary may make such a designation on the ,secretary's own initiative or in response to a request by a developer pursuant to subsection 7a7 or 7b7 of section #ehg;,f4 ,in making such a designation for a test or category of tests1 the ,secretary shall consider-- 7i7 whether the test1 or category of tests1 is low-risk2 7ii7 the existence of and ability to develop mitigating measures sufficient for such test category to meet the low-risk standard2 and 7iii7 such other factors as the ,secretary determines to be appropriate for the protection of the public health4 7#c7 ,humanitarian test exemption 7,a7 ,in general ,an in vitro clinical test that meets the criteria under subparagraph 7,b7 is exempt from premarket review under section #ehg;,b and may be lawfully offered subject to the other applicable requirements of this subchapter1 if the developer of the test-- 7i7 maintains documentation 7which may include literature citations in specialized medical journals1 textbooks1 specialized medical society proceedings1 and governmental statistics publications1 or1 if no such studies or literature citations exist1 credible conclusions from appropriate research or surveys7 demonstrating that such test meets and continues to meet the criteria described in this subsection2 and 7ii7 makes such documentation available to the ,secretary upon request4 7,b7 ,criteria for exemption ,an in vitro clinical test is exempt as described in subparagraph 7,a7 if-- 7i7 the in vitro clinical test is intended by the developer for use for a diagnostic purpose for-- 7,i7 a noncontagious disease or condition that affects not more than #aj1jjj 7or such other higher number determined by the ,secretary7 individuals in the ,united ,states per year2 or 7,,ii7 a contagious disease or condition that affects not more than #a1ejj individuals in the ,united ,states per year2 7ii7 the in vitro clinical test meets the applicable standard described in section #ehg7b72 7iii7 the labeling and advertising for the in vitro clinical test are not false or misleading2 7iv7 the in vitro clinical test is not likely to cause or contribute to serious adverse health consequences2 and 7v7 the in vitro clinical test is not intended for screening4 7,c7 ,exception for certain tests ,an in vitro clinical test intended to inform the use of a specific individual or specific type of biological product1 drug1 or device shall be eligible for an exemption from premarket review under this subsection only if1 the developer submits a request under section #ehg;,f7e7 for informal feedback and the ,secretary determines that such in vitro clinical test is eligible for an exemption from premarket review under this subsection4 7#d7 ,custom tests and low-volume tests ,an in vitro clinical test is exempt from premarket review under section #ehg;,b1 quality requirements under section #ehg,k1 and listing requirements under section #ehg;,j1 and may be lawfully offered subject to the other applicable requirements of this ,act1 if-- 7,a7 such in vitro clinical test-- 7i7 is a test protocol performed for not more than #e patients per year 7or such other higher number determined by the ,secretary71 in a laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that-- 7,i7 meets the requirements to perform tests of high-complexity in which the test protocol was developed2 or 7,,ii7 meets the requirements to perform tests of high-complexity within the same corporate organization and having common ownership by the same parent corporation as the laboratory in which such test protocol was developed2 or 7ii7 is an in vitro clinical test developed to diagnose a unique pathology or physical condition of a specific patient or patients 7including an in vitro clinical test modified for such purpose71 upon the prescription or order of a health care practitioner licensed to prescribe or order such test1 or a health care professional or other specially qualified person designated under regulations to prescribe or order such test1 for which no other in vitro clinical test is commercially available in the ,united ,states1 and is-- 7,i7 not intended for use with respect to more than #e 7or such other higher number determined by the ,secretary7 other patients2 and 7,,ii7 not included in any test menu or template test report or other promotional materials1 and is not otherwise advertised2 and 7,b7 the developer of the in vitro clinical test-- 7i7 maintains documentation demonstrating that such test meets the applicable criteria described in subparagraph 7,a72 7ii7 makes such documentation1 such as a prescription order requesting the custom test for an individual patient1 available to the ,secretary upon request2 and 7iii7 informs the ,secretary1 on an annual basis1 in a manner prescribed by the ,secretary by guidance1 that such test was offered4 7#e7 ,in vitro clinical tests under a technology certification order ,an in vitro clinical test that is within the scope of a technology certification order under section #ehg;,d is exempt from premarket review under section #ehg;,b4 7#f7 ,modified tests 7,a7 ,in general ,an in vitro clinical test that is modified is exempt from premarket review under section #ehg;,b if-- 7i7 the modification is made by-- 7,i7 the developer that obtained premarket approval for the unmodified version of the test under section #ehg;,b2 or 7,,ii7 a clinical laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that meets the requirements for performing high complexity testing1 to a lawfully offered in vitro clinical test1 including another developer's lawfully offered in vitro clinical test1 excluding investigational in vitro clinical tests offered under section #ehg,s1 and the modified test is performed-- 7aa7 in the same clinical laboratory in which it was developed for which a certification is still in effect under section #cec that meets the requirements to perform tests of high complexity2 7bb7 by another clinical laboratory for which a certificate is in effect under section #cec that meets the requirements to perform tests of high complexity1 is within the same corporate organization1 and has common ownership by the same parent corporation as the laboratory in which the test was developed2 or 7cc7 by a clinical laboratory for which a certificate is in effect under section #cec that meets the requirements to perform tests of high complexity and is within a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention1 if the test was developed by the ,centers for ,disease ,control and ,prevention or another laboratory within such public health laboratory network2 7ii7 the modification does not-- 7,i7 constitute a significant change to the indications for use1 except for changes to a specimen type1 as specified in the guidance issued under subparagraph 7,e72 7,,ii7 cause the test to no longer comply with applicable mitigating measures under section #ehg;,e or restrictions under section #ehg,o2 7,,iii7 significantly change performance claims or significantly and adversely change performance1 unless provided for under an approved change protocol under section #ehg;,b7a77#c77;,h72 or 7,,iv7 constitute an adverse change in the safety of the in vitro clinical test for individuals who come in contact with the in vitro clinical test2 7iii7 the test meets the applicable standard as described in section #ehg7b72 7iv7 the labeling and advertising are not false or misleading2 and 7v7 the test is not likely to cause or contribute to serious adverse health consequences4 7,b7 ,certain modifications ,a modification to extend specimen stability is exempt from premarket review under section #ehg;,b if the modified test meets the requirements in clauses 7ii7 through 7v7 of subparagraph 7,a74 7,c7 ,modifications under a change protocol ,notwithstanding subparagraph 7,a71 a modification made under a change protocol pursuant to subsection 7a77#b77;,h7 of section #ehg;,b is exempt from review under such section4 7,d7 ,documentation ,a person who modifies an in vitro clinical test in a manner that is a modification described in this paragraph shall-- 7i7 document the modification that was made and the basis for determining that the modification1 considering the changes individually and collectively1 is a type of modification described in subparagraph 7,a71 7,b71 or 7,c72 and 7ii7 provide such documentation to the ,secretary upon request or inspection4 7,e7 ,guidance ,not later than #cj months after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall issue guidance regarding the in vitro clinical tests that are modified and exempt from premarket review under section #ehg;,b pursuant to this paragraph4 ,such guidance shall include considerations for changes to a specimen type that may be made by a developer without the requirement of premarket review under #ehg;,b4 7b7 ,manual tests 7#a7 ,exemption ,an in vitro clinical test is exempt from all requirements of this subchapter if the output of such in vitro clinical test is the result of direct1 manual observation1 without the use of automated instrumentation or software for intermediate or final interpretation1 by a qualified laboratory professional1 and such in vitro clinical test-- 7,a7 is developed and used within a single clinical laboratory for which a certificate is in effect under section #cec of the ,public ,health ,service ,act that meets the requirements under section #cec for performing high-complexity testing2 7,b7 is not a specimen receptacle1 instrument1 or an in vitro clinical test that includes an instrument or specimen receptacle that is not approved under or exempt from section #ehg;,b2 7,c7 is not a high-risk test1 or is a high-risk test that the ,secretary has determined meets at least one condition in paragraph 7#b7 and is otherwise appropriate for this exemption2 and 7,d7 is not intended for testing donors1 donations1 or recipients of blood1 blood components1 human cells1 tissues1 cellular-based products1 or tissue-based products4 7#b7 ,high-risk test limitation or condition ,a high-risk test may be exempt under paragraph 7#a7 from the requirements of this subchapter only if-- 7,a7 no components or parts of such test1 including any reagent1 is introduced into interstate commerce under the exemption under subsection 7e71 and any article for taking or deriving specimens from the human body used in conjunction with the test remains subject to the requirements of this subchapter2 or 7,b7 the test has been developed in accordance with the applicable test design and quality requirements under section #ehg,k4 7c7 ,public health surveillance activities 7#a7 ,in general ,the provisions of this subchapter shall not apply to a test intended by the developer to be used solely for public health surveillance activities4 7#b7 ,exclusion ,an in vitro clinical test used for public health surveillance activities is not excluded from the provisions of this subchapter pursuant to this subsection if such test is intended for use in making clinical decisions for individual patients4 7d7 ,general laboratory equipment ,as set forth in section #bja7ss77#c77;,c71 general purposes laboratory equipment is not an in vitro clinical tests and is not subject to the requirements of this subchapter4 7e7 ,components and ,parts 7#a7 ,in general ,subject to paragraph 7#b71 a component or part described in section #bja7ss77#b77;,g7 is-- 7,a7 exempt from the requirements of this subchapter if it is intended for further development as described in paragraph 7#c72 or 7,b7 subject to the requirements of this subchapter and regulated based on its risk when used as intended by the developer1 notwithstanding its subsequent use by a developer as a component1 part1 or raw material of another in vitro clinical test4 7#b7 ,inapplicability to other tests ,notwithstanding paragraph 7#a71 an in vitro clinical test that is described in section #bja7ss77#a77;,b7 and that uses a component or part described in such subparagraph shall be subject to the requirements of this subchapter1 unless the test is otherwise exempt under this section4 7#c7 ,further development ,a component1 part1 or raw material 7as described in paragraph 7#a77 is intended for further development 7for purposes of such paragraph7 if-- 7,a7 it is intended solely for use in the development of another in vitro clinical test2 and 7,b7 in the case of such a test that is introduced or delivered for introduction into interstate commerce after the date of enactment of the ,,valid ,act of #bjbc1 the labeling of such test bears the following statement3 ,this product is intended solely for further development of an in vitro clinical test and is exempt from ,,fda regulation4 ,this product must be evaluated by the in vitro clinical test developer if it is used with or in the development of an in vitro clinical test44 7f7 ,general exemption authority ,the ,secretary may1 by order published in the ,federal ,register following notice and an opportunity for comment1 exempt a class of persons from any section under this subchapter upon a finding that such exemption is appropriate for the protection of the public health and other relevant considerations4 7g7 ,other exemptions ,an in vitro clinical test that is intended solely for use in forensic analysis or law enforcement activity is exempt from the requirements of this subchapter4 ,an in vitro clinical test that is intended for use in making clinical decisions for individual patients1 or whose individually identifiable results may be reported back to an individual patient or the patient's health care provider1 even if also intended for forensic analysis or law enforcement purposes1 is not intended solely for forensic analysis or law enforcement for purposes of this subsection4 7h7 ,revocation 7#a7 ,in general ,the ,secretary may revoke any exemption under this section with respect to in vitro clinical tests with the same indications for use if new clinical information indicates that the exemption of an in vitro clinical test or tests from premarket review under section #ehg;,b has a reasonable probability of severe adverse health consequences1 including the absence1 delay1 or discontinuation of appropriate medical treatment4 7#b7 ,process ,any action under paragraph 7#a7 shall be made by publication of a notice of such proposed action on the website of the ,food and ,drug ,administration1 the consideration of comments to a public docket on such proposal1 and publication of a final action on such website within #fj calendar days of the close of the comment period posted to such public docket1 notwithstanding subchapter ,,ii of chapter #e of title #e1 ,united ,states ,code4 7i7 ,pre-,analytical instrument ,a pre-analytical instrument is exempt from premarket review under section #ehg;,b and may be lawfully offered subject to the other applicable requirements of this ,act1 if either of the following applies3 7#a7 ,such instrument provides additional information regarding the sample or performs an action on the sample but is not preparing or processing the sample and does not perform any function of an analytical instrument4 ,such types of pre-analytical instruments include barcode readers1 sample movers1 and sample identifiers4 7#b7 ,such instrument processes or prepares the sample prior to use on an analytical instrument1 does not perform any function of an analytical instrument1 and does not select1 isolate1 or prepare a part of a sample based on specific properties4 ,such types of pre-analytical instruments may include sample mixers1 ,,dna extractors and those used to dilute samples4 #ehg;,d4 ,technology certification 7a7 ,definitions ,in this section3 7#a7 ,eligible in vitro clinical test ,the term eligible in vitro clinical test means an in vitro clinical test that is not-- 7,a7 a component or part of an in vitro clinical test as described in section #bja7ss77#b77;,g7 unless it is a component or part and is regulated based on its own risk under section #ehg;,c7e77#a77;,b7 or as part of an otherwise eligible in vitro clinical test2 7,b7 an instrument under section #bja7ss77#b77;,d7 or an in vitro clinical test that includes an instrument that is subject to section #ehg;,b1 but is not approved under1 or exempt from1 section #ehg;,b2 7,c7 a specimen receptacle under section #bja7ss77#b77;,e7 or an in vitro clinical test that includes a specimen receptacle that is subject to section #ehg;,b1 but is not approved under1 or exempt from1 section #ehg;,b2 7,d7 an in vitro clinical test1 including reagents used in such tests1 intended for use for testing donors1 donations1 and recipients of blood1 blood components1 human cells1 tissues1 cellular-based products1 or tissue-based products2 7,e7 high-risk2 7,f7 a combination product1 unless such test has been determined to be eligible to be introduced into interstate commerce under a technology certification order pursuant to the regulatory pathway designation process described in section #ehg;,f1 or as described in subsection 7k71 and the drug or biological product constituent part complies with the requirements of section #ejc7;g7 applicable to the drug or biological product2 or 7,g7 a first-of-a-kind in vitro clinical test1 unless such test has been determined to be eligible to be introduced into interstate commerce under a technology certification order pursuant to the regulatory pathway designation process described in section #ehg;,f1 or as described in subsection 7k74 7#b7 ,eligible person ,the term eligible person means an in vitro clinical test developer unless such developer-- 7,a7 is a laboratory subject to section #cec of the ,public ,health ,service ,act and does not have in effect a certificate applicable to the category of laboratory examination or other procedure2 7,b7 was a laboratory1 or an owner or operator or any employee of a laboratory1 found to have committed a significant violation of section #cec of the ,public ,health ,service ,act that resulted in a suspended1 revoked1 or limited certificate within the #b-year period preceding the date of the submission of the application for a technology certificate under subsection 7c7 and such violation has not been resolved2 or 7,c7 has been found to have submitted information to the ,secretary1 or otherwise disseminated information1 that-- 7i7 made false or misleading statements relevant to the requirements of this subchapter2 or 7ii7 violated any requirement of this ,act1 where such violation exposed individuals to serious risk of illness1 injury1 or death1 unless-- 7,i7 such violation has been resolved2 or 7,,ii7 such violation is not pertinent to any in vitro clinical test within the scope of the technology certification that such developer seeks4 7b7 ,applicability 7#a7 ,in general ,an in vitro clinical test is not subject to section #ehg;,b and may be introduced into interstate commerce if the in vitro clinical test-- 7,a7 is an eligible in vitro clinical test2 7,b7 is developed by an eligible person2 7,c7 falls within the scope of a technology certification order issued under this section and that is in effect2 7,d7 complies with the conditions of the technology certification order1 including with applicable mitigating measures under section #ehg;,e1 restrictions under section #ehg,o1 and performance standards under section #ehg,r2 and 7,e7 meets the applicable standard described in section #ehg7b74 7#b7 ,scope 7,a7 ,in general ,subject to subparagraph 7,b71 the scope of a technology certification order issued under this section shall apply to one or more technologies with multiple in vitro clinical tests utilizing a technology that does not significantly differ in control mechanisms1 energy sources1 or operating principles and for which development1 including design1 and analytical and clinical validation1 of the in vitro clinical tests would be addressed through similar procedures1 and be no broader than-- 7i7 a single technology type2 or 7ii7 a fixed combination of technologies4 7,b7 ,technology type ,a technology type described in this paragraph may include clot detection1 colorimetric 7non-immunoassay71 electrochemical 7non-immunoassay71 enzymatic 7non-immunoassay71 flow cytometry1 fluorometry 7non-immunoassay71 immunoassay1 mass spectrometry or chromatography1 microbial culture1 next generation sequencing1 nephlometric or turbidimetric 7non-immunoassay71 singleplex or multiplex non-,,ngs nucleic acid analysis1 slide-based technology1 spectroscopy1 and any other technology1 as the ,secretary determines appropriate4 7c7 ,application for technology certification 7#a7 ,in general ,a developer seeking a technology certification order shall submit an application under this subsection1 which shall contain the information specified under paragraph 7#b74 7#b7 ,content of application ,a developer that submits an application for a technology certification shall include all necessary information to make a showing that all eligible in vitro clinical tests developed within the scope of the technology certification order will meet the applicable standard1 including-- 7,a7 the name and address of the developer2 7,b7 a table of contents for the application and the identification of the information the developer claims as trade secret or confidential commercial or financial information2 7,c7 the signature of the individual filing the application or an authorized representative2 7,d7 a statement identifying the scope of the proposed technology certification intended to be introduced into interstate commerce under the application2 7,e7 information establishing that the developer submitting the application is an eligible person2 7,f7 quality procedures showing that eligible in vitro clinical tests covered under the technology certification will conform to the applicable quality requirements of section #ehg,k with respect to-- 7i7 design controls1 including related purchasing controls and acceptance activities2 7ii7 complaint investigation1 adverse event reporting1 and corrections and removals2 and 7iii7 process validation1 as applicable2 7,g7 procedures for analytical and clinical validation1 including all procedures for validation1 verification1 and acceptance criteria1 and an explanation as to how such procedures1 when used1 provide a showing that eligible in vitro clinical tests within the proposed scope of the technology certification order are analytically and clinically valid2 7,h7 procedures that provide a showing that in vitro clinical tests covered by the proposed scope of the technology certification order will be safe for individuals who come into contact with in vitro clinical tests covered by such order2 7,i7 a proposed listing submission under section #ehg;,j7b7 for in vitro clinical tests that the developer intends to introduce into interstate commerce upon receiving a technology certification order1 which shall not be construed to limit the developer from introducing additional tests not included in such submission under the same technology certification order2 7,j7 information concerning one or more representative in vitro clinical tests1 including-- 7i7 a test within the scope of the technology certification application with the appropriate analytical complexity at the time of the submission of the application under this section to serve as the representative test2 7ii7 the information specified in subsection 7a7 or 7b7 of section #ehg;,b1 as applicable1 for the representative in vitro clinical test or tests1 unless the ,secretary determines that such information is not necessary2 7iii7 a summary of a risk assessment of the in vitro clinical test2 7iv7 an explanation of the choice of the representative in vitro clinical test or tests for the technology certification application and how such test adequately demonstrates the range of procedures that the developer includes in the application under subparagraphs 7,f71 7,g71 7,h71 and 7,i72 and 7v7 a brief explanation of the ways in which the procedures included in the application under subparagraphs 7,f71 7,g71 7,h71 and 7,i7 have been applied to the representative in vitro clinical test or tests2 and 7,k7 such other information necessary to make a determination on a technology certification application as the ,secretary may determine necessary4 7#c7 ,reference to existing applications ,with respect to the content requirements in the technology certification application described in paragraph 7#b71 a developer may incorporate by reference any content of an application previously submitted by the developer4 7d7 ,action on an application for technology certification 7#a7 ,secretary response 7,a7 ,in general ,as promptly as practicable1 and not later than #ij days after receipt of an application under subsection 7c71 the ,secretary shall-- 7i7 if the ,secretary finds that all of the grounds in paragraph 7#c7 are met1 issue a technology certification order granting the application1 which-- 7,i7 may include reasonable conditions of certification2 and 7,,ii7 shall specify the scope of the technology certification2 or 7ii7 deny the application1 if the ,secretary finds 7and sets forth the basis of such finding as part of or accompanying such denial7 that one or more grounds for granting the application specified in paragraph 7#c7 are not met4 7,b7 ,extension ,the timeline described in subparagraph 7,a7 may be extended by mutual agreement between the ,secretary and the applicant4 7#b7 ,deficient applications 7,a7 ,in general ,if1 after receipt of an application under this section1 the ,secretary determines that any portion of such application is deficient1 the ,secretary1 not later than #fj days after receipt of such application1 shall provide to the applicant a description of such deficiencies and identify the information required to resolve such deficiencies4 7,b7 ,converting to premarket applications ,when responding to the deficiency letter1 the developer may convert the application for technology certification under subsection 7c7 into a premarket application under section #ehg;,b4 7#c7 ,technology certification order ,the ,secretary shall issue an order granting a technology certification under this section if1 on the basis of the information submitted to the ,secretary as part of the application and any other information with respect to such applicant1 the ,secretary finds that-- 7,a7 there is a showing that in vitro clinical tests within the scope of the technology certification order will meet the applicable standard2 7,b7 the methods used in1 and the facilities or controls used for1 the development of eligible in vitro clinical tests covered by the proposed scope of the technology certification conform to the applicable requirements of section #ehg,k with respect to-- 7i7 design controls1 including related purchasing controls and acceptance activities2 7ii7 complaint investigation1 adverse event reporting1 and corrections and removals2 and 7iii7 process validation1 as applicable2 7,c7 based on a fair evaluation of all material facts1 the applicant's proposed labeling and advertising are not false or misleading in any particular2 7,d7 the application does not contain a false statement of material fact2 7,e7 there is a showing that the representative in vitro clinical test or tests-- 7i7 meet the applicable standard2 and 7ii7 reasonably represent the range of procedures required to be submitted in the application2 7,f7 the applicant has agreed to permit1 upon request1 authorized employees of the ,food and ,drug ,administration or persons accredited1 or recognized under this ,act1 an opportunity to inspect at a reasonable time and in a reasonable manner the facilities and all pertinent equipment1 finished and unfinished materials1 containers1 and labeling therein1 including all things 7including records1 files1 papers1 and controls7 bearing on whether an in vitro clinical test is adulterated1 misbranded1 or otherwise in violation of this ,act1 and permits such authorized employees or persons accredited under this ,act to view and to copy and verify all records pertinent to the application and the in vitro clinical test2 and 7,g7 based on other data and information the ,secretary may require under subsection 7c77#b77,k71 the ,secretary finds that such data and information support granting a technology certification order4 7#d7 ,review of denials ,an applicant whose application has been denied under this subsection may obtain review of such denial under section #ehg,p4 7e7 ,supplements 7#a7 ,supplemental applications 7,a7 ,in general ,with respect to any of the following changes related to a technology certification order1 a supplemental application to a technology certification order shall be submitted by the holder of the technology certification order describing such proposed changes1 and the in vitro clinical test with such changes may not be introduced into interstate commerce until a technology certification order for such supplemental application is granted3 7i7 ,any significant change to the procedures provided in support of the application for technology certification submitted under subparagraph 7,g7 or 7,h7 of subsection 7c77#b74 7ii7 ,any significant change to the procedures provided in support of the application for technology certification submitted under subparagraph 7,f7 of subsection 7c77#b74 7,b7 ,secretary action on supplemental applications ,any action by the ,secretary on a supplemental application shall be in accordance with subsection 7d71 and any order resulting from such supplement shall be treated as an amendment to a technology certification order4 7#b7 ,content of application 7,a7 ,in general ,a supplemental application for a change to an in vitro clinical test under a technology certification order shall-- 7i7 contain all necessary information to make a showing that any in vitro clinical test affected by such change that is within the scope of the technology certification order will meet the applicable standard2 and 7ii7 be limited to such information that is needed to support the change4 7,b7 ,content ,unless otherwise specified by the ,secretary1 a supplemental application under this subsection shall include-- 7i7 a description of the change1 including a rationale for implementing such change2 7ii7 a description of how the change was evaluated2 7iii7 data from a representative in vitro clinical test or tests that supports a showing that1 in using the modified procedure or procedures1 all eligible in vitro clinical tests within the scope of the technology certification will meet the applicable standard2 7iv7 as applicable1 information to demonstrate that the modified procedure or procedures submitted under subsection 7c77#b77;,f7 continue to conform to applicable requirements under section #ehg,k2 and 7v7 any other information requested by the ,secretary4 7#c7 ,changes in response to a public health risk 7,a7 ,in general ,if the holder of a technology certification makes a change to an in vitro clinical test or tests to address a potential risk to public health by adding a new specification or test method1 such holder may immediately implement such change and shall submit a notification for such change to the ,secretary within #cj days4 7,b7 ,content ,any notification to the ,secretary under this paragraph shall include-- 7i7 a summary of the relevant change2 7ii7 the rationale for implementing such change2 7iii7 7,i7 if such a change necessitates a change to the procedures reviewed as part of the granted technology certification order1 the modified procedures2 or 7,,ii7 if the procedures were not changed1 an explanation as to why they were not changed2 and 7iv7 if such a change necessitates a change to the procedures reviewed as part of the granted technology certification order1 data from a representative in vitro clinical test or tests that support a showing that1 in using the modified procedures1 all eligible in vitro clinical tests within the scope of the technology certification will meet the applicable standard4 7f7 ,temporary hold 7#a7 ,in general ,subject to the process specified in paragraph 7#b71 and based on one or more findings under paragraph 7#d71 the ,secretary may issue a temporary hold prohibiting any holder of a technology certification order issued under this section from introducing into interstate commerce an in vitro clinical test that was not previously the subject of a listing under section #ehg;,j4 ,the temporary hold shall identify the grounds for the temporary hold under paragraph 7#d7 and the rationale for such finding4 7#b7 ,process for issuing a temporary hold ,if the ,secretary makes a finding that a temporary hold may be warranted based on one or more grounds specified in paragraph 7#d71 the ,secretary shall promptly notify the holder of the technology certification order of such finding and provide #cj calendar days for the developer to come into compliance with or otherwise resolve the finding4 7#c7 ,written requests ,any written request to the ,secretary from the holder of a technology certification order that a temporary hold under paragraph 7#a7 be removed shall receive a decision1 in writing and specifying the reasons therefore1 within #ij days after receipt of such request4 ,any such request shall include information to support the removal of the temporary hold4 7#d7 ,grounds for temporary hold ,the ,secretary may initiate a temporary hold under this subsection upon a finding that the holder of a technology certification order-- 7,a7 is not in compliance with the conditions of the technology certification order pursuant to subsection 7b77#a77;,d72 7,b7 offers one or more in vitro clinical tests with advertising or labeling that is false or misleading2 7,c7 has reported a correction or removal of an in vitro clinical test that is offered under a technology certification order under this section and has failed to demonstrate that the issue or issues causing the correction or removal does not adversely impact the ability of other in vitro clinical tests offered under the same technology certification order to meet the applicable standard2 or 7,d7 has introduced into interstate commerce an in vitro clinical test under a technology certification order and such test is adulterated or misbranded1 based on a determination by the ,secretary1 and has failed to demonstrate that the issue or issues causing the adulteration or misbranding does not adversely impact the ability of other in vitro clinical tests offered under the same technology certification granted under this section to meet the applicable standard4 7g7 ,withdrawal ,the ,secretary may1 after due notice and opportunity for an informal hearing1 issue an order withdrawing a technology certification order including all tests introduced into interstate commerce under the technology certification order if the ,secretary finds that-- 7#a7 the application1 supplement1 or report under subsection 7h7 contains false or misleading information or fails to reveal a material fact2 7#b7 such holder fails to correct false or misleading labeling or advertising upon the request of the ,secretary2 7#c7 in connection with a technology certification1 the holder provides false or misleading information to the ,secretary2 or 7#d7 the holder of such technology certification order fails to correct the grounds for a temporary hold within a timeframe specified in the temporary hold order4 7h7 ,reports to ,congress 7#a7 ,in general ,not later than #a year after the effective date of the ,,valid ,act of #bjbc1 and annually thereafter for the next #d years1 the ,secretary shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives1 and make publicly available1 including through posting on the website of the ,food and ,drug ,administration1 a report containing the information described in paragraph 7#b74 7#b7 ,content 7,a7 ,in general ,each report under paragraph 7#a7 shall address1 at a minimum-- 7i7 the total number of applications for technology certifications filed1 issued1 withdrawn1 and denied2 7ii7 the total number of technology certification orders the ,secretary put on temporary hold under subsection 7h7 and the number of technology certification orders withdrawn under subsection 7i72 7iii7 the types of technologies for which the ,secretary issued technology certification orders2 7iv7 the total number of holders of technology certification orders that are in effect2 and 7v7 the total number of in vitro clinical test categories that required premarket review under section #ehg;,b that were redesignated as eligible in vitro clinical tests under this section4 7,b7 ,final report ,the fifth report submitted under paragraph 7#a7 shall include a summary of1 and responses to1 comments raised in the docket4 7,c7 ,performance reports ,the reports required under this section may be issued with performance reports as required under section #i of the ,,valid ,act of #bjbc4 7i7 ,public meeting and input 7#a7 ,public docket ,not later than #cj days after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall establish a public docket to receive comments concerning recommendations for implementation of this section1 including criteria and procedures for subsections 7c7 through 7h74 ,the public docket shall remain open for at least #a year after the establishment of the public docket4 7#b7 ,public meeting ,not later than #ahj days after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall convene a public meeting to which stakeholders from organizations representing patients and consumers1 academia1 and the in vitro clinical test industry are invited to discuss the technology certification process including application requirements1 inspections1 alignment with third-party accreditors1 and the definition of the term technology under section #ehg4 7j7 ,regulations ,the ,secretary shall issue regulations regarding the technology certification process1 including describing criteria or procedures relating to technology certification under this section1 which shall be subject to public comment for a minimum of #fj days from issuance prior to finalizing such regulations after considering the comments received4 ,the regulation shall include an outline of the application process1 opportunities to meet with officials of the ,food and ,drug ,administration1 and plans to streamline inspections4 7k7 ,notification 7#a7 ,in general ,notwithstanding subsection 7a77#a71 a first-of-a-kind in vitro clinical test or a combination product that meets the definition of a moderate-risk test under section #ehg may be introduced into interstate commerce under a technology certification order that has been issued by the ,secretary1 subject to other applicable requirements if-- 7,a7 the developer provides notification to the ,secretary #fj days prior to introducing such tests into interstate commerce that includes information demonstrating that the test is moderate-risk and within the scope of the applicable technology certification order2 and 7,b7 the ,secretary has not issued a notification to the developer under paragraph 7#b7 before such time has elapsed4 7#b7 ,notification from ,secretary ,the ,secretary shall issue a notification to the developer that such test may not be introduced into interstate commerce under such order if the ,secretary determines that-- 7,a7 such test-- 7i7 does not meet the definition of a moderate-risk test under section #ehg2 7ii7 is not eligible to be introduced into interstate commerce under any of subparagraphs 7,a7 through 7,e7 of subsection 7a77#a72 or 7iii7 is not eligible to be introduced into interstate commerce under the referenced technology certification order issued by the ,secretary because it is not within the scope of the technology certification order under subsection 7b77#b72 or 7,b7 based on the information included in the notification submitted by the developer pursuant to this subsection1 there is insufficient information for the ,secretary to make the determinations described in clauses 7i71 7ii71 and 7iii7 of subparagraph 7,a74 #ehg;,e4 ,mitigating measures 7a7 ,establishment of mitigating measures 7#a7 ,establishing1 changing1 or withdrawing 7,a7 ,establishment ,the ,secretary may establish and require1 on the basis of evidence1 mitigating measures for any in vitro clinical test or category of in vitro clinical tests with the same indications for use that is introduced or delivered for introduction into interstate commerce after the ,secretary establishes any such mitigating measures4 7,b7 ,methods of establishment ,the ,secretary may establish mitigating measures-- 7i7 under the process set forth in subparagraph 7,d72 7ii7 as provided under section #ehg;,f2 or 7iii7 through a premarket approval or technology certification order1 which may establish mitigating measures for an individual in vitro clinical test or a category of in vitro clinical tests4 7,c7 ,methods of change or withdrawal ,the ,secretary may change or withdraw mitigating measures-- 7i7 under the process set forth in subparagraph 7,d72 or 7ii7 as provided under section #ehg;,f4 7,d7 ,process for establishment1 change1 or withdrawal ,notwithstanding subchapter ,,ii of chapter #e of title #e1 ,united ,states ,code1 the ,secretary may1 upon the initiative of the ,secretary or upon petition of an interested person1 establish1 change1 or withdraw mitigating measures for an in vitro clinical test or category of in vitro clinical tests by-- 7i7 publishing a proposed order in the ,federal ,register2 7ii7 providing an opportunity for public comment for a period of not less than #cj #fj calendar days2 and 7iii7 after consideration of any comments submitted1 publishing a final order in the ,federal ,register that responds to the comments submitted1 and which shall include a reasonable transition period4 7,e7 ,effect of mitigating measures on grandfathered tests ,a mitigating measure shall not be required by the ,secretary for an in vitro clinical test subject to section #ehg;,g7a74 7#b7 ,in vitro clinical tests previously cleared or exempt as devices with special controls 7,a7 ,in general ,any special controls applicable to an in vitro clinical test previously cleared or exempt under section #eaj7k71 or classified under section #eac7;f77#b7 prior to date of enactment of the ,,valid ,act of #bjbc1 including any such special controls established during the period beginning on the date of enactment of the ,,valid ,act of #bjbc and ending on the effective date of such ,act 7as described in section #e7;b7 of such ,act7-- 7i7 shall continue to apply to such in vitro clinical test after such effective date2 and 7ii7 are deemed to be mitigating measures as of the effective date specified in section #e7;a77#a77;,a7 of the ,,valid ,act of #bjbc4 7,b7 ,changes ,notwithstanding subparagraph 7,a71 the ,secretary may establish1 change1 or withdraw mitigating measures for such tests or category of tests using the procedures under paragraph 7#a74 7b7 ,documentation 7#a7 ,in vitro clinical tests subject to premarket review ,the developer of an in vitro clinical test subject to premarket review under section #ehg;,b and to which mitigating measures apply shall maintain documentation in accordance with the applicable quality requirements under section #ehg,k and make such documentation available to the ,secretary upon request or inspection4 7#b7 ,other tests ,the developer of an in vitro clinical test that is offered under a technology certification order or other exemption from premarket review under section #ehg;,b and to which mitigating measures apply shall-- 7,a7 maintain documentation in accordance with the applicable quality requirements under section #ehg,k demonstrating that such mitigating measures continue to be met following a test modification by the developer2 7,b7 make such documentation available to the ,secretary upon request or inspection2 and 7,c7 include in the performance summary for such test a brief description of how such mitigating measures are met1 if applicable4 #ehg;,f4 ,regulatory pathway designation 7a7 ,pathway determinations 7#a7 ,in general ,after considering available evidence with respect to an in vitro clinical test or category of in vitro clinical tests with the same intended use1 including the identification1 establishment under paragraph 7#d71 and implementation of mitigating measures under section #ehg;,e1 as appropriate1 the ,secretary may1 upon the initiative of the ,secretary or upon request of a developer1 determine that-- 7,a7 such in vitro clinical test is high-risk and subject to premarket review under section #ehg;,b2 7,b7 such in vitro clinical tests1 including a first-of-a-kind test1 is moderate-risk and subject to abbreviated premarket review under section #ehg;,b7b7 or technology certification under section #ehg;,d7a77#a72 or 7,c7 such in vitro clinical test1 including a first-of-a-kind test is low-risk or otherwise exempt from premarket review under section #ehg;,b4 7#b7 ,requests 7,a7 ,submissions by developers 7i7 ,abbreviated premarket review2 technology certification ,a developer submitting a request that the ,secretary make a determination as described in paragraph 7#a77;,b7 shall submit information to support that the in vitro clinical test is moderate-risk or propose mitigating measures1 if applicable1 that would support such a determination4 7ii7 ,low-risk2 exempt from premarket review ,a developer submitting a request that the ,secretary make a determination as described in paragraph 7#a77;,c7 shall submit information that the in vitro clinical test is low-risk1 or otherwise appropriate for exemption from premarket review under section #ehg;,b and propose mitigating measures1 if applicable1 that would support such a determination4 7,b7 ,response by the ,secretary ,not later than #cj days after receiving a request under clause 7i7 or 7ii7 of subparagraph 7,a71 the ,secretary shall provide a timely response describing whether or not the ,secretary will initiate the process for making a determination under paragraph 7#a77;,b7 or 7#a77;,c7 as described in paragraph 7#d74 7#c7 ,sufficiency of mitigating measures ,when determining whether mitigating measures for an in vitro clinical test1 or category of in vitro clinical tests1 are sufficient to make such test moderate-risk or low-risk1 the ,secretary shall take into account the following3 7,a7 ,the degree to which the technology for the intended use of the in vitro clinical test is well-characterized1 taking into consideration factors that include one or more of the following3 7i7 ,peer-reviewed literature4 7ii7 ,practice guidelines4 7iii7 ,consensus standards4 7iv7 ,recognized standards of care4 7v7 ,use of such technology1 including historical use4 7vi7 ,multiple scientific publications by different authors4 7vii7 ,adoption by the scientific or clinical community4 7viii7 ,real world evidence4 7,b7 ,whether the criteria for performance of the test are well-established to be sufficient for the intended use4 7,c7 ,the clinical circumstances under which the in vitro clinical test is used1 including whether the in vitro clinical test is the sole determinate for the diagnosis or treatment of the targeted disease1 and the availability of other tests 7such as confirmatory or adjunctive tests7 or relevant material standards4 7,d7 ,whether such mitigating measures sufficiently mitigate the risk of harm such that the test or category of tests is moderate-risk or low-risk4 7#d7 ,process 7,a7 ,in general ,for a test that is not first-of-a-kind1 any action under paragraph 7#a7 shall be made by publication of a notice of such proposed action on the website of the ,food and ,drug ,administration1 the consideration of comments to a public docket on such proposal1 and publication of a final action on such website within #fj calendar days of the close of the comment period posted to such public docket1 notwithstanding subchapter ,,ii of chapter #e of title #e1 ,united ,states ,code4 7,b7 ,process for first-of-a-kind test ,in the case of an in vitro clinical test that is first-of-a-kind1 the process is as follows3 7i7 ,any determination that the test is subject to premarket approval or abbreviated premarket review under subparagraph 7,a7 or 7,b7 of paragraph 7#a7 shall be published on the website of the ,food and ,drug ,administration1 notwithstanding subclause ,,ii of chapter #e of title #e1 ,united ,states ,code1 only after the in vitro clinical test is approved under section #ehg;,b4 ,until that time1 the determination shall not be binding on other in vitro clinical tests4 7ii7 ,any determination other than those made under clause 7i7 shall be made by publication of a notice of final action on the website of the ,food and ,drug ,administration1 notwithstanding subchapter ,,ii of chapter #e of title #e1 ,united ,states ,code4 7#e7 ,no effect on grandfathering determinations ,a determination under paragraph 7#a7 shall have no effect on the applicability of section #ehg;,g to an in vitro clinical tests4 7b7 ,transition period ,upon a decision by the ,secretary to change a regulatory pathway designation1 or reclassifies an in vitro clinical test1 or category of in vitro clinical tests1 the ,secretary shall provide an appropriate transition period with respect to any new requirements4 7c7 ,appeals ,a decision by the ,secretary under this section shall be deemed a significant decision subject to appeal under section #ehg,p4 7d7 ,advisory committee ,the ,secretary may request recommendations from an advisory committee under section #ehg;,h pursuant to carrying out this section4 7e7 ,request for informal feedback ,before submitting a premarket application or technology certification application for an in vitro clinical test-- 7#a7 the developer of the test may submit to the ,secretary a written request for a meeting1 conference1 or written feedback to discuss and provide information relating to the regulation of such in vitro clinical test which may include-- 7,a7 the submission process and the type and amount of evidence expected to demonstrate the applicable standard2 7,b7 which regulatory pathway is appropriate for an in vitro clinical test2 and 7,c7 an investigation plan for an in vitro clinical test1 including a clinical protocol2 and 7#b7 upon receipt of such a request1 the ,secretary shall-- 7,a7 if a meeting is requested-- 7i7 within #fj calendar days after such receipt1 or within such time period as may be agreed to by the developer1 meet or confer with the developer submitting the request2 and 7ii7 within #ae calendar days after such meeting or conference1 provide to the developer a written record or response describing the issues discussed and conclusions reached in the meeting or conference2 and 7,b7 if written feedback is requested1 provide feedback to the requestor within #ge days after such receipt4 #ehg;,g4 ,grandfathered in vitro clinical tests 7a7 ,in general ,subject to subsection 7d71 an in vitro clinical test is exempt from the requirements of this subchapter specified in subsection 7b7 if-- 7#a7 the test was first offered for clinical use1 and was not intended solely for investigational use1 not later than #de days after the date of enactment of the ,,valid ,act of #bjbc2 7#b7 the test was developed by a clinical laboratory for which a certificate was in effect under section #cec of the ,public ,health ,service ,act that meets the requirements for performing tests of high complexity2 7#c7 the test is performed-- 7,a7 in the same clinical laboratory in which the test was developed for which a certification is still in effect under section #cec of the ,public ,health ,service ,act that meets the requirements to perform tests of high complexity2 7,b7 by another clinical laboratory for which a certificate is in effect under section #cec of such ,act that meets the requirements to perform tests of high complexity1 and that is within the same corporate organization and having common ownership by the same parent corporation as the laboratory in which the test was developed2 or 7,c7 in the case of a test that was developed by the ,centers for ,disease ,control and ,prevention or another laboratory in a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention1 by a clinical laboratory for which a certificate is in effect under section #cec of such ,act that meets the requirements to perform tests of high complexity1 and that is within a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention2 7#d7 the test does not have in effect an approval under section #eae1 a clearance under section #eaj7k71 an authorization under section #eac7;f77#b71 or an exemption under section #ebj7m71 or licensure under section #cea of the ,public ,health ,service ,act2 7#e7 any modification to the test on or after the date that is #de days after the date of enactment of the ,,valid ,act of #bjbc is made by the initial developer1 conforms with section #ehg;,c7a77#f77;,a77ii71 and does not meet the criteria in subsection 7d77#a72 7#f7 when used as an investigational in vitro clinical test1 such test complies with section #ehg,s1 as applicable2 7#g7 the test is offered with an order from an authorized person as required under section #cec of the ,public ,health ,service ,act1 and was offered with a prescription required under section #hji4cj7;f7 of title #ba1 ,code of ,federal ,regulations prior to the effective date of this subchapter2 7#h7 the test is not for use with home specimen collection1 unless the specimen is collected with a collection container1 receptacle1 or kit that-- 7,a7 has been approved1 cleared1 or authorized by the ,secretary for home specimen collection and the collection is performed pursuant to the approved1 cleared1 or authorized labeling1 including any indication for use as prescription use or over-the-counter use1 or 7,b7 is exempt from premarket review and its use is consistent with applicable limitations on the exemption2 7#i7 the test is not a specimen receptacle or instrument2 7#aj7 each test report for the test bears a statement that reads as follows3 ,this in vitro clinical test was introduced into commerce prior to the application of the ,,valid ,act and is exempt from ,,fda premarket review42 and 7#aa7 the developer of the test-- 7,a7 maintains documentation demonstrating that the test meets and continues to meet the criteria set forth in this subsection2 and 7,b7 makes such documentation available to the ,secretary upon request4 7b7 ,exemptions applicable to grandfathered tests ,an in vitro clinical test that meets the criteria specified in subsection 7a7 is exempt from premarket review under #ehg;,b1 labeling requirements under #ehg,l1 and test design requirements and quality requirements under #ehg,k1 and may be lawfully offered subject to the other applicable requirements of this ,act4 7c7 ,modifications ,in the case of an in vitro clinical test that meets the criteria specified in subsection 7a71 such test continues to qualify for the exemptions described in subsection 7b7 if the test is modified and the modification is of a type described in subsection 7a77#e71 and the person modifying such in vitro clinical test-- 7#a7 documents each such modification and maintains documentation of the basis for such determination2 7#b7 provides such documentation relating to the change to the ,secretary upon request or inspection2 and 7#c7 does not modify the in vitro clinical test such that it no longer meets the criteria under subsection 7a74 7d7 ,request for information 7#a7 ,criteria ,the criteria described in this paragraph are any of the following3 7,a7 ,there is a lack of valid scientific evidence to support that the in vitro clinical test is analytically valid or clinically valid4 7,b7 ,such in vitro clinical test is being offered by its developer with any false or misleading analytical or clinical claims4 7,c7 ,it is probable that such in vitro clinical test will cause serious adverse health consequences4 7#b7 ,process 7,a7 ,written request for information ,the ,secretary may issue a written request to a developer identifying specific scientific concerns1 based on credible information1 with an in vitro clinical test1 which indicate that one or more of the criteria described in paragraph 7#a7 apply to such in vitro clinical test4 ,such written request shall include specific information requests pertaining to such criteria4 7,b7 ,deadline for submitting information ,not later than #de days after receiving a request for information under subparagraph 7,a7-- 7i7 the developer of an in vitro clinical test-- 7,i7 may seek a teleconference prior to the submission of information under subclause 7,,ii7 to discuss the ,secretary's request2 and 7,,ii7 shall submit the information requested pursuant to subparagraph 7,a71 and may include in such submission a request for a teleconference2 and 7ii7 the ,secretary shall-- 7,i7 schedule a teleconference requested under clause 7i77,i72 and 7,,ii7 hold a teleconference if requested within #aj days of the ,secretary's receipt of the information submitted under clause 7i77,,ii74 7,c7 ,review deadline ,upon receiving a submission under subparagraph 7,b71 the ,secretary shall-- 7i7 review the submitted information within #de calendar days of such receipt1 which may include communication with the developer2 and 7ii7 determine whether the criteria listed in paragraph 7#a7 apply to the in vitro clinical test and communicate such determination to the developer as described in subparagraph 7,d74 7,d7 ,communication and results of determination ,the ,secretary shall notify the developer1 in writing1 of the ,secretary's determination under subparagraph 7,c71 as follows3 7i7 ,if the ,secretary determines that none of the criteria listed in paragraph 7#a7 apply to the in vitro clinical test1 such test shall be exempt from relevant requirements of this subchapter1 as set forth in subsection 7b71 subject to the criteria under subsection 7a74 7ii7 ,if the ,secretary determines that one or more of the criteria listed in paragraph 7#a7 apply to the test but such a determination may be resolved within a reasonable time1 and the test has not been previously subject to this subsection on the basis of the same or substantially similar scientific concerns identified in the written request issued under paragraph 7d77#b77;,a7-- 7,i7 the ,secretary shall notify the developer of such a determination and allow the developer to seek a teleconference to discuss the finding2 7,,ii7 the developer shall submit information demonstrating resolution of the determination within #ae days of receiving such notification2 and 7,,iii7 the ,secretary shall make a determination within #cj days of the receipt of such submission of information as to whether the criteria under paragraph 7#a7 continue to apply to the test and1 if through such determination the ,secretary determines that-- 7aa7 none of the criteria listed in paragraph 7#a7 apply to the test1 such test shall be exempt from relevant requirements of the subchapter as set forth in subsection 7b71 subject to applicable limitations2 or 7bb7 one or more of the criteria listed in paragraph 7#a7 apply to the in vitro clinical test1 such test is not exempt as set forth in this section and shall not be offered unless approved under section #ehg;,b1 or1 upon a determination by the ,secretary pursuant to section #ehg;,f1 offered under a technology certification order under section #ehg;,d or offered as a low-risk test4 7iii7 ,if the ,secretary determines that one or more of the criteria listed in paragraph 7#a7 apply to the in vitro clinical test and clause 7ii7 does not apply1 the in vitro clinical test is not exempt as set forth in this section and shall not be offered unless approved under section #ehg;,b1 or upon a determination by the ,secretary pursuant to section #ehg;,f1 offered under a technology certification order under section #ehg;,d or offered as a low-risk test4 #ehg;,h4 ,advisory committees 7a7 ,in general ,the ,secretary may establish advisory committees or use advisory committee panels of experts established before the date of enactment of the ,,valid ,act of #bjbc 7including a device classification panel under section #eac7 for the purposes of providing expert scientific advice and making recommendations related to-- 7#a7 the approval of an application for an in vitro clinical test submitted under this subchapter1 including for evaluating1 as applicable1 the analytical validity1 clinical validity1 and safety of in vitro clinical tests2 7#b7 the potential effectiveness of mitigating measures for a determination of the applicable regulatory pathway under section #ehg;,f7b7 or risk evaluation for an in vitro clinical test or tests2 7#c7 quality requirements under section #ehg,k or applying such requirements to in vitro clinical tests developed or imported by developers2 7#d7 appeals under section #ehg,p2 or 7#e7 such other purposes as the ,secretary determines appropriate4 7b7 ,appointments 7#a7 ,voting members ,the ,secretary shall appoint to each committee established under subsection 7a71 as voting members1 individuals who are qualified by training and experience to evaluate in vitro clinical tests referred to the committee for the purposes specified in subsection 7a71 including individuals with1 to the extent feasible1 scientific expertise in the development of such in vitro clinical tests1 laboratory operations1 and the use of in vitro clinical tests4 ,the ,secretary shall designate one member of each committee to serve as chair4 7#b7 ,nonvoting members ,in addition to the individuals appointed pursuant to paragraph 7#a71 the ,secretary shall appoint to each committee established under subsection 7a71 as nonvoting members-- 7,a7 a representative of consumer interests2 and 7,b7 a representative of interests of in vitro clinical test developers not directly affected by the matter to be brought before the committee4 7#c7 ,limitation ,no individual who is a regular full-time employee of the ,united ,states and engaged in the administration of this ,act may be a member of any advisory committee established under subsection 7a74 7#d7 ,education and training ,the ,secretary shall1 as appropriate1 provide education and training to each new committee member before such member participates in a committee's activities1 including education regarding requirements under this ,act and related regulations of the ,secretary1 and the administrative processes and procedures related to committee meetings4 7#e7 ,meetings ,the ,secretary shall ensure that scientific advisory committees meet regularly and at appropriate intervals so that any matter to be reviewed by such a committee can be presented to the committee not more than #fj calendar days after the matter is ready for such review4 ,meetings of the committee may be held using electronic or telephonic communication to convene the meetings4 7#f7 ,compensation ,members of an advisory committee established under subsection 7a71 while attending meetings or conferences or otherwise engaged in the business of the advisory committee-- 7,a7 shall be entitled to receive compensation at rates to be fixed by the ,secretary1 but not to exceed the daily equivalent of the rate in effect for positions classified above level ,,gs-#ae of the ,general ,schedule2 and 7,b7 may be allowed travel expenses as authorized by section #egjc of title #e1 ,united ,states ,code1 for employees serving intermittently in the ,government service4 7c7 ,guidance ,the ,secretary may issue guidance on the policies and procedures governing advisory committees established under subsection 7a74 #ehg;,i4 ,breakthrough in vitro clinical tests 7a7 ,in general ,the purpose of this section is to encourage the ,secretary1 and provide the ,secretary with sufficient authority1 to apply efficient and flexible approaches to expedite the development of1 and prioritize the review of1 in vitro clinical tests that represent breakthrough technologies4 7b7 ,establishment of program ,the ,secretary shall establish a program to expedite the development of1 and provide for the priority review of1 in vitro clinical tests4 7c7 ,eligibility ,the program developed under subsection 7b7 shall be available for any in vitro clinical test that-- 7#a7 provides or enables more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions2 and 7#b7 is a test-- 7,a7 that represents a breakthrough technology2 7,b7 for which no approved alternative in vitro clinical test exists1 including no in vitro clinical test offered under a technology certification order2 7,c7 that offers a clinically meaningful advantage over existing alternative in vitro clinical tests that are approved 7including in vitro clinical tests offered under a technology certification order71 including the potential to reduce or eliminate the need for hospitalization1 improve patient quality of life1 facilitate patients' ability to manage their own care 7such as through self-directed personal assistance71 or establish long-term clinical efficiencies2 or 7,d7 the availability of which is in the best interest of patients or public health4 7d7 ,designation 7#a7 ,request ,to receive breakthrough designation under this section1 an applicant may request that the ,secretary designate the in vitro clinical test for expedited development and priority review4 ,any such request for designation may be made at any time prior to1 or at the time of1 the submission of an application under section #ehg;,b or #ehg;,d1 and shall include information demonstrating that the test meets the criteria described in subsection 7c74 7#b7 ,determination ,not later than #fj calendar days after the receipt of a request under paragraph 7#a71 the ,secretary shall determine whether the in vitro clinical test that is the subject of the request meets the criteria described in subsection 7c74 ,if the ,secretary determines that the test meets the criteria1 the ,secretary shall designate the test for expedited development and priority review4 7#c7 ,review ,review of a request under paragraph 7#a7 shall be undertaken by a team that is composed of experienced staff and senior managers of the ,food and ,drug ,administration4 7#d7 ,withdrawal 7,a7 ,in general ,the designation of an in vitro clinical test under this subsection is deemed to be withdrawn1 and such in vitro clinical test shall no longer be eligible for designation under this section1 if an application for approval for such test under section #ehg;,b or #ehg;,d is denied4 ,such test shall be eligible for breakthrough designation upon a new request for such designation4 7,b7 ,exception ,the ,secretary may not withdraw a designation granted under this subsection based on the subsequent approval or technology certification of another in vitro clinical test that-- 7i7 is designated under this section2 or 7ii7 was given priority review under section #eae;,b4 7e7 ,actions ,for purposes of expediting the development and review of in vitro clinical tests under this section1 the ,secretary may take the actions and additional actions set forth in paragraphs 7#a7 and 7#b71 respectively1 of section #eae;,b7e7 when reviewing such tests4 ,any reference or authorization in section #eae;,b7e7 with respect to a device shall be deemed a reference or authorization with respect to an in vitro clinical test for purposes of this section4 7f7 ,guidance ,not later than #cj months after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall issue final guidance on the implementation of this section4 ,such guidance shall-- 7#a7 set forth the process by which a person may seek a designation under subsection 7d72 7#b7 provide a template for request under subsection 7d72 7#c7 identify the criteria the ,secretary will use in evaluating a request for designation2 and 7#d7 identify the criteria and processes the ,secretary will use to assign a team of staff1 including team leaders1 to review in vitro clinical tests designated for expedited development and priority review1 including any training required for such personnel to ensure effective and efficient review4 7g7 ,rules of construction ,nothing in this section shall be construed to affect-- 7#a7 the criteria and standards for evaluating an application pursuant to section #ehg;,b or #ehg;,d1 including the recognition of valid scientific evidence as described in section #ehg7bj7 and consideration and application of the least burdensome means described under section #ehg;,,aa7c72 7#b7 the authority of the ,secretary with respect to clinical holds under section #ehg,s2 7#c7 the authority of the ,secretary to act on an application pursuant to section #ehg;,b before completion of an establishment inspection1 as the ,secretary determines appropriate2 or 7#d7 the authority of the ,secretary with respect to postmarket surveillance under section #ehg,x4 #ehg;,j4 ,registration and listing 7a7 ,registration requirement 7#a7 ,in general ,each person described in subsection 7b77#a7 shall-- 7,a7 during the period beginning on ,october #a and ending on ,december #ca of each year1 register with the ,secretary the name of such person1 places of business of such person1 all establishments engaged in the activities specified under this paragraph1 the establishment registration number of each such establishment1 and a point of contact for each such establishment1 including an electronic point of contact2 and 7,b7 submit an initial registration containing the information required under subparagraph 7,a7-- 7i7 in accordance with the timelines for submission under subsection 7c71 if the establishment is engaged in any activity described in subsection 7b77#a7 on the effective date of this section1 unless the ,secretary establishes by guidance a date later than such date for all or a category of such establishments2 or 7ii7 not later than #cj days prior to engaging in any activity described in subsection 7b77#a71 if the establishment is not engaged in any activity described in this paragraph on the effective date of this section4 7#b7 ,registration numbers ,the ,secretary may assign a registration number to any person or an establishment registration number to any establishment registered in accordance with this section4 ,registration information shall be made publicly available by publication on the website maintained by the ,food and ,drug ,administration1 in accordance with subsection 7d74 7#c7 ,inspection ,each person or establishment that is required to be registered with the ,secretary under this section shall be subject to inspection pursuant to section #gjd4 7b7 ,listing ,information for ,in ,vitro ,clinical ,tests 7#a7 ,in general ,each person who-- 7,a7 is a developer2 and 7,b7 introduces or proposes to begin the introduction or delivery for introduction into interstate commerce through an exemption under subsection 7a77#a71 7a77#b71 7a77#c71 or 7g7 of section #ehg;,c or section #ehg;,g or through the filing of an application under section #ehg;,b or section #ehg;,d1 shall submit a listing to the ,secretary containing the information described in paragraph 7#b71 or 7#d71 as applicable1 in accordance with the applicable schedule described under subsection 7c74 ,such listing shall be prepared in such form and manner as the ,secretary may specify in guidance4 ,listing information shall be submitted through the comprehensive test information system in accordance with section #ehg,t1 as appropriate4 7#b7 ,submissions ,each developer submitting a listing under paragraph 7#a7 shall electronically submit to the comprehensive test information system described in section #ehg,t the following information1 as applicable1 for each in vitro clinical test for which such person is a developer in the form and manner prescribed by the ,secretary1 taking into account the least burdensome requirements under section #ehg;,,aa7c73 7,a7 ,name of the establishment and its establishment registration number4 7,b7 ,contact information for the official correspondent for the listing4 7,c7 ,name 7common name and trade name1 if applicable7 of the in vitro clinical test and its test listing number 7when available74 7,d7 ,the certificate number for any laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that meets the requirements to perform high-complexity testing and that is the developer of the in vitro clinical test1 and the certificate number under such section for any laboratory that is performing the test1 is within the same corporate organization1 and has common ownership by the same parent corporation4 7,e7 ,whether the in vitro clinical test is1 as applicable1 offered as a test approved under section #ehg;,b1 offered under a granted technology certification order1 or offered as an exempt in vitro clinical test under section #ehg;,c or #ehg;,g4 7,f7 ,indications for use information under section #ehg7aj74 7,g7 ,a brief summary of the analytical and clinical performance of the in vitro clinical test1 and as applicable1 the lot release criteria4 7,h7 ,a brief description of conformance with any applicable mitigating measures1 restrictions1 and standards4 7,i7 ,representative labeling for the in vitro clinical test1 as appropriate4 7#c7 ,test listing number ,the ,secretary may assign a test listing number to each in vitro clinical test that is the subject of a listing under this section4 ,the process for assigning test listing numbers may be established through guidance1 and may include the recognition of standards1 formats1 or conventions developed by a third-party organization4 7#d7 ,grandfathered tests ,a developer offering a test that is a grandfathered in vitro clinical test under section #ehg;,g7a7 shall submit listing information required under subparagraphs 7,a7 through 7,f7 of paragraph 7#b71 and may submit a statement of the performance specifications for such in vitro clinical tests4 7#e7 ,exempt tests ,a developer of an in vitro clinical test who introduces or proposes to begin the introduction or delivery for introduction into interstate commerce that is otherwise exempt from the requirement to submit listing information pursuant to an exemption under section #ehg;,c may submit listing information under this subsection4 7c7 ,timelines for submission of listing information 7#a7 ,in general ,the timelines for submission of registration and listing under subsections 7a7 and 7b7 are as follows3 7,a7 ,for an in vitro clinical test that was listed as a device under section #eaj7;j7 prior to the effective date of this section1 a person shall maintain a device listing under section #eaj until such time as the system for submitting the listing information required under subsection 7b7 becomes available and thereafter shall submit the listing information not later than the later of #a year after the system for submitting the listing under this section becomes available or the effective date of this section4 7,b7 ,for an in vitro clinical test that is subject to grandfathering under section #ehg;,g7a7 a person shall submit the listing information required under subsection 7b77#d7 within #aj calendar days of offering the test after the effective date of this section4 7,c7 ,for an in vitro clinical test that is not described in subparagraph 7,a7 or 7,b71 a person shall submit the required listing information as follows3 7i7 ,for an in vitro clinical test that is not exempt from premarket approval under section #ehg;,b1 a person shall submit the required listing information1 prior to offering the in vitro clinical test and not later than #cj business days after the date of approval of the premarket approval application4 7ii7 ,for an in vitro clinical test that is exempt from premarket review under section #ehg;,c1 the required listing information shall be submitted prior to offering the in vitro clinical test4 7#b7 ,updates 7,a7 ,updates after changes ,each developer required to submit listing information under this section shall update such information within #aj business days of any change that causes any previously listed information to be inaccurate or incomplete4 7,b7 ,annual updates ,each developer required to submit listing information under this section shall update its information annually during the period beginning on ,october #a and ending on ,december #ca of each year4 7d7 ,public availability of listing information 7#a7 ,in general ,listing information submitted pursuant to this section shall be made publicly available on the website of the ,food and ,drug ,administration in accordance with paragraph 7#c74 7#b7 ,confidentiality ,listing information for an in vitro clinical test that is subject to premarket approval or technology certification shall remain confidential until such date as the in vitro clinical test receives the applicable premarket approval or the developer receives a technology certification order and for subsequent tests introduced under a technology certification order until their introduction4 7#c7 ,exceptions from public availability requirements ,the public listing requirements of this subsection shall not apply to any registration and listing information submitted under subsection 7a7 or 7b71 if the ,secretary determines that such information-- 7,a7 is a trade secret or confidential commercial or financial information2 or 7,b7 if posted1 could compromise national security4 7e7 ,submission of information by accredited persons ,if agreed upon by the developer1 the information required under this section may be submitted by a person accredited under section #ehg,q4 #ehg,k4 ,test design and quality requirements 7a7 ,applicability 7#a7 ,in general ,each developer shall establish and maintain quality requirements in accordance with the applicable requirements set forth in subsection 7b74 7#b7 ,certified laboratory requirements ,a developer shall establish and maintain quality requirement under subsection 7b77#b7 or 7b77#c71 as applicable1 if such developer is a clinical laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that-- 7,a7 is certified to perform high-complexity testing2 7,b7 develops an in vitro clinical test that is for use only-- 7i7 within the laboratory certified by the ,secretary under such section #cec in which such test was developed2 or 7ii7 within another laboratory certified by the ,secretary under such section #cec if such laboratory is-- 7,i7 within the same corporate organization and has common ownership by the same parent corporation as the laboratory in which the test was developed2 or 7,,ii7 within a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention1 if the test is developed by a public health laboratory or the ,centers for ,disease ,control and ,prevention2 and 7,c7 does not manufacture1 produce1 or distribute in vitro clinical tests other than laboratory test protocols4 7#c7 ,regulations ,the ,secretary shall promulgate quality system regulations implementing this section4 ,in promulgating such regulations under this section1 the ,secretary shall consider whether1 and to what extent1 international harmonization is appropriate4 7#d7 ,quality systems for hybrid developers of both laboratory test protocols and other in vitro clinical tests ,an entity that develops both laboratory test protocols and other in vitro clinical tests shall comply with subsection 7b77#a7 for activities related to the development of any in vitro clinical test that is not a laboratory test protocol and with subsection 7b77#b7 or 7b77#c71 as applicable1 for activities related to the development of any laboratory test protocol4 7b7 ,quality requirements 7#a7 ,in general ,the quality requirements applicable under this section shall-- 7,a7 avoid duplication of regulations and guidance under section #cec of the ,public ,health ,service ,act1 such that laboratories would not be subject to conflicting regulatory obligations with respect to the same activity2 7,b7 not apply to laboratory operations2 and 7,c7 include1 as applicable1 subject to subparagraphs 7,a7 and 7,b7 and paragraphs 7#b7 and 7#c7-- 7i7 management responsibilities2 7ii7 quality audits2 7iii7 personnel2 7iv7 design controls2 7v7 document controls2 7vi7 purchasing controls2 7vii7 identification and traceability2 7viii7 production and process controls2 7ix7 acceptance activities2 7x7 nonconforming in vitro clinical tests2 7xi7 corrective and preventive action2 7xii7 labeling and packaging controls2 7xiii7 handling1 storage1 distribution1 and installation2 7xiv7 complaints and records2 7xv7 servicing2 and 7xvi7 statistical techniques4 7#b7 ,exception for laboratory test protocols ,developers that are developing test protocols for use as described in subsection 7a77#b77;,b77i7 are exempt from the requirements under paragraph 7#a77;,c7 except for the requirements described in clauses 7iv71 7ix71 7xi71 and 7xiv7 of such paragraph4 7#c7 ,quality requirements for certain laboratories distributing laboratory test protocols within organizations or public health networks ,quality requirements applicable to the developer who is distributing a laboratory test protocol as described in subsection 7a77#b77;,b77ii7 shall consist of the following3 7,a7 ,clauses 7iv71 7ix71 7xi71 7xiv71 7xii7 of paragraph 7#a77;,b74 7,b7 ,the requirement to maintain records of the laboratories to which the laboratory test protocol is distributed4 7c7 ,regulations ,in implementing quality requirements for test developers that participate in international audit programs under this section1 the ,secretary shall-- 7#a7 for purposes of facilitating international harmonization1 consider whether the developer participates in an international audit program in which the ,united ,states participates and recognizes compliance with1 or conformance to1 such standards recognized by the ,secretary2 and 7#b7 ensure a least burdensome approach described in section #ehg;,,aa7c7 by leveraging1 to the extent applicable1 the quality assurance requirements applicable to developers certified by the ,secretary under section #cec of the ,public ,health ,service ,act4 #ehg,l4 ,labeling requirements 7a7 ,in general ,an in vitro clinical test shall bear or be accompanied by labeling1 as applicable1 that meets the requirements set forth in subsections 7b7 and 7c71 unless such test is exempt under subsection 7d7 or 7e74 7b7 ,labels 7#a7 ,in general ,the label of an in vitro clinical test1 shall meet the requirements set forth in paragraph 7#b7 if there is an immediate container to which the label is applied4 7#b7 ,regulations ,the label of an in vitro clinical test shall state the name and place of business of its developer and meet the requirements set forth in regulations promulgated in accordance with this section4 7c7 ,labeling 7#a7 ,in general ,labeling of an in vitro clinical test1 including labeling in the form of a package insert1 website1 standalone laboratory reference document1 or other similar document shall include-- 7,a7 adequate directions for use and shall meet the requirements set forth in regulations promulgated under this section1 except as provided in subsection 7d7 or 7e72 and 7,b7 the information described in paragraph 7#b71 as applicable4 7#b7 ,content ,labeling of an in vitro clinical test shall include-- 7,a7 the test listing number that was provided to the developer at the time of listing2 7,b7 information to facilitate reporting an adverse event2 7,c7 information regarding accessing the performance summary data displayed in the listing database for the test2 7,d7 the indications for use of the in vitro clinical test2 and 7,e7 any warnings1 contraindications1 or limitations4 7#c7 ,public availability of information ,the ,secretary shall make all of the information described in paragraph 7#b7 with respect to each in vitro clinical test available to the public1 as applicable1 in accordance with section #ehg,t1 except to the extent that the ,secretary determines that such information-- 7,a7 is trade secret or confidential commercial or financial information2 or 7,b7 if posted1 could compromise national security4 7#d7 ,additional requirements ,labeling for an in vitro clinical test used for immunohematology testing shall meet the applicable requirements set forth in part #ffj of title #ba1 ,code of ,federal ,regulations 7or any successor regulations71 related to the labeling of blood grouping reagents1 reagent red blood cells1 and anti-human globulin4 7d7 ,exemptions and alternative requirements 7#a7 ,in general 7,a7 ,in general ,with respect to an in vitro clinical test that meets the criteria of subparagraph 7,b71 the state in one place regulations under section #hji4aj7;b7 of title #ba1 ,code of ,federal ,regulations 7or any successor regulations7 may be satisfied by the laboratory posting such information on its website or in multiple documents1 if such documents are maintained and accessible in one place4 7,b7 ,applicable tests ,an in vitro clinical test meets the criteria of this subparagraph if such test is-- 7i7 developed by a laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that meets the requirements to perform tests of high-complexity2 and 7ii7 performed in-- 7,i7 the same laboratory in which such test was developed2 or 7,,ii7 by another laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act that-- 7aa7 meets the requirements to perform tests of high complexity2 and 7bb7 is under common ownership and control as the laboratory that developed the test4 7#b7 ,test instrument labeling ,unless the instrument is the entire test system1 the labeling for an instrument is not required to bear the information indicated in paragraphs 7#c71 7#d71 7#e71 7#g71 7#h71 7#i71 7#aj71 7#aa71 7#ab71 and 7#ac7 of section #hji4aj7;b7 of title #ba1 ,code of ,federal ,regulations 7or any successor regulations74 7#c7 ,reagent labeling ,for purposes of compliance with subsection 7c77#a71 the labeling for a reagent intended for use as a replacement in an in vitro clinical test may be limited to that information necessary to identify the reagent adequately and to describe its proper use in the test4 7#d7 ,investigational use ,a shipment or other delivery of an in vitro clinical test for investigational use pursuant to section #ehg,s shall be exempt from the labeling requirements of subsections 7b7 and 7c77#a7 and from any standard promulgated through regulations1 except as required under section #cec of the ,public ,health ,service ,act or section #ehg,r of this ,act4 7#e7 ,general purpose laboratory reagents ,the labeling of general purpose laboratory reagents 7such as hydrochloric acid7 whose uses are generally known by persons trained in their use need not bear the directions for use required by subsection 7c77#a77;,a74 7#f7 ,over-the-counter test specimen receptacle labeling ,the labeling for over-the-counter test specimen receptacles for drugs of abuse testing shall bear the name and place of business of the developer included in the registration under section #ehg;,j and any information specified in applicable regulations promulgated under this section1 in language appropriate for the intended users4 7e7 ,tests in the strategic national stockpile 7#a7 ,in general ,the ,secretary may grant an exception or alternative to any provision listed in this section1 unless explicitly required by a statutory provision outside this subchapter1 for specified lots1 batches1 or other units of an in vitro clinical test1 if the ,secretary determines that compliance with such labeling requirement could adversely affect the availability of such products that are1 or will be1 included in the ,strategic ,national ,stockpile under section #cai;,f-#b of the ,public ,health ,service ,act4 7#b7 ,regulations ,the ,secretary may issue regulations amending section #hji4aa of title #ba1 ,code of ,federal ,regulations 7or any successor regulation7 to apply in full or in part to in vitro clinical tests and in vitro clinical test developers4 7f7 ,regulations ,the ,secretary shall issue regulations related to standardized1 general content and format for in vitro clinical test labeling pursuant to this subsection4 #ehg,m4 ,adverse event reporting 7a7 ,in general ,each in vitro clinical test developer shall establish and maintain a system for establishing and maintaining records of adverse events and reporting adverse events in accordance with this section4 7b7 ,submission of individual reports ,a developer shall submit an individual adverse event report not later than #e calendar days after the developer receives or becomes aware of an adverse event that reasonably suggests that an in vitro clinical test may-- 7#a7 have caused or contributed to a patient or user death2 or 7#b7 present an imminent threat to public health4 7c7 ,submission of quarterly reports ,as applicable1 a developer shall submit quarterly reports that include any in vitro clinical test errors and serious injuries that occurred during the applicable quarter4 ,such quarterly reports shall be submitted not later than the end of the quarter following the quarter in which the developer receives or becomes aware of such adverse events4 7d7 ,definitions ,for the purposes of this section-- 7#a7 the term in vitro clinical test error means a failure of an in vitro clinical test to meet its performance specifications1 or to otherwise perform as intended by the developer1 including an inaccurate result resulting from such failure2 and 7#b7 the term serious injury means-- 7,a7 a significant delay in a diagnosis that results in the absence1 delay1 or discontinuation of critical medical treatment or that irreversibly or seriously and negatively alters the course of a disease or condition2 or 7,b7 an injury that-- 7i7 is life threatening2 7ii7 results in permanent impairment of a body function or permanent damage to a body structure2 or 7iii7 necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure4 7e7 ,regulations ,the ,secretary shall promulgate regulations to implement this section4 #ehg,n4 ,corrections and removals 7a7 ,regulations ,the ,secretary shall promulgate regulations1 or amend existing regulations1 as appropriate1 to implement this section4 7b7 ,reports of corrections and removals 7#a7 ,in general ,each in vitro clinical test developer shall report to the ,secretary any correction or removal of an in vitro clinical test undertaken by such developer if the correction or removal was undertaken-- 7,a7 to reduce the risk to health posed by the in vitro clinical test2 or 7,b7 to remedy a violation of this ,act caused by the in vitro clinical test which may present a risk to health4 7#b7 ,exception for in vitro clinical tests offered under a technology certification order ,for any eligible test offered under a technology certification order under section #ehg;,d1 a correction and removal report for any correction or removal of an in vitro clinical test should demonstrate that the issue or issues causing the correction or removal do not adversely impact the ability of other in vitro clinical tests offered under the same technology certification order to meet the applicable standard4 7c7 ,timing ,a developer shall submit any report required under this subsection to the ,secretary within #ae business days of initiating such correction or removal4 7d7 ,recordkeeping ,a developer of an in vitro clinical test that undertakes a correction or removal of an in vitro clinical test which is not required to be reported under this subsection shall keep a record of such correction or removal4 7e7 ,recall communications ,upon the reporting of a correction or removal by the developer-- 7#a7 the ,secretary shall classify such correction or removal under this section within #de calendar days2 and 7#b7 not later than #gj calendar days after the developer or other responsible party notifies the ,secretary that it has completed a recall action1 the ,secretary shall provide the developer or other responsible party with a written statement closing the recall action or stating the reasons the ,secretary cannot close the recall at that time4 #ehg,o4 ,restricted in vitro clinical tests 7a7 ,applicability 7#a7 ,in general ,for the types of in vitro clinical tests described in paragraph 7#c71 the ,secretary may require1 in issuing an approval of an in vitro clinical test under section #ehg;,b1 granting a technology certification order under section #ehg;,d1 or in issuing a determination under section #ehg;,f7a71 or by issuing a regulation1 that such test1 or category of tests1 be restricted to sale1 distribution1 or use upon such conditions as the ,secretary may prescribe under paragraph 7#b74 7#b7 ,conditions ,the ,secretary may prescribe conditions under this section1 based on available evidence1 with respect to an in vitro clinical test described in paragraph 7#c71 that are determined to be needed due to the potential for harmful effect of such test 7including any resulting absence1 significant delay1 or discontinuation of appropriate medical treatment71 and are necessary to ensure that the test meets the applicable standard4 7#c7 ,in vitro clinical tests subject to restrictions ,the restrictions or conditions authorized under this section may be applied by the ,secretary to any high-risk or moderate-risk in vitro clinical test1 prescription home-use in vitro clinical test1 direct-to-consumer in vitro clinical test1 or over-the-counter in vitro clinical test4 7b7 ,labeling and advertising of a restricted in vitro clinical test ,the labeling and advertising of an in vitro clinical test to which restrictions apply under subsection 7a7 shall bear such appropriate statements of the restrictions as the ,secretary may prescribe in an approval under section #ehg;,b1 an order under section #ehg;,d1 a determination under section #ehg;,f7a71 or in regulation1 as applicable4 7c7 ,device restrictions ,an in vitro clinical test that was offered as a restricted device prior to the date of enactment of this subchapter-- 7#a7 shall continue to comply with the applicable restrictions under section #eae or section #ebj7;e7 until this subchapter takes effect2 and 7#b7 except for in vitro clinical tests required to meet the requirements of section #hji4cj of title #ba1 ,code of ,federal ,regulations prior to the effective date of this subchapter specified in section #e7;a77#a77;,a7 of the ,,valid ,act of #bjbc1 such restrictions described in paragraph 7#a7 shall be deemed to be restrictions under this subchapter as of such effective date4 #ehg,p4 ,appeals 7a7 ,significant decision 7#a7 ,in general ,the ,secretary shall-- 7,a7 maintain a substantive summary of the scientific and regulatory rationale for any significant decision of the ,food and ,drug ,administration pursuant to section #ehg;,f1 regarding-- 7i7 the submission of an application for1 or a review of1 an in vitro clinical test under section #ehg;,b or section #ehg;,d2 7ii7 an exemption under section #ehg;,c2 or 7iii7 any requirements for mitigation measures to an in vitro clinical test or category of in vitro clinical tests2 and 7,b7 include in such summaries documentation of significant controversies or differences of opinion and the resolution of such controversies or differences of opinion4 7#b7 ,provision of documentation ,upon request1 the ,secretary shall furnish a substantive summary described in paragraph 7#a7 to the person who has made1 or is seeking to make1 a submission described in such paragraph4 7#c7 ,application of least burdensome requirements ,the substantive summary required under this subsection shall include a brief statement regarding how the least burdensome requirements were considered and applied consistent with section #ehg;,,aa7c71 as applicable4 7b7 ,review of significant decisions 7#a7 ,request for supervisory review of significant decision ,a developer may request a supervisory review of the significant decision described in subsection 7a77#a74 ,such review may be conducted at the next supervisory level or higher above the agency official who made the significant decision4 7#b7 ,submission of request ,a developer requesting a supervisory review under paragraph 7#a7 shall submit such request to the ,secretary not later than #cj days after the decision for which the review is requested and shall indicate in the request whether such developer seeks an in-person meeting or a teleconference review4 7#c7 ,timeframe ,the ,secretary shall schedule an in-person or teleconference review1 if so requested1 not later than #cj days after such request is made4 ,the ,secretary shall issue a decision to the developer requesting a review under this subsection not later than #de days after the request is made under paragraph 7#a71 or1 in the case of a developer who requests an in-person meeting or teleconference1 #cj days after such meeting or teleconference4 7c7 ,advisory panels ,the process established under subsection 7a7 shall permit the appellant to request review by an advisory committee established under section #ehg;,g when there is a dispute involving substantial scientific fact4 ,if an advisory panel meeting is held1 the ,secretary shall make a determination under this subsection not later than #de days after the requested advisory committee meeting has concluded4 7d7 ,least burdensome review ,any developer who has submitted an application under section #ehg;,b or #ehg;,d may request a supervisory review of a request for additional information during an evaluation of such submission within #fj calendar days of receipt of the additional information request from the ,secretary4 7e7 ,availability of all remedies ,the procedures set forth in this section shall be in addition to1 and not in lieu of1 other remedies available to the developer4 #ehg,q4 ,accredited persons 7a7 ,in general 7#a7 ,authorization ,beginning on the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall accredit persons for any of the following purposes3 7,a7 ,reviewing applications for premarket approval under section #ehg;,b and making findings with respect to such applications4 7,b7 ,reviewing applications for technology certification under section #ehg;,d and making recommendations to the ,secretary with respect to such applications4 7,c7 ,conducting inspections as specified in subsection 7c7 of in vitro clinical test developers and other persons required to register pursuant to section #ehg;,j4 7#b7 ,persons submitting applications ,a person submitting an application for premarket approval under section #ehg;,b or an application for technology certification under section #ehg;,d may submit such application to the ,secretary or to a person accredited pursuant to subparagraph 7,a7 or 7,b7 of paragraph 7#a74 7b7 ,accredited persons application reviews1 findings1 and recommendations 7#a7 ,requirements for premarket application 7,a7 ,review1 finding1 and recommendation requirements ,an accredited person receiving an application for premarket approval under section #ehg;,b shall either-- 7i7 provide to the ,secretary1 together with the application for premarket approval submitted by the applicant1 a recommendation based on a finding that the criteria for approval of the application under section #ehg;,b7e77#b77;,a7 are met and issue a copy of such finding to the applicant1 which finding shall plainly state-- 7,i7 the basis for the accredited person's finding that the criteria under section #ehg;,b7e77#b77;,a7 are met2 and 7,,ii7 any proposed restrictions1 mitigating measures1 or conditions of approval under section #ehg;,b7e77#b77;,b71 as applicable2 or 7ii7 provide a notification to the applicant that the accredited person cannot find that the criteria for approval of the application under section #ehg;,b7e77#b77;,a7 are met and the reasons for such decision4 7,b7 ,requesting missing or clarifying information ,after receipt of an application from an accredited person under this section1 the ,secretary may request missing or clarifying information from the applicant concerning the application1 which the accredited person shall promptly provide4 7,c7 ,secretary action on recommendation that approval criteria are met ,if the accredited person transmits a recommendation to the ,secretary under subparagraph 7,a77i71 then prior to the date that is #de calendar days after the transmittal date1 the ,secretary shall consider such recommendation and make a determination to-- 7i7 approve the application for premarket approval under section #ehg;,b7e77#b7 with appropriate restrictions1 mitigating measures1 or conditions of approval1 as applicable2 or 7ii7 deny approval of the application by issuing a written notice that reflects appropriate management input and concurrence to the accredited person and the applicant detailing the scientific basis for the ,secretary's determination that the criteria for issuance of an approval under section #ehg;,b7e77#b77;,a7 have not been met4 7,d7 ,effect of inaction on recommendation ,if the ,secretary fails to take an action under subparagraph 7,c7 the ,secretary shall-- 7i7 within #de calendar days after the transmittal date1 provide written feedback to the applicant that-- 7,i7 includes all outstanding issues with the application preventing the ,secretary from taking an action under subparagraph 7,b72 7,,ii7 reflects appropriate management input and concurrence2 and 7,,iii7 includes action items for the ,secretary1 the applicant1 or both1 as appropriate1 with an estimated date of completion for the ,secretary and the applicant to complete their respective tasks1 as applicable2 and 7ii7 promptly schedule a meeting or teleconference to discuss the feedback provided under clause 7i71 unless the ,secretary and applicant agree that the outstanding issues are adequately presented through written correspondence and a meeting or teleconference is not necessary4 7#b7 ,requirements for technology certification 7,a7 ,review and recommendation requirements ,an accredited person receiving an application for technology certification under section #ehg;,d shall either-- 7i7 provide to the ,secretary1 together with the application for technology certification submitted by the applicant1 a recommendation that the criteria for issuance of a technology certification order under section #ehg;,d7d77#c7 are met and issue a copy of such recommendation to the applicant1 which recommendation shall plainly state the basis for the accredited person's recommendation that the criteria under section #ehg;,d7d77#c7 are met2 or 7ii7 provide a notification to the applicant that the accredited person cannot recommend that the criteria for issuance of a technology certification order under section #ehg;,d7d77#c7 are met and the reasons for such decision4 7,b7 ,requesting missing or clarifying information ,after receipt of an application under this section1 the accredited person may request missing or clarifying information from the applicant concerning the application1 which the applicant shall promptly provide4 7,c7 ,secretary action on recommendation for issuance of a technology certification order ,if the accredited person transmits a recommendation to the ,secretary under clause 7i7 of subparagraph 7,a71 then prior to the date that is #fj calendar days after the transmittal date the ,secretary shall-- 7i7 issue the technology certification order under section #ehg;,d7d77#c71 consistent with such recommendation from the accredited person2 or 7ii7 deny approval of the application by issuing a written notice to the accredited person and the applicant detailing the scientific basis for a determination by the ,secretary that the criteria for issuance of a technology certification order under section #ehg;,d7d77#c7 have not been met4 7c7 ,requirements for inspections 7#a7 ,in general ,when conducting inspection1 persons accredited under subsection 7a77#a77;,c7 shall record in writing their specific observations and shall present their observations to the designated representative of the inspected establishment4 7#b7 ,inspection report requirements ,each person accredited under subsection 7a77#a77;,c7 shall prepare and submit to the ,secretary an inspection report in a form and manner designated by the ,secretary for conducting inspections4 ,any statement or representation made by an employee or agent of an establishment to a person accredited to conduct inspections under subsection 7a77#a77;,c7 shall be subject to section #ajja of title #ah1 ,united ,states ,code4 7#c7 ,savings clause ,nothing in this section affects the authority of the ,secretary to inspect any in vitro clinical test developer or other person registered under section #ehg;,j or recognize inspections conducted by auditing organizations as described under section #gjd7;g77#ae74 7#d7 ,inspection limitations ,the ,secretary shall ensure that inspections carried out under this section are not duplicative of inspections carried out under section #cec of the ,public ,health ,service ,act4 ,inspections under this section shall be limited to the data and information necessary-- 7,a7 for routine surveillance activities of facilities associated with an approved application under section #ehg;,b or issuance of a technology certification order under section #ehg;,d2 or 7,b7 to meet the requirements for premarket approval under section #ehg;,b or issuance of a technology certification order under section #ehg;,d1 as applicable4 7d7 ,accreditation 7#a7 ,accreditation program ,the ,secretary may provide for accreditation under this section through programs administered by the ,food and ,drug ,administration1 by other non-,federal government agencies1 or by qualified nongovernmental organizations4 ,a person may be accredited for the review of applications submitted under sections #ehg;,b as described in subsection 7a77#a77;,a71 for the review of applications submitted under section #ehg;,d as described in subsection 7a77#a77;,b71 and to conduct inspection activities under subsection 7a77#a77;,c71 or for a subset of such reviews or activities4 7#b7 ,eligible persons 7,a7 ,minimum qualifications ,an accredited person1 at a minimum1 shall-- 7i7 not be an employee of the ,federal ,government2 7ii7 not engage in the activities of a developer1 as defined in section #ehg7g72 7iii7 not be a person required to register under section #ehg;,j1 unless such person has established sufficient processes and protocols to separate activities to develop in vitro clinical tests and the activities for which such person would be accredited under subsection 7a7 and discloses applicable information under this section2 7iv7 not be owned or controlled by1 and shall have no organizational1 material1 or financial affiliation with1 an in vitro clinical test developer or other person required to register under section #ehg;,j2 7v7 be a legally constituted entity permitted to conduct the activities for which it seeks accreditation2 7vi7 ensure that the operations of such person are in accordance with generally accepted professional and ethical business practices2 and 7vii7 include in its request for accreditation a commitment to1 at the time of accreditation and at any time it is performing activities pursuant to this section-- 7,i7 certify that the information reported to the ,secretary accurately reflects the data or protocol reviewed1 and the documented inspection findings1 as applicable2 7,,ii7 limit work to that for which competence and capacity are available2 7,,iii7 treat information received or learned1 records1 reports1 and recommendations as proprietary information of the person submitting such information2 and 7,,iv7 in conducting the activities for which the person is accredited in respect to a particular in vitro clinical test1 protect against the use of any employee or consultant who has a financial conflict of interest regarding that in vitro clinical test4 7,b7 ,waiver ,the ,secretary may waive any requirements in clause 7i71 7ii71 7iii71 or 7iv7 of subparagraph 7,a7 upon making a determination that such person has implemented other appropriate controls sufficient to ensure a competent and impartial review4 7#c7 ,accreditation process 7,a7 ,accreditation process guidance and regulations ,not later than #ahj days after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall issue draft guidance specifying the process for submitting a request for accreditation and reaccreditation under this section1 including the form and content of information to be submitted1 including the criteria that the ,secretary will consider to accredit or deny accreditation and1 not later than #a year after the close of the comment period for the draft guidance1 issue final guidance4 7,b7 ,response to request ,the ,secretary shall respond to a request for accreditation or reaccreditation within #fj calendar days of the receipt of the request4 ,the ,secretary's response may be to accredit or reaccredit the person1 to deny accreditation1 or to request additional information in support of the request4 ,if the ,secretary requests additional information1 the ,secretary shall respond within #fj calendar days of receipt of such additional information to accredit or deny the accreditation4 7,c7 ,type of accreditation ,the accreditation or reaccreditation of a person shall specify the particular activity or activities under subsection 7a7 for which such person is accredited1 and shall include any limitation to certain eligible in vitro clinical tests4 7,d7 ,public list ,the ,secretary shall publish on the website of the ,food and ,drug ,administration a list of persons who are accredited under this section4 ,such list shall be updated on at least a monthly basis4 ,the list shall specify the particular activity or activities under this section for which the person is accredited4 7,e7 ,audit ,the ,secretary may audit the performance of persons accredited under this section for purposes of ensuring that such persons continue to meet the published criteria for accreditation1 and may modify the scope or particular activities for which a person is accredited if the ,secretary determines that such person fails to meet one or more criteria for accreditation4 7,f7 ,suspension or withdrawal ,the ,secretary may suspend or withdraw accreditation of any person accredited under this section1 after providing notice and an opportunity for an informal hearing1 when such person is substantially not in compliance with the requirements of this section or the published criteria for accreditation1 or poses a threat to public health1 or fails to act in a manner that is consistent with the purposes of this section4 7,g7 ,reaccreditation ,accredited persons may be initially accredited for up to #c years4 ,after expiration of such initial period1 persons may be reaccredited for unlimited additional #e-year periods1 as determined by the ,secretary4 7e7 ,compensation of accredited persons ,compensation of an accredited person shall be determined by agreement between the accredited person and the person who engages the services of the accredited person1 and shall be paid by the person who engages such services4 7f7 ,international harmonization ,notwithstanding any other provision of this section1 to facilitate international harmonization the ,secretary may recognize persons accredited or recognized by governments1 who have also entered into information sharing agreements1 including confidentiality commitments1 with the ,commissioner of ,food and ,drugs4 7g7 ,information sharing agreements ,an accredited person may enter into an agreement with a test developer to provide information to the comprehensive test information system under section #ehg,t1 including any requirements under section #ehg;,j4 7h7 ,reports ,not later than #b years after the effective date of the ,,valid ,act of #bjbc1 and annually thereafter for the next #d years1 the ,secretary shall post on the website of the ,food and ,drug ,administration1 a report describing the ,secretary's performance in implementing this section1 including the ,secretary's progress in minimizing duplicative reviews of applications for which an accredited person finds the criteria for approval are met4 ,such reports shall include1 for each period-- 7#a7 with regard to premarket approval applications-- 7,a7 the total number of findings transmitted to the ,secretary under subsection 7b77#a77;,a77i72 7,b7 the total number of determinations made by the ,secretary under subsection 7b77#a77;,b77i7 within #cj calendar days of the transmittal date to approve an application2 7,c7 the total number of determinations made by the ,secretary under subsection 7b77#a77;,b77ii7 within #cj calendar days of the transmittal date to deny approval of an application2 and 7,d7 the total number of applications that were approved and the total number of applications that were denied approval1 after the ,secretary failed to make a determination within #cj calendar days of the transmittal date under subsection 7b77#a77;,b72 and 7#b7 with regard to applications for technology certification-- 7,a7 the total number of recommendations transmitted to the ,secretary under subsection 7b77#b77;,a77i72 7,b7 the total number of determinations made by the ,secretary under subsection 7b77#b77;,b77i7 to issue a technology certification order1 including determinations made within #cj days of the transmittal date2 7,c7 the total number of determinations made by the ,secretary under subsection 7b77#b77;,b77ii7 to deny the application for technology certification1 including determinations made within #cj calendar days of the transmittal date2 and 7,d7 the total number of technology certification orders issued1 and the total number of applications for technology certification that were denied1 including applications denied after the ,secretary failed to make a determination within #cj calendar days of the transmittal date under subsection 7b77#b77;,b74 #ehg,r4 ,recognized standards 7a7 ,in general ,the ,secretary may recognize all or part of appropriate standards established by nationally or internationally recognized standards development organizations for which a person may submit a declaration of conformity in order to meet a requirement under this subchapter to which that standard is applicable4 ,standards for in vitro diagnostic devices previously recognized under section #ead7;c7 shall be considered recognized standards under this section4 ,recognized and proposed standards shall be accessible to the public at no charge4 ,the application of any such consensus standard shall only apply prospectively4 ,the ,secretary shall issue regulations establishing the criteria and process1 for such recognition and adoption4 7b7 ,amendment process ,the procedures established in this section or in regulation or guidance issued under this section shall apply to amendment of an existing standard4 #ehg,s4 ,investigational use 7a7 ,in general ,subject to the conditions prescribed in subsections 7c71 7d71 7e71 7f71 and 7g71 an in vitro clinical test for investigational use shall be exempt from the requirements of this subchapter1 other than sections #ehg;,a1 #ehg,p1 #ehg,t1 and #ehg,v4 ,the ,secretary may amend parts #ej1 #ed1 and #ef of title #ba of the ,code of ,federal ,regulations to apply to in vitro clinical tests to permit the investigational use of such tests by experts qualified by scientific training and experience4 7b7 ,regulations 7#a7 ,in general ,not later than #c years after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall promulgate regulations to implement this section4 7#b7 ,variation ,the requirements in the regulations promulgated under this section shall take into account variations based on-- 7,a7 the scope and duration of clinical testing to be conducted under investigation that is the subject of such application2 7,b7 the number of human subjects that are to be involved in such testing2 7,c7 the need to permit changes to be made to the in vitro clinical test involved during testing conducted in accordance with a plan required under subsection 7c77#f72 or 7,d7 whether the clinical testing of such in vitro clinical test is for the purpose of developing data to obtain approval to offer such test4 7c7 ,application for investigational use ,the following shall apply with respect to in vitro clinical tests for investigational use3 7#a7 ,significant risk and other studies ,in the case of an in vitro clinical test the investigational use of which poses a significant risk to the human subject or involves an exception from informed consent for emergency research1 a sponsor of an investigation of such a test seeking an investigational use exemption shall submit to the ,secretary an investigational use application with respect to the in vitro clinical test in accordance with paragraphs 7#c7 and 7#d74 7#b7 ,non-significant risk studies ,in the case of an in vitro clinical test1 the investigational use of which is not described in paragraph 7#a7-- 7,a7 the sponsor of such investigation shall-- 7i7 ensure such investigation is conducted in compliance with an investigational plan approved by an institutional review committee and the labeling of the in vitro clinical test involved clearly and conspicuously states1 ,for investigational use only1 as specified in paragraph 7#d77;,a77ii72 7ii7 ensure each investigator obtains informed consent as required under part #ej1 #ed1 and #ef of title #ba1 ,code of ,federal ,regulations 7or any successor regulations71 subject to the exceptions set forth in paragraph 7#f77;,c72 7iii7 establish and maintain records with respect to all requirements in this subparagraph2 7iv7 maintain records and make reports as required by the ,secretary pursuant to regulations issued under subsection 7b72 and 7v7 ensure that investigators monitor investigations1 maintain records and make reports as required by the ,secretary pursuant to regulations issued under subsection 7b72 and 7,b7 the sponsor may rely on any exception or exemption described in paragraph 7#d7 or as established by the ,secretary in regulations issued under subsection 7b74 7#c7 ,application ,an investigational use application shall be submitted in such time and manner and contain such information as the ,secretary may require in regulation1 and shall include an investigational plan for proposed clinical testing and assurances that the sponsor submitting the application will-- 7,a7 establish and maintain records relevant to the investigation of such in vitro clinical test2 and 7,b7 submit to the ,secretary annual reports of data obtained as a result of the investigational use of the in vitro clinical test during the period covered by the exemption that the ,secretary reasonably determines will enable the ,secretary-- 7i7 to ensure compliance with the conditions for the exemption specified in paragraph 7#d72 7ii7 to review the progress of the investigation involved2 and 7iii7 to evaluate the ability to meet the applicable standard4 7#d7 ,conditions for exemption ,an application for an investigational use exemption with respect to a significant risk study shall be granted if each of the following conditions is met3 7,a7 ,the risks to the subjects of the in vitro clinical test are outweighed by the anticipated benefits of the test to the subjects and the importance of the knowledge to be gained1 and adequate assurance of informed consent is provided in accordance with paragraphs 7#f77;,b7 and 7#f77;,c74 7,b7 ,the proposed labeling for the in vitro clinical test involved clearly and conspicuously states ,for investigational use only4 7,c7 ,such other requirements the ,secretary determines-- 7i7 are necessary for the protection of the public health and safety2 and 7ii7 do not unduly delay investigation4 7#e7 ,coordination with investigational new drug applications ,any requirement for the submission of a report to the ,secretary pursuant to an application for an investigational new drug exemption involving an in vitro clinical test shall supersede the reporting requirement under paragraph 7#c77;,b71 but only to the extent the requirement with respect to the application for exemption with respect to the drug is duplicative of the reporting requirement under such paragraph4 7#f7 ,investigational plan1 procedures1 and conditions ,with respect to an investigational plan submitted under paragraph 7#c71 the sponsor submitting such plan shall-- 7,a7 promptly notify the ,secretary of the approval or the suspension or termination of the approval of such plan by an institutional review committee2 7,b7 in the case of an in vitro clinical test made available to investigators for clinical testing1 obtain agreements from each investigator that any testing of the in vitro clinical test involving human subjects will be under such investigator's supervision and in accordance with paragraph 7,c7 and submit such agreements to the ,secretary that ensure-- 7i7 all investigators will comply with this section1 regulations promulgated or revised under this section1 and applicable human subjects regulations2 and 7ii7 the investigator will ensure that-- 7,i7 informed consent is obtained as required under part #ej of title #ba1 ,code of ,federal ,regulations 7or any successor regulations71 amended to apply to in vitro clinical tests2 and 7,,ii7 the requirements for institutional review board under part #ef of title #ba of the ,code of ,federal ,regulations 7or successor regulations71 amended to apply to in vitro clinical tests1 are met2 and 7,c7 ensure that informed consent will be obtained from each human subject 7or the representative of such subject7 of proposed clinical testing involving such in vitro clinical test1 except where1 subject to such other conditions as the ,secretary may prescribe-- 7i7 the proposed clinical testing poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights1 safety1 and welfare of the human subject2 or 7ii7 the investigator conducting or supervising the clinical testing determines in writing that there exists a life-threatening situation involving the human subject of such testing which necessitates the use of such in vitro clinical test and it is not feasible to obtain informed consent from the subject and there is not sufficient time to obtain such consent from a representative of such subject4 7#g7 ,concurred by licensed physician ,the determination required by paragraph 7#f77;,c77ii7 shall be concurred in writing by a licensed physician who is not involved in the testing of the human subject with respect to which such determination is made unless immediate use of the in vitro clinical test is required to save the life of the human subject of such testing and there is not sufficient time to obtain such concurrence4 7#h7 ,significant risk ,for purposes of this subsection1 the term significant risk means1 with respect to an in vitro clinical test1 that the use of such in vitro clinical test-- 7,a7 is of substantial importance in performing an activity or activities described in section #bja7ss77#a7 for1 a serious or life-threatening disease or condition without confirmation of the diagnosis by a medically established diagnostic product or procedure2 7,b7 requires an invasive sampling procedure that presents a significant risk to the human subject1 provided that routine venipuncture shall not be considered an invasive sampling procedure2 or 7,c7 otherwise presents a potential for serious risk to the health of a human subject4 7d7 ,review of applications 7#a7 ,in general ,the ,secretary may issue an order approving an investigation as proposed1 approving it with conditions or modifications1 or disapproving it4 7#b7 ,failure to act ,unless the ,secretary1 not later than #cj calendar days after the date of the submission of an application for an investigational use exemption that meets the requirements of subsection 7c71 issues an order under paragraph 7#a7 and notifies the sponsor submitting the application1 the application shall be treated as approved as of such date without further action by the ,secretary4 7#c7 ,denial ,the ,secretary may deny an investigational use application submitted under this subsection if the ,secretary determines that the investigation with respect to which the application is submitted does not conform to the requirements of subsection 7c74 ,a notification of such denial submitted to the sponsor with respect to such a request shall contain the order of disapproval and a complete statement of the reasons for the ,secretary's denial of the application4 7e7 ,withdrawal of exemption 7#a7 ,in general ,the ,secretary may1 by administrative order1 withdraw an exemption approved under this section with respect to an in vitro clinical test1 including an exemption treated as approved based on the ,secretary's failure to act pursuant to subsection 7d77#b71 if the ,secretary determines that an investigation conducted under such an exemption does not meet the applicable conditions under subsection 7c77#c7 for such exemption4 7#b7 ,opportunity to be heard 7,a7 ,in general ,subject to subparagraph 7,b71 an order withdrawing an investigational use exemption granted under this section may be issued only after the ,secretary provides the sponsor of the in vitro clinical test with an opportunity for an informal hearing4 7,b7 ,exception ,an order referred to in subparagraph 7,a7 with respect to an investigational use exemption granted under this section may be issued on a preliminary basis before the provision of an opportunity for an informal hearing if the ,secretary determines that the continuation of testing under the exemption will result in an unreasonable risk to the public health4 ,the ,secretary will provide an opportunity for an informal hearing promptly following any preliminary action under this subparagraph4 7f7 ,changes 7#a7 ,in general ,the regulations promulgated under subsection 7b7 shall provide1 with respect to an in vitro clinical test for which an exemption under this subsection is in effect1 procedures and conditions under which changes are allowed without the additional approval of an application for an exemption or submission of a supplement to such an application4 ,such regulations shall provide that such a change may be made if-- 7,a7 the sponsor determines1 on the basis of credible information 7as defined in regulations7 that the change meets the conditions specified in paragraph 7#b72 and 7,b7 the sponsor submits to the ,secretary1 not later than #e calendar days after making the change1 a notice of the change4 7#b7 ,conditions ,the conditions specified in this paragraph are that-- 7,a7 in the case of developmental changes to an in vitro clinical test1 including manufacturing changes1 the changes-- 7i7 do not constitute a significant change in design or in basic principles of operation2 7ii7 do not affect the rights1 safety1 or welfare of the human subjects involved in the investigation2 and 7iii7 are made in response to information gathered during the course of an investigation2 and 7,b7 in the case of changes to clinical protocols applicable to the test1 the changes do not affect-- 7i7 the validity of data or information resulting from the completion of an approved clinical protocol1 or the relationship of likely patient risk to benefit relied upon to approve a product2 7ii7 the scientific soundness of a plan submitted under subsection 7c77#c72 or 7iii7 the rights1 safety1 or welfare of the human subjects involved in the investigation4 7g7 ,clinical hold 7#a7 ,in general ,at any time1 the ,secretary may impose a clinical hold with respect to an investigation of an in vitro clinical test if the ,secretary makes a written determination described in paragraph 7#b74 ,the ,secretary shall1 in imposing such clinical hold1 specify the basis for the clinical hold1 including the specific information available to the ,secretary which served as the basis for such clinical hold1 and confirm such determination in writing4 ,the applicant may immediately appeal any such determination pursuant to section #ehg,p4 7#b7 ,determination 7,a7 ,in general ,for purposes of paragraph 7#a71 a determination described in this subparagraph with respect to a clinical hold is a determination that1 based on credible evidence1 the in vitro clinical test involved represents an unreasonable risk to the safety of the persons who are the subjects of the clinical investigation1 taking into account the qualifications of the clinical investigators1 information about the in vitro clinical test1 the design of the clinical investigation1 the condition for which the in vitro clinical test is to be investigated1 and the health status of the subjects involved4 7,b7 ,removal of clinical hold ,any written request to the ,secretary from the sponsor of an investigation that a clinical hold be removed shall receive a decision1 in writing and specifying the reasons therefor1 within #cj days after receipt of such request4 ,any such request shall include sufficient information to support the removal of such clinical hold4 #ehg,t4 ,comprehensive test information system 7a7 ,establishment ,not later than #b years after the date of enactment of the ,,valid ,act of #bjbc1 the ,secretary shall make available a comprehensive test information system for in vitro clinical tests that is designed to-- 7#a7 provide a transparent interface on the website of the ,food and ,drug ,administration for stakeholders1 to the extent permitted by applicable law1 which may include access to the-- 7,a7 regulatory pathway designation information for each in vitro clinical test or tests with the same indications for use2 7,b7 registration and listing information provided by developers under section #ehg;,j1 including the use of a link for labels2 7,c7 adverse event reports submitted under section #ehg,m1 as appropriate2 7,d7 reports of corrections and removals submitted under section #ehg,n2 and 7,e7 other information pertaining to an in vitro clinical test or tests with the same indications for use1 as the ,secretary determines appropriate2 and 7#b7 provide a secure portal for electronic submission1 including applications and other in vitro clinical test submissions1 registration and listing information1 and adverse event reports1 which provides protections from unauthorized disclosure of information1 including of-- 7,a7 trade secret or confidential commercial or financial information2 and 7,b7 information that could compromise national security4 7b7 ,submission function ,the comprehensive test information system shall serve as the electronic submission service for test developers submitting information for applications under sections #ehg;,b and #ehg;,d4 #ehg,u4 ,preemption 7a7 ,in general ,except as provided in subsection 7b71 no ,state1 ,tribal1 or local government 7or political subdivision thereof7 may establish or continue in effect any requirement-- 7#a7 that is different from1 or in addition to1 any requirement applicable to an in vitro clinical test under this ,act2 or 7#b7 with respect to the analytical validity1 clinical validity1 or safety for individuals who come into contact with such an in vitro clinical test4 7b7 ,exceptions ,subsection 7a7 shall not be construed to affect the authority of a ,state1 ,tribal1 or local government to do any of the following3 7#a7 ,to license laboratory personnel1 health care practitioners1 or health care facilities or to regulate any aspect of a health care practitioner-patient relationship4 7#b7 ,to enforce laws of general applicability1 such as zoning laws1 environmental laws1 labor laws1 and general business laws4 7#c7 ,to authorize laboratories to develop and perform an in vitro clinical test1 pursuant to a law enacted by a ,state prior to ,january #a1 #bjbb1 as long as such law does not impose requirements that are different from any requirement applicable to an in vitro clinical test under this ,act4 ,if a ,state has enacted such a law1 the ,secretary shall exempt such test for laboratories in that ,state from compliance with this subchapter4 7c7 ,clarification ,nothing in this section shall be construed to-- 7#a7 modify any action for damages or the liability of any person under the law of any ,state2 or 7#b7 shift liability to health care practitioners or other users4 #ehg,v4 ,adulteration ,an in vitro clinical test shall be deemed to be adulterated3 7#a7 ,if it consists in whole or in part of any filthy1 putrid1 or decomposed substance4 7#b7 ,if it has been developed1 prepared1 packed1 or held under insanitary conditions whereby it may have been contaminated with filth1 or whereby it may have been rendered injurious to health4 7#c7 ,if its container or package is composed1 in whole or in part1 of any poisonous or deleterious substance which may render the contents injurious to health4 7#d7 ,if it bears or contains1 for purposes of coloring only1 a color additive which is unsafe within the meaning of section #gba7;a74 7#e7 ,if its analytical or clinical validity1 as applicable1 or with respect to a specimen receptacle1 its safety1 falls below that which it purports or is represented to possess4 7#f7 ,if it is required to be1 declared to be1 purports to be1 or is represented as being1 in conformity with any performance standard established or recognized under section #ehg,r and is not in conformity with such standard4 7#g7 ,if it is required to be in compliance with mitigating measures established under section #ehg;,e and is not in conformity with such mitigating measures4 7#h7 ,if it fails to have in effect an approved premarket application under section #ehg;,b1 unless such in vitro clinical test is in compliance with the requirements for-- 7,a7 offering without an approved premarket application under section #ehg;,d7b77#a72 7,b7 an exemption from premarket approval under section #ehg;,c or #ehg;,g2 or 7,c7 investigational use pursuant to section #ehg,s4 7#i7 ,if it is not in conformity with any condition established under section #ehg;,b or #ehg;,d4 7#aj7 ,if it purports to be an in vitro clinical test subject to an exemption under section #ehg;,c and it fails to meet or maintain any criteria1 condition1 or requirement of such exemption4 7#aa7 ,if it has been granted an exemption under section #ehg,s for investigational use1 and the person granted such exemption or any investigator who uses such in vitro clinical test under such exemption fails to comply with a requirement prescribed by or under such section4 7#ab7 ,if it fails to meet the quality requirements prescribed in or established under section #ehg,k 7as applicable71 or the methods used in1 or facilities or controls used for1 its development1 packaging1 storage1 or installation are not in conformity with applicable requirements established under such section4 7#ac7 ,if it has been developed1 processed1 packaged1 or held in any establishment1 factory1 or warehouse and the owner1 operator or agent of such establishment1 factory1 or warehouse delays1 denies1 or limits an inspection1 or refuses to permit entry or inspection4 7#ad7 ,if it is not in compliance with any restriction required under section #ehg,o4 #ehg,w4 ,misbranding ,an in vitro clinical test shall be deemed to be misbranded3 7#a7 ,if its labeling is false or misleading in any particular4 7#b7 ,if in a package form unless it bears a label containing-- 7,a7 the name and place of business of the test developer1 packager1 or distributor2 and 7,b7 an accurate statement of the quantity of contents in terms of weight1 measure1 or numerical count1 unless an exemption is granted by the ,secretary by the issuance of guidance1 such as with respect to small packages4 7#c7 ,if any word1 statement1 or other information required by or under authority of this ,act to appear on the label or labeling1 including a test report1 is not prominently placed thereon with such conspicuousness 7as compared with other words1 statements1 designs1 or devices1 in the labeling7 and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use4 7#d7 ,unless its labeling bears adequate directions for use and such adequate warnings as are necessary for the protection of users of the in vitro clinical test and recipients of the results of such in vitro clinical test1 including patients1 consumers1 donors1 and related health care professionals4 ,required labeling for in vitro clinical tests intended for use in health care facilities1 blood establishments1 or by a health care professional may be made available solely by electronic means1 provided that the labeling complies with all applicable requirements of law1 and that the test developer1 or distributor affords such users the opportunity to request the labeling in paper form1 and after such request1 promptly provides the requested information without additional cost4 7#e7 ,if there is a reasonable probability that it could cause serious or adverse health consequences or death1 including through absence1 delay1 or discontinuation in diagnosis or treatment1 when used in the manner prescribed1 recommended1 or suggested in the labeling thereof4 7#f7 ,if it was developed1 sterilized1 packaged1 repackaged1 relabeled1 installed1 or imported in an establishment not duly registered under section #ehg;,j or it was not included in a listing under section #ehg;,j1 in accordance with timely reporting requirements under this subchapter4 7#g7 ,in the case of any in vitro clinical test subject to restrictions under section #ehg,o1 7#a7 if its advertising is false or misleading in any particular1 7#b7 if it is offered for clinical use1 sold1 distributed1 or used in violation of such restrictions1 or 7#c7 unless the test developer or distributor includes in all advertisements and other descriptive printed matter that such person issues or causes to be issued1 a brief statement of the indications for use of the in vitro clinical test and relevant warnings1 precautions1 side effects1 and contraindications4 ,this paragraph shall not be applicable to any printed matter that the ,secretary determines to be labeling as defined in section #bja7m74 7#h7 ,if it is subject to a mitigating measure established under section #ehg;,e and does not bear such labeling as may be prescribed in such mitigating measure4 7#i7 ,if it is subject to a standard established under section #ehg,r and it does not bear such labeling as may be prescribed in such standard4 7#aj7 ,unless it bears such labeling as may be required by or established under an applicable labeling requirement under this ,act4 7#aa7 ,if there was a failure to comply with any requirement prescribed in or under section #ehg;,d1 #ehg;,j1 #ehg,k1 #ehg,l1 #ehg,m1 #ehg,n1 #ehg,x1 #ehg,y1 #ehg,z1 or to provide any report1 material1 or other information required with respect to in vitro clinical tests under this subchapter4 #ehg,x4 ,postmarket surveillance 7a7 ,in general 7#a7 ,in general ,in addition to other applicable requirements under this ,act1 the ,secretary may issue an order requiring a developer of a high-risk or moderate-risk in vitro clinical test to conduct postmarket surveillance of such in vitro clinical test1 if the failure of the in vitro clinical test is reasonably likely to result in serious adverse health consequences or death from use of such in vitro clinical test4 7#b7 ,consideration ,in determining whether to require a developer to conduct postmarket surveillance of an in vitro clinical test1 the ,secretary shall take into consideration the benefits and risks for the patient and the least burdensome requirements under section #ehg;,,aa7c74 7b7 ,surveillance approval 7#a7 ,in general ,each developer required to conduct surveillance of an in vitro clinical test shall submit1 within #cj days of receiving an order from the ,secretary1 a plan for the required surveillance4 ,the ,secretary1 within #fj days of the receipt of such plan1 shall determine if the person designated to conduct the surveillance has the appropriate qualifications and experience to undertake such surveillance and if the plan will result in useful data that can reveal unforeseen adverse events or other information necessary to protect the health of patients or the public4 7#b7 ,timeline ,the developer shall commence surveillance under this section not later than #ae months after the day on which the ,secretary orders such postmarket surveillance1 unless the ,secretary determines more time is needed to commence surveillance4 7#c7 ,prospective surveillance ,the ,secretary may order a prospective surveillance period of up to #c years4 ,any determination by the ,secretary that a longer period is necessary shall be made by mutual agreement between the ,secretary and the developer or1 if no agreement can be reached1 upon the completion of a dispute resolution process pursuant to section #efb4 #ehg,y4 ,electronic format for submissions 7a7 ,in general ,all submissions to the ,food and ,drug ,administration with respect to an in vitro clinical test1 unless otherwise agreed to by the ,secretary1 shall-- 7#a7 be made electronically2 and 7#b7 with respect to the information required under sections #ehg;,b and #ehg;,d1 utilize the system described in section #ehg,t4 7b7 ,electronic format ,beginning on such date as the ,secretary specifies in final guidance issued under subsection 7c71 submissions for in vitro clinical tests1 including recommendations submitted by accredited and recognized persons under section #ehg,q1 and any appeals of action taken by the ,secretary with respect to such submissions1 shall be submitted in such electronic format as specified by the ,secretary in such guidance4 7c7 ,guidance ,the ,secretary shall issue guidance implementing this section4 ,such guidance may-- 7#a7 provide standards for the electronic submission required under subsection 7a7 or the submission in electronic format required under subsection 7b72 7#b7 set forth criteria for waivers of1 or exemptions from1 the requirements of subsection 7a7 or 7b72 and 7#c7 provide any other information for the efficient implementation and enforcement of this section4 #ehg,z4 ,postmarket remedies 7a7 ,safety ,notice 7#a7 ,in general ,if the ,secretary determines that an in vitro clinical test presents an unreasonable risk of substantial harm to the public health1 and notification under this subsection is necessary to eliminate the unreasonable risk of such harm and no more practicable means is available under the provisions of this ,act 7other than this section7 to eliminate the risk1 the ,secretary may issue such order as may be necessary to ensure that adequate safety notice is provided in an appropriate form1 by the persons and means best suited under the circumstances1 to all health care professionals who prescribe1 order1 or use the in vitro clinical test and to any other person 7including developers1 importers1 distributors1 retailers1 and users7 who should properly receive such notice4 7#b7 ,notice to individuals ,an order under this subsection shall require that the individuals subject to the risk with respect to which the order is to be issued be included in the persons to be notified of the risk unless the ,secretary determines that notice to such individuals would present a greater danger to the health of such individuals than no such notice4 ,if the ,secretary makes such a determination with respect to such individuals1 the order shall require the health care professionals who prescribed1 ordered1 or used the in vitro clinical test provide notification to the individuals for whom the health professionals prescribed1 ordered1 or used such test1 of the risk presented by such in vitro clinical test and of any action which may be taken by or on behalf of such individuals to eliminate or reduce such risk4 ,before issuing an order under this subsection1 the ,secretary shall consult with the persons required to give notice under the order4 7b7 ,repair1 ,replacement1 or ,refund 7#a7 ,determination after an informal hearing 7,a7 ,in general ,if1 after affording opportunity for an informal hearing1 the ,secretary determines that-- 7i7 an in vitro clinical test presents an unreasonable risk of substantial harm to the public health2 7ii7 there are reasonable grounds to believe that the in vitro clinical test was not properly developed or manufactured considering the state of the art as it existed at the time of its development2 7iii7 there are reasonable grounds to believe that the unreasonable risk was not caused by failure of a person other than a developer1 importer1 distributor1 or retailer of the in vitro clinical test to exercise due care in the installation1 maintenance1 repair1 or use of the in vitro clinical test2 and 7iv7 the notice authorized by subsection 7a7 would not by itself be sufficient to eliminate the unreasonable risk and action described in paragraph 7#b7 of this subsection is necessary to eliminate such risk1 the ,secretary may order the developer1 importer1 or any distributor of such in vitro clinical test1 or any combination of such persons1 to submit to him within a reasonable time a plan for taking one or more of the actions described in paragraph 7#b74 ,an order issued under the preceding sentence which is directed to more than one person shall specify which person may decide which action shall be taken under such plan and the person specified shall be the person who the ,secretary determines bears the principal1 ultimate financial responsibility for action taken under the plan unless the ,secretary cannot determine who bears such responsibility or the ,secretary determines that the protection of the public health requires that such decision be made by a person 7including a health professional or user of the in vitro clinical test7 other than the person the ,secretary determines bears such responsibility4 7,b7 ,secretary approval of plan ,the ,secretary shall approve a plan submitted pursuant to an order issued under subparagraph 7,a7 unless the ,secretary determines 7after affording opportunity for an informal hearing7 that the action or actions to be taken under the plan or the manner in which such action or actions are to be taken under the plan will not assure that the unreasonable risk with respect to which such order was issued will be eliminated4 ,if the ,secretary disapproves a plan1 the ,secretary shall order a revised plan to be submitted within a reasonable time4 ,if the ,secretary determines 7after affording opportunity for an informal hearing7 that the revised plan is unsatisfactory or if no revised plan or no initial plan has been submitted to the ,secretary within the prescribed time1 the ,secretary shall-- 7i7 prescribe a plan to be carried out by the person or persons to whom the order issued under subparagraph 7,a7 was directed2 or 7ii7 after affording an opportunity for an informal hearing1 by order prescribe a plan to be carried out by a person who is a developer1 importer1 distributor1 or retailer of the in vitro clinical test with respect to which the order was issued but to whom the order under subparagraph 7,a7 was not directed4 7#b7 ,actions on a plan ,the actions that may be taken under a plan submitted under an order issued under paragraph 7#a77;,a7 are as follows3 7,a7 ,to repair the in vitro clinical test so that it does not present the unreasonable risk of substantial harm with respect to which the order under paragraph 7#a77;,a7 was issued4 7,b7 ,to replace the in vitro clinical test with a like or equivalent test which is in conformity with all applicable requirements of this ,act4 7,c7 ,to refund the purchase price of the in vitro clinical test 7less a reasonable allowance for use if such in vitro clinical test has been in the possession of the user for one year or more at the time of notice ordered under subsection 7a71 or at the time the user receives actual notice of the unreasonable risk with respect to which the order was issued under paragraph 7#a77;,a71 whichever occurs first74 7#c7 ,no charge ,no charge shall be made to any person 7other than a developer1 importer1 distributor1 or retailer7 for using a remedy described in paragraph 7#b7 and provided under an order issued under paragraph 7#a71 and the person subject to the order shall reimburse each person 7other than a developer1 manufacturer1 importer1 distributor1 or retailer7 who is entitled to such a remedy for any reasonable and foreseeable expenses actually incurred by such person in using such remedy4 7c7 ,reimbursement ,an order issued under subsection 7b77#a77;,a7 with respect to an in vitro clinical test may require any person who is a developer1 importer1 distributor1 or retailer of the in vitro clinical test to reimburse any other person who is a developer1 importer1 distributor1 or retailer of such in vitro clinical test for such other person's expenses actually incurred in connection with carrying out the order if the ,secretary determines such reimbursement is required for the protection of the public health4 ,any such requirement shall not affect any rights or obligations under any contract to which the person receiving reimbursement or the person making such reimbursement is a party4 7d7 ,recall ,authority 7#a7 ,in general ,if the ,secretary finds that there is a reasonable probability that an in vitro clinical test approved under section #ehg;,b or offered under a technology certification order under section #ehg;,d would cause serious1 adverse health consequences or death1 including by the absence1 significant delay1 or discontinuation of appropriate medical treatment1 the ,secretary shall issue an order requiring the appropriate person 7including the developers1 importers1 distributors1 or retailers of the in vitro clinical test7-- 7,a7 to immediately cease distribution of such in vitro clinical test2 and 7,b7 to immediately notify health professionals and applicable in vitro clinical test user facilities of the order and to instruct such professionals and facilities to cease use of such in vitro clinical test4 7#b7 ,informal hearing ,the order issued under paragraph 7#a77;,a71 shall provide the person subject to the order with an opportunity for an informal hearing1 to be held not later than #aj calendar days after the date of the issuance of the order1 on the actions required by the order and on whether the order should be amended to require a recall of such in vitro clinical test4 ,if1 after providing an opportunity for such a hearing1 the ,secretary determines that inadequate grounds exist to support the actions required by the order1 the ,secretary shall vacate the order4 7#c7 ,amended order 7,a7 ,in general ,if1 after providing an opportunity for an informal hearing under paragraph 7#b71 the ,secretary determines that the order should be amended to include a recall of the in vitro clinical test with respect to which the order was issued1 the ,secretary shall1 except as provided in subparagraph 7,b71 amend the order to require a recall4 ,the ,secretary shall specify a timetable in which the recall will occur and shall require periodic reports describing the progress of the recall4 7,b7 ,requirements ,an amended order under subparagraph 7,a7-- 7i7 shall not include recall of the in vitro clinical test from individuals2 7ii7 shall not include recall of an in vitro clinical test from test user facilities if the ,secretary determines that the risk of recalling such in vitro clinical test from the facilities presents a greater health risk than the health risk of not recalling the in vitro clinical test from use2 and 7iii7 shall provide for notice to individuals subject to the risks associated with the use of such in vitro clinical test4 ,in providing the notice required by this clause1 the ,secretary may use the assistance of health professionals who prescribed1 ordered1 or used such an in vitro clinical test for individuals4 7#d7 ,clarification ,the remedy provided by this subsection shall be in addition to remedies provided by subsections 7a71 7b71 and 7c74 #ehg;,,aa4 ,applicability 7a7 ,in general ,an in vitro clinical test shall be subject to the requirements of this subchapter1 except as otherwise provided in this subchapter4 ,laboratory operations shall not be subject to the requirements of this subchapter4 7b7 ,interstate commerce ,any in vitro clinical test that is offered1 including by making available for clinical use in the ,united ,states is deemed to be an act that constitutes introduction into interstate commerce for purposes of enforcing the requirements of this ,act4 7c7 ,least burdensome requirements 7#a7 ,in general ,in carrying out this subchapter1 the ,secretary shall consider the least burdensome means necessary to meet the applicable standard1 and other regulatory requirements1 as determined by the ,secretary4 7#b7 ,necessary defined ,for purposes of paragraph 7#a71 the term necessary means the minimum required information that would support a determination by the ,secretary that the application meet the applicable standard or regulatory requirement1 as determined by the ,secretary4 7d7 ,service of orders ,orders of the ,secretary under this section with respect to applications under subsection 7a7 or 7b7 of section #ehg;,b or supplements under subsection 7f7 of such section shall be served-- 7#a7 in person by any officer or employee of the ,department of ,health and ,human ,services designated by the ,secretary2 or 7#b7 by mailing the order by registered mail or certified mail or electronic equivalent addressed to the applicant at the last known address in the records of the ,secretary4 7e7 ,laboratories and blood and tissue establishments 7#a7 ,relation to laboratory certification pursuant to section #cec of the ,public ,health ,service ,act ,nothing in this subchapter shall be construed to modify the authority of the ,secretary with respect to laboratories or clinical laboratories under section #cec of the ,public ,health ,service ,act4 7#b7 ,avoiding duplication ,in implementing this subchapter1 the ,secretary shall avoid issuing or enforcing regulations or guidance that are duplicative of regulations or guidance under section #cec of the ,public ,health ,service ,act such that laboratories would be subject to conflicting regulatory obligations with respect to the same activity4 7#c7 ,blood and tissue ,nothing in this subchapter shall be construed to modify the authority of the ,secretary with respect to laboratories1 establishments1 or other facilities to the extent they are engaged in the propagation1 manufacture1 or preparation1 including filling1 labeling1 packaging1 and storage1 of blood1 blood components1 human cells1 tissues1 or tissue products pursuant to any requirements under this ,act or section #cea or #cfa of the ,public ,health ,service ,act4 7f7 ,not combination product 7#a7 ,in general ,a product constituted of a device and an in vitro clinical test is not a combination product and may be regulated as a device or as a device and in vitro clinical test1 notwithstanding section #bja7ss77#c74 7#b7 ,guidance ,not later than ,october #a1 #bjbf1 the ,secretary shall issue final guidance1 after an opportunity for public comment1 addressing the considerations for regulating a product described in paragraph 7#a74 ,such guidance shall take into account the least burdensome requirements under subsection 7c74 7g7 ,practice of medicine ,nothing in this subchapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any lawfully offered in vitro clinical test for any condition or disease within a legitimate health care practitioner-patient relationship pursuant to applicable ,federal or ,state law4 7h7 ,sale1 distribution1 labeling ,nothing in this section shall be construed to limit the authority of the ,secretary to establish or enforce restrictions on the sale1 distribution1 or labeling of an in vitro clinical test under this ,act4 7i7 ,promotion of unapproved uses ,nothing in this section shall be construed to alter any prohibition on the promotion of unapproved uses of legally offered in vitro clinical tests4 7j7 ,voluntary submissions ,nothing in section #ehg;,c shall be construed to prevent a developer developing a test described in such section1 including an academic medical center laboratory described in subsection 7a77#g7 of such section1 from filing an application under section #ehg;,b or section #ehg;,d1 or from adhering to the requirements of section #ehg,k with regard to a test protocol described in section #ehg,k or for any other test or use of a test4 #ehg;,,bb4 ,judicial review 7a7 ,in general ,not later than #cj days after an order issued pursuant to section #ehg;,b or #ehg;,d1 any person adversely affected by such order may file a petition with the ,united ,states ,court of ,appeals for the ,district of ,columbia or for the circuit wherein such person resides or has a principal place of business for judicial review of such order1 in accordance with the procedure set forth in section #eag7;a74 7b7 ,application of provisions ,subsections 7a7 through 7e7 of section #eag shall apply with respect to a petition under subsection 7a7 of this section in the same manner such subsections apply to a petition under section #eag4 ,subsection 7f7 of section #eag shall apply to an order issued under section #ehg;,b or #ehg;,d4 4 #d4 ,enforcement and other provisions 7a7 ,prohibited acts ,section #cja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cca7 is amended-- 7#a7 in paragraphs 7a71 7b71 7c71 7g71 7h71 7k71 7q71 7r71 and 7y71 by inserting in vitro clinical test1 after device1 each place it appears2 7#b7 in paragraph 7g71 by inserting after misbranded the following3 1 and the development within any ,territory of any in vitro clinical test that is adulterated or misbranded2 7#c7 in paragraph 7y71 by inserting or #ehg,q after section #ebc each place it appears2 7#d7 in paragraph 7ff71 by striking or device and inserting 1 device1 or in vitro clinical test2 and 7#e7 by adding at the end1 the following3 7fff7 7#a7 ,forging1 counterfeiting1 simulating1 or falsely representing1 or without proper authority using any mark1 stamp1 tag1 label1 or other identification upon any in vitro clinical test or container1 packaging1 or labeling thereof so as to render such in vitro clinical test a counterfeit in vitro clinical test4 7#b7 ,making1 selling1 disposing of1 or keeping in possession1 control1 or custody1 or concealing any punch1 die1 plate1 stone1 or other thing designed to print1 imprint1 or reproduce the trademark1 trade name1 or other identifying mark or imprint of another or any likeness of any of the foregoing upon any in vitro clinical test or container1 packaging1 or labeling thereof so as to render such in vitro clinical test a counterfeit in vitro clinical test4 7#c7 ,the doing of any act which causes an in vitro clinical test to be a counterfeit in vitro clinical test1 or the sale or dispensing1 or the holding for sale or dispensing1 of a counterfeit in vitro clinical test4 7ggg7 7#a7 ,the introduction or delivery for introduction into interstate commerce of an in vitro clinical test in violation of section #ehg;,a7a74 7#b7 ,the making of a false1 fraudulent1 or deceptive statement about an in vitro clinical test that is exempt from premarket review under section #ehg;,c4 7#c7 ,the failure to maintain complete and accurate documentation for an exemption as required under section #ehg;,c or the failure to provide labeling required under section #ehg,l4 7#d7 ,with respect to an in vitro clinical test1 the submission of any application1 report1 or listing under this ,act that is false or misleading in any material respect4 7#e7 ,the failure to comply with a condition of approval1 or restriction required under an approved application under section #ehg;,b2 the failure to perform a risk analysis required by section #ehg;,b2 the failure to submit an annual update required under section #ehg;,j7c77#b77;,b72 or the failure to complete postmarket surveillance as required under section #ehg,x4 7#f7 ,the failure to comply with applicable requirements to submit an application or report under section #ehg;,d7e74 7#g7 ,the failure to comply with applicable mitigating measures established under section #ehg;,e or to submit1 maintain1 or make available the documentation required under section #ehg;,e7b72 or the failure to comply with applicable performance standards established under section #ehg,r4 7#h7 ,the failure to register in accordance with section #ehg;,j1 the failure to provide information required under section #ehg;,j7b71 or the failure to maintain or submit information required under section #ehg;,j7c74 7#i7 ,the failure to comply with requirements under section #ehg,m or #ehg,n1 the failure to comply with a restriction required under section #ehg,o1 or the failure to comply with labeling and advertising requirements under section #ehg,o7b74 7#aj7 ,the failure to comply with the requirements of section #ehg,q4 7#aa7 ,the failure to comply with any requirement of section #ehg,s2 the failure to furnish any notification1 information1 material1 or report required under section #ehg,s2 or the failure to comply with an order issued under section #ehg,s4 7#ab7 ,the failure to furnish information requested by the ,secretary under #ehg;,g7d77#b74 4 7b7 ,penalties ,section #cjc of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ccc7 is amended-- 7#a7 in subsection 7b77#h71 by inserting or counterfeit in vitro clinical test after counterfeit drug2 7#b7 in subsection 7c7-- 7,a7 by striking 2 or 7#e7 and inserting 2 7#e72 and 7,b7 by inserting before the period at the end the following3 2 or 7#f7 for having violated section #cja7;fff77#b7 if such person acted in good faith and had no reason to believe that use of the punch1 die1 plate1 stone1 or other thing involved would result in an in vitro clinical test being a counterfeit in vitro clinical test1 or for having violated section #cja7;fff77#c7 if the person doing the act or causing it to be done acted in good faith and had no reason to believe that the in vitro clinical test was a counterfeit in vitro clinical test2 and 7#c7 in subsection 7f77#a7-- 7,a7 in subparagraph 7,a7-- 7i7 by inserting or in vitro clinical tests after which relates to devices2 7ii7 by inserting or section #ehg,q7a77#a7 after section #gjd7;g72 and 7iii7 by inserting or in vitro clinical tests1 as applicable before the period at the end of the second sentence2 and 7,b7 in subparagraph 7,b77i71 by striking or #ebj7;f7 and inserting 1 #ebj7;f71 #ehg,k1 or #ehg,m14 7c7 ,seizure ,section #cjd of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ccd7 is amended-- 7#a7 in subsection 7a77#b7-- 7,a7 by striking 1 and 7,e7 and inserting 1 7,e72 and 7,b7 by inserting before the period at the end the following3 1 and 7,f7 ,any in vitro clinical test that is a counterfeit in vitro clinical test1 7,g7 ,any container1 packaging1 or labeling of a counterfeit in vitro clinical test1 and 7,h7 ,any punch1 die1 plate1 stone1 labeling1 container1 or other thing used or designed for use in making a counterfeit in vitro clinical test2 7#b7 in subsection 7d77#a71 by inserting in vitro clinical test1 after device12 and 7#c7 in subsection 7g7-- 7,a7 in paragraph 7#a71 by inserting 1 in vitro clinical test1 after device each place it appears2 and 7,b7 in paragraph 7#b7-- 7i7 in subparagraph 7,a71 by inserting 1 in vitro clinical test1 after device2 and 7ii7 in subparagraph 7,b71 by inserting or in vitro clinical test after device each place it appears4 7d7 ,debarment1 temporary denial of approval1 and suspension ,section #cjf of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cce;a7 is amended by adding at the end the following3 7n7 ,in vitro clinical tests2 mandatory debarment regarding third-,party inspections and reviews 7#a7 ,in general ,if the ,secretary finds that a person has been convicted of a felony for a violation of section #cja7;gg7 or #cja7;fff77#a71 the ,secretary shall debar such person from being accredited under section #ehg,q and from carrying out activities under an agreement described in section #hjc7;b74 7#b7 ,debarment period ,the ,secretary shall debar a person under paragraph 7#a7 for the following periods3 7,a7 ,the period of debarment of a person 7other than an individual7 shall not be less than #a year or more than #aj years1 but if an act leading to a subsequent debarment under such paragraph occurs within #aj years after such person has been debarred under such paragraph1 the period of debarment shall be permanent4 7,b7 ,the debarment of an individual shall be permanent4 7#c7 ,termination of debarment2 judicial review2 other matters ,subsections 7c77#c71 7d71 7e71 7i71 7j71 and 7l77#a7 apply with respect to a person 7other than an individual7 or an individual who is debarred under paragraph 7#a7 to the same extent and in the same manner as such subsections apply with respect to a person who is debarred under subsection 7a77#a71 or an individual who is debarred under subsection 7a77#b71 respectively4 4 7e7 ,expanded access to unapproved therapies and diagnostics ,section #efa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb7 is amended-- 7#a7 in subsections 7a7 through 7d7-- 7,a7 by striking or investigational devices each place it appears and inserting 1 investigational devices1 or investigational in vitro clinical tests2 and 7,b7 by striking or investigational device each place it appears 7other than the second such place in paragraph 7#c77;,a77 of subsection 7c77 and inserting 1 investigational device1 or investigational in vitro clinical test2 7#b7 in subsection 7b77#d7 by striking or #ebj7;g7 each place it appears and inserting 1 #ebj7;g71 or #ehg,s2 7#c7 in subsection 7c7-- 7,a7 by amending the subsection heading to read3 ,treatment ,investigational ,new ,drug ,applications1 ,treatment ,investigational ,device ,exemptions1 and ,treatment ,investigational in ,vitro ,clinical ,test ,exemptions42 7,b7 in paragraph 7#c77;,a71 by striking or investigational device exemption in effect under section #ebj7;g7 and inserting 1 investigational device exemption in effect under section #ebj7;g71 or investigational in vitro clinical test exemption under section #ehg,s2 7,c7 by striking or treatment investigational device exemption each place it appears and inserting 1 treatment investigational device exemption1 or treatment investigational in vitro clinical test exemption2 7,d7 in paragraph 7#e71 by striking or #ebj7;g7 and inserting 1 #ebj7;g71 or #ehg,s2 and 7,e7 in the matter following paragraph 7#g7 by striking or #ebj7;g7 each place it appears and inserting 1 #ebj7;g71 or #ehg,s2 and 7#d7 by amending subsection 7e7 to read as follows3 7e7 ,definitions ,in this section1 the terms investigational drug1 investigational device1 investigational in vitro clinical test1 treatment investigational new drug application1 treatment investigational device exemption1 and treatment investigational in vitro clinical test exemption shall have the meanings given the terms in regulations prescribed by the ,secretary4 4 7f7 ,optimizing global clinical trials ,section #efi;,a7b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h;a7b77 is amended-- 7#a7 by striking subsection each place it appears and inserting paragraph2 and 7#b7 by inserting an in vitro clinical test1 as defined in paragraph 7ss7 of such section1 before or a biological product4 7g7 ,patient participation in medical product discussion ,the heading of subsection 7a7 of section #efi;,c of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h;c7 is amended by striking drugs and devices and inserting drugs1 devices1 and in vitro clinical tests4 7h7 ,regulations and hearings ,clause 7ii7 of section #gja7;h77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cga7;h77#a77;,c77 is amended-- 7#a7 by inserting and in vitro clinical tests after devices2 and 7#b7 by moving the margin of such clause #b ems to the left4 7i7 ,records ,section #gjc of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgc7 is amended-- 7#a7 by inserting in vitro clinical tests1 after devices1 each place such term appears2 and 7#b7 by inserting in vitro clinical test1 after device1 each place such term appears4 7j7 ,factory inspection ,section #gjd of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgd7 7other than subsection 7g77 is amended-- 7#a7 by striking drugs or devices each place it appears and inserting drugs1 devices1 or in vitro clinical tests2 7#b7 in subsection 7a77#a71 in the fourth sentence1 by striking or chapter ,,ix and inserting section #ehg,s1 section #ehg,m1 section #ehg,n1 or chapter ,,ix2 7#c7 after making the amendments in paragraphs 7#a7 and 7#b71 by inserting in vitro clinical tests1 after devices1 each place it appears2 7#d7 in subsection 7a77#b77;,b7-- 7,a7 by inserting or in vitro clinical tests after prescribe or use devices2 and 7,b7 by inserting or in vitro clinical tests after process devices2 7#e7 by inserting in vitro clinical test1 after device1 each place it appears2 7#f7 in subsection 7e71 by inserting 1 or section #ehg,m1 #ehg,n1 or #ehg,s1 after section #eai or #ebj7;g72 7#g7 in subsection 7f77#c7-- 7,a7 in subparagraph 7,a71 by striking or at the end2 7,b7 in subparagraph 7,b71 by striking the period at the end and inserting 2 or2 and 7,c7 after subparagraph 7,b71 by inserting the following3 7,c7 is accredited under section #ehg,q4 2 and 7#h7 by adding at the end the following3 7i7 ,for purposes of this section1 the term establishment includes a laboratory performing an in vitro clinical test4 4 7k7 ,publicity ,section #gje7;b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cge7;b77 is amended by inserting in vitro clinical tests1 after devices14 7l7 ,presumption ,section #gji of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;a7 is amended by inserting in vitro clinical test1 after device14 7m7 ,listing and certification of color additives for foods1 drugs1 and cosmetics ,section #gba7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;e7a77 is amended-- 7#a7 in the matter preceding paragraph 7#a71 by inserting or in vitro clinical tests after or devices2 and 7#b7 in the flush text following paragraph 7#b7-- 7,a7 by inserting or an in vitro clinical test after a device2 and 7,b7 by inserting or in vitro clinical tests after devices4 7n7 ,imports and exports ,section #hja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cha7 is amended-- 7#a7 in subsection 7a7-- 7,a7 by inserting in vitro clinical tests1 after devices1 each place it appears2 and 7,b7 by inserting in the case of an in vitro clinical test1 the test does not conform to the applicable requirements of section #ehg,k1 or after requirements of section #ebj7;f71 or2 7#b7 in subsection 7d77#c7-- 7,a7 in subparagraph 7,a7-- 7i7 in the matter preceding clause 7i71 by inserting and no component of an in vitro clinical test or other article of in vitro clinical test that requires further processing1 after health-related purposes2 7ii7 in clause 7i71 by striking drug or device and inserting drug1 device1 or in vitro clinical test2 and 7iii7 in clause 7i77,i71 by inserting in vitro clinical test1 after device12 and 7,b7 in subparagraph 7,b71 by inserting in vitro clinical test1 after device12 7#c7 in subsection 7e77#a71 by inserting in vitro clinical test1 after device12 and 7#d7 in subsection 7o7-- 7,a7 by inserting or in vitro clinical test after device2 and 7,b7 by inserting 1 or under section #ehg;,j of each foreign establishment1 after section #eaj7;i7 of each establishment4 7o7 ,office of international relations ,section #hjc of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #chc7 is amended-- 7#a7 in subsection 7b7-- 7,a7 in the matter preceding paragraph 7#a71 by inserting and in vitro clinical tests after devices2 and 7,b7 in paragraph 7#a71 by striking 1 and and inserting and quality requirements established under section #ehg,k2 and2 and 7#b7 in subsection 7c7-- 7,a7 in paragraph 7#b71 by inserting in vitro clinical tests1 after devices12 and 7,b7 in paragraph 7#d71 by inserting or in vitro clinical tests after devices4 7p7 ,recognition of foreign government inspections ,section #hji7;a77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #chd;e7a77#a77 is amended by inserting 1 or of foreign establishments registered under section #ehg;,j1 after #eaj7;h74 7q7 ,food and drug administration ,section #ajjc7;b77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cic7;b77#b77 is amended-- 7#a7 in subparagraph 7,d71 by striking and at the end2 7#b7 in subparagraph 7,e71 by striking the semicolon at the end and inserting 2 and2 and 7#c7 by adding at the end the following3 7,f7 in vitro clinical tests are analytically and clinically valid2 4 7r7 ,office of women's health ,section #ajaa7;b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cii;b7b77 is amended-- 7#a7 in paragraph 7#a71 by inserting in vitro clinical tests1 after devices12 and 7#b7 in paragraph 7#d71 by inserting in vitro clinical test developers1 after device manufacturers14 7s7 ,countermeasure provisions of the public health service act ,title ,,iii of the ,public ,health ,service ,act is amended-- 7#a7 in section #cai;,f-#a7;a77#b77;,a7 7#db ,u4,s4,c4 #bdg;d-#f;a7a77#b77;,a77-- 7,a7 in the matter preceding clause 7i7-- 7i7 by striking or device and inserting device2 and 7ii7 by inserting or an in vitro clinical tests 7as that term is defined in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7ss7771 after ,act 7#ba ,u4,s4,c4 #cba7;h77712 and 7,b7 in each of clauses 7ii7 and 7iii71 by striking or device and inserting device1 or in vitro clinical test2 7#b7 in section #cai;,f-#b7;c77#a77;,b7 7#db ,u4,s4,c4 #bdg;d-#f;b7c77#a77;,b77-- 7,a7 by striking or device and inserting device2 and 7,b7 by inserting 1 or an in vitro clinical test 7as that term is defined in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7ss777 after ,act 7#ba ,u4,s4,c4 #cba7;h77712 and 7#c7 in section #cai;,f-#c7;i77#g7 7#db ,u4,s4,c4 #bdg;d-#f;d7i77#g77-- 7,a7 in the matter preceding subparagraph 7,a7-- 7i7 by striking or device and inserting device2 and 7ii7 by inserting or an in vitro clinical tests 7as that term is defined in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7ss7771 after ,act 7#ba ,u4,s4,c4 #cba7;h772 7,b7 in subparagraph 7,a7-- 7i7 by moving the margin of clause 7iii7 #b ems to the left2 and 7ii7 in clause 7iii71 by striking or device and inserting device1 or in vitro clinical test2 and 7,c7 in subparagraph 7,b7-- 7i7 in clause 7i71 by striking approved or cleared and inserting approved1 cleared1 or offered under a technology certification order2 and 7ii7 in clause 7ii71 by striking or #ebj7;g7 and inserting 1 #ebj7;g71 or #ehg,s4 #e4 ,transition 7a7 ,implementation 7#a7 ,effective date 7,a7 ,in general ,except as otherwise provided in this section1 the amendments made by this ,act shall take effect on ,october #a1 #bjbh 7in this section and in subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act1 referred to in this section as the effective date of this ,act74 7,b7 ,exceptions 7i7 ,in general ,the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary7 may take the actions described in paragraph 7#b71 and may expend such funds as the ,secretary determines necessary to ensure an orderly transition prior to the effective date of this ,act4 7ii7 ,implementation of certain provisions ,the ,secretary may implement sections #ehg;,j and #ehg,u of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by section #c7 beginning on ,october #a1 #bjbd1 and such sections may take effect not earlier than ,october #a1 #bjbh1 to the extent and for the purposes indicated in such sections4 ,in the case of a developer who1 between ,october #a1 #bjbd1 and the effective date of this ,act1 registers under such section #ehg;,j with respect to an article that is an in vitro clinical test1 such developer shall not be required to register with respect to such article under section #eaj of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj74 7#b7 ,actions ,the ,secretary-- 7,a7 shall-- 7i7 within #a year of the date of enactment of this ,act1 hold the public meetings described in section #ehg;,d7i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by section #c72 and 7ii7 within #c years of the date of enactment of this ,act1 promulgate final regulations required under the amendments made by this ,act2 and 7,b7 may take additional actions after the date of enactment that the ,secretary determines necessary to ensure an orderly transition1 including-- 7i7 establishment of mitigating measures for an in vitro clinical test or category of in vitro clinical tests1 which may not take effect until after the effective date described in paragraph 7#a77;,a72 and 7ii7 establishment of the comprehensive test information system under section #ehg,t of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c4 7#c7 ,applicability of guidance and regulations ,notwithstanding the date on which guidance or regulations are issued under paragraph 7#b7 and section #ehg,k of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 no guidance or regulations issued pursuant to the amendments made by this ,act shall be implemented or take effect until the effective date of this ,act1 except as otherwise specified in this ,act 7including the amendments made by this ,act74 7#d7 ,implementation requirements ,in the event that the ,secretary fails to promulgate the regulations required under section #ehg;,b7a77#d71 #ehg;,d7j71 or #ehg,s7b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 by the deadline described in subsection 7a77#b77;,a77ii71 the ,secretary shall1 within #ae days of such missed deadline-- 7,a7 submit a report to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives providing information related to the status of such regulations1 including-- 7i7 a rationale for missing the applicable deadline described in such subsection2 7ii7 a description of actions taken to the date of submission of the report to promulgate each such regulations2 7iii7 the expected timeline for promulgating each such regulations2 7iv7 an assessment of the impact of the delay in promulgating such regulations on developers of in vitro clinical tests1 including an economic assessment2 and 7v7 an assessment of the impact of the delay in promulgating such regulations on patients2 and 7,b7 open a public docket for purposes of soliciting public comments on the impact of the delay in promulgating such regulations4 7b7 ,application of authorities to in vitro clinical tests under review on the effective date of this act ,for any in vitro clinical test for which a submission for approval under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e71 clearance under section #eaj7k7 of such ,act 7#ba ,u4,s4,c4 #cfj7k771 authorization under section #eac7;f77#b7 of such ,act 7#ba ,u4,s4,c4 #cfj;c7f77#b771 or licensure under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 is pending on the effective date of this ,act1 including transitional in vitro clinical tests as described in subsection 7c71 the ,secretary may review and take action on such submission after the effective date of this ,act according to the statutory provision under which such submission was submitted4 7c7 ,application of authorities to transitional ,in vitro clinical tests 7#a7 ,definition ,for purposes of this section1 the term transitional in vitro clinical test means an in vitro clinical test that-- 7,a7 7i7 is first offered for clinical use during the period beginning on the date that is #de days after the date of enactment of this ,act and ending on the effective date of this ,act2 or 7ii7 is offered solely for investigational use during the period beginning on the date of enactment of this ,act and ending on the effective date of this ,act2 7,b7 is developed by a clinical laboratory certified by the ,secretary under section #cec of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc;a7 that meets the requirements for performing high-complexity testing and performed-- 7i7 in the same clinical laboratory in which the test was developed and for which a certification is still in effect under such section #cec that meets the requirements to perform tests of high complexity2 7ii7 by another laboratory for which a certificate is in effect under such section #cec that meets the requirements to perform tests of high complexity1 is within the same corporate organization1 and has common ownership by the same parent corporation as the laboratory in which the test was developed2 or 7iii7 in the case of a test that was developed by the ,centers for ,disease ,control and ,prevention or another laboratory in a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention1 by a clinical laboratory for which a certificate is in effect under such section #cec that meets the requirements to perform tests of high complexity1 and that is within a public health laboratory network coordinated or managed by the ,centers for ,disease ,control and ,prevention2 and 7,c7 when first offered1 is not approved under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 cleared under section #eaj7k7 of such ,act1 authorized under section #eac7;f77#b7 of such ,act1 subject to a humanitarian device exemption under section #ebj7m7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7m771 subject to an exemption for investigation use under section #ebj7;g7 of such ,act 7#ba ,u4,s4,c4 #cfj;j7g771 authorized under section #efd of such ,act 7#ba ,u4,s4,c4 #cfj;bbb-#c71 or licensed under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb74 7#b7 ,premarket review or technology certification ,a transitional in vitro clinical test that is not exempt from premarket review under section #ehg;,c of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 may continue to be offered1 sold1 or distributed1 as applicable1 without marketing authorization until completion of the ,secretary's review of the premarket application or technology certification application under section #ehg;,b or #ehg;,d1 as applicable1 if-- 7,a7 such in vitro clinical test is a high-risk test 7as defined in section #ehg of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c7 and the application for such test is submitted not later than #ij days after the effective date of this ,act2 or 7,b7 such in vitro clinical test is a moderate-risk test 7as defined in such section #ehg71 the developer lists the test in accordance with section #ehg;,j within #aj calendar days of the effective date of this subchapter1 and the application for such test is submitted not later than #a year after the effective date of this ,act4 7#c7 ,investigational use request ,a transitional in vitro clinical test described in paragraph 7#a77;,a77ii7 that is used in a significant risk investigation may continue to be offered for investigational use until completion of the ,secretary's review of an application under #ehg,s1 if such application is submitted not later than #ij days after the effective date of this ,act4 7#d7 ,tests approved by ,new ,york ,state ,notwithstanding paragraph 7#b71 a transitional in vitro clinical test that has been approved by the ,new ,york ,state ,department of ,health may continue to be offered1 sold1 or distributed1 as applicable1 after the effective date if-- 7,a7 starting on the effective date of this ,act1 the in vitro clinical test complies with the requirements of subchapter ,j of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act1 except for section #ehg;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 and design control provisions of section #ehg,k of such ,act2 7,b7 each test report for the test bears a statement of adequate prominence that reads as follows3 ,this in vitro clinical test was developed and first introduced prior to the effective date of the ,,valid ,act of #bjbc4 ,this test was approved by the ,new ,york ,state ,department of ,health1 but the test has not been reviewed by the ,food and ,drug ,administration42 7,c7 a premarket application under section #ehg;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 or technology certification application under section #ehg;,d of such ,act1 as added by section #c1 is submitted no later than-- 7i7 #e years after the effective date of this ,act1 if the in vitro clinical test is approved by the ,new ,york ,state ,department of ,health as a genetic testing molecular test1 a microbiology molecular test1 an oncology molecular test1 or any other type of molecular test2 or 7ii7 #b years after the effective date of this ,act1 if the in vitro clinical test is approved by the ,new ,york ,state ,department of ,health as a type of test not described in clause 7i72 and 7,d7 a test in compliance with this paragraph may continue to be offered1 sold1 or distributed1 as applicable1 until the completion of the ,secretary's review of the premarket application or technology certification application described in subparagraph 7,c74 7d7 ,conversion 7#a7 ,deemed premarket approval ,beginning on the effective date of this ,act-- 7,a7 any in vitro clinical test with a premarket approval under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e7 or a licensure under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 is deemed to be approved pursuant to an application under section #ehg;,b7a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act2 and 7,b7 any in vitro clinical test 7as so defined7 that was cleared under section #eaj7k7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj7k77 or authorized under section #eac7;f77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;c7f77#b77 is deemed to be approved pursuant to an application under section #ehg;,b7b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act4 7#b7 ,deemed investigational use exemption ,any in vitro clinical test that has an investigational device exemption in effect under section #ebj7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;j7g77 is deemed to have an investigational use exemption in effect under section #ehg,s of such ,act1 as added by this ,act1 beginning on the effective date of this ,act4 7#c7 ,deemed humanitarian device exemption ,any in vitro clinical test that has an approved humanitarian device exemption under section #ebj7m7 of such ,act is deemed to have a humanitarian test exemption under section #ehg;,a7g7 of such ,act1 as added by this ,act1 beginning on the effective date of this ,act4 7#d7 ,deemed designated breakthrough ,any in vitro clinical test that has received a breakthrough device designation under section #eae;,b7e77#a77;,d7 of such ,act 7#ba ,u4,s4,c4 #cfj;e-#c7;e77#a77;,d77 is deemed to have a breakthrough in vitro clinical test designation under section #ehg;,c of such ,act1 as added by this ,act1 beginning on the effective date of this ,act4 7#e7 ,deemed request for informal feedback ,with regard to any in vitro clinical test that is the subject of a pre-submission request described in the guidance1 ,requests for ,feedback and ,meetings for ,medical ,device ,submissions3 ,the ,q-,submission ,program1 issued by the ,food and ,drug ,administration on ,january #f1 #bjba1 such request is deemed to constitute a request for informal feedback under section #ehg;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 beginning on the effective date of this ,act4 7e7 ,previously classified devices ,notwithstanding section #ehg of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 for purposes of subchapter ,j of chapter ,v of such ,act1 as added by section #c1 the following apply3 7#a7 ,in the case of an in vitro clinical test type that has been classified by the ,secretary as a class ,i device pursuant to section #eac of such ,act 7#ba ,u4,s4,c4 #cfj;c71 such in vitro clinical test shall be low-risk1 unless the in vitro clinical test is a test described in the second sentence of section #eaj7l77#a7 of such ,act or the test is redesignated by the ,secretary pursuant to section #ehg;,f of such ,act4 7#b7 ,in the case of an in vitro clinical test type that has been classified by the ,secretary as a class ,,ii device pursuant to section #eac of such ,act 7#ba ,u4,s4,c4 #cfj;c71 such in vitro clinical test shall be moderate-risk1 unless inaccurate results from the test would be immediately life threatening or the test is redesignated by the ,secretary pursuant to section #ehg;,f of such ,act4 7#c7 ,in the case of an in vitro clinical test type that has been classified by the ,secretary as a class ,,iii device pursuant to section #eac of such ,act 7#ba ,u4,s4,c4 #cfj;c7 or an in vitro clinical test licensed pursuant to section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb71 such in vitro clinical test shall be high-risk1 unless redesignated by the ,secretary pursuant to section #ehg;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 #f4 ,emergency use authorization 7a7 ,in general ,section #efd of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#c7 is amended-- 7#a7 by inserting or developer after manufacturer1 each place such term appears2 7#b7 in subsection 7a7-- 7,a7 in paragraphs 7#a7 and 7#d77;,c71 by inserting in vitro clinical test1 before or biological product each place such term appears2 7,b7 in paragraph 7#b77;,a71 by striking or #eae and inserting #eae1 or #ehg;,b2 and 7,c7 by adding at the end the following3 7,f7 ,the terms develop and developer1 with respect to an in vitro clinical test1 have the meanings given such terms in section #ehg4 2 7#c7 in subsection 7b71 by inserting or developer after manufacturer each place such term appears2 7#d7 in subsection 7e7-- 7,a7 by inserting or developers after manufacturers each place such term appears2 7,b7 in paragraph 7#b77;,b77ii71 by inserting or develop after not manufacture2 7,c7 in paragraph 7#c7-- 7i7 in subparagraph 7,a71 by striking or #ebj7;f77#a7 and inserting 1 #ebj7;f77#a71 or #ehg,v2 7ii7 in subparagraph 7,b71 by striking and at the end2 7iii7 in subparagraph 7,c71 by striking the period and inserting or #ehg,o2 and2 and 7iv7 by adding at the end the following3 7,d7 quality requirements 7with respect to in vitro clinical tests7 under section #ehg,k4 2 and 7,d7 in paragraph 7#d7-- 7i7 in subparagraph 7,a71 by striking 2 or and inserting a semicolon2 7ii7 in subparagraph 7,b71 by striking the period and inserting 2 or2 and 7iii7 by adding at the end the following3 7,c7 with respect to in vitro clinical tests1 requirements applicable to restricted in vitro clinical tests pursuant to section #ehg,o4 2 7#e7 in subsection 7k71 by striking or #ebj7;g7 and inserting #ebj7;g71 or #ehg,s2 and 7#f7 in subsection 7m7-- 7,a7 in the subsection heading1 by striking ,laboratory tests associated with devices inserting in vitro clinical tests after devices2 and 7,b7 in paragraph 7#a7-- 7i7 by striking to a device and inserting to an in vitro clinical test2 and 7ii7 by striking such device and inserting such in vitro clinical test4 7b7 ,emergency use of medical products ,section #efd;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#c;a7 is amended-- 7#a7 in subsection 7a7-- 7,a7 in paragraph 7#b71 by inserting in vitro clinical test1 after device12 and 7,b7 by adding at the end the following3 7#c7 ,developer ,the term developer1 with respect to an in vitro clinical test1 has the meaning given such term in section #ehg4 2 7#b7 by inserting or developer after manufacturer each place it appears2 and 7#c7 in subsection 7c77#a7-- 7,a7 by inserting or quality requirements after good manufacturing practice requirements2 and 7,b7 by striking or #ebj7;f77#a7 and inserting 1 #ebj7;f77#a71 or #ehg,k4 7c7 ,products held for emergency use ,section #efd;,b7#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#c;b7#b77 is amended-- 7#a7 in subparagraph 7,a71 by striking or #eae and inserting #eae1 or #ehg;,b2 and 7#b7 in subparagraph 7,b71 by striking or #ebj and inserting #ebj1 or #ehg,s4 #g4 ,antimicrobial susceptibility tests ,section #eaa;,a of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;a-#b7 is amended-- 7#a7 in subsection 7a77#a77;,c7-- 7,a7 by striking clear under section #eaj7k71 classify under section #eac7;f77#b71 or approve under section #eae and inserting approve under section #ehg;,b1 exempt from premarket review under section #ehg;,c1 or grant a technology certification order under section #ehg;,d2 and 7,b7 by striking testing devices and inserting in vitro clinical tests2 7#b7 in subsection 7c77#e7-- 7,a7 by striking drug or device and inserting drug1 device1 or in vitro clinical test2 and 7,b7 by striking the drug or the device and inserting the drug1 device1 or in vitro clinical test2 7#c7 in subsection 7e7-- 7,a7 in the heading1 by striking testing devices and inserting ,in vitro clinical tests2 7,b7 in paragraph 7#a7-- 7i7 by striking #eaj1 #eac1 and #eae1 and inserting #ehg;,b1 and #ehg;,d2 7ii7 by striking antimicrobial susceptibility testing device and inserting antimicrobial susceptibility in vitro clinical test2 and 7iii7 by striking such device and inserting such in vitro clinical test2 and 7,c7 in paragraph 7#b7-- 7i7 in the heading1 by striking testing devices and inserting in vitro clinical tests2 7ii7 in subparagraphs 7,a7 and 7,b7 7other than clause 7iii7 of such subparagraph 7,b771 by striking device each place it appears and inserting in vitro clinical test2 7iii7 in subparagraph 7,b77iii71 by striking a device and inserting an in vitro clinical test2 and 7iv7 by amending subparagraph 7,c7 to read as follows3 7,c7 ,the antimicrobial susceptibility in vitro clinical test meets all other requirements to be approved under section #ehg;,b1 to be exempted from premarket review under section #ehg;,c1 or to be offered under a technology certification order under section #ehg;,d4 2 7#d7 in subsection 7f71 by amending paragraph 7#a7 to read as follows3 7#a7 ,the term antimicrobial susceptibility in vitro clinical test means an in vitro clinical test that utilizes susceptibility test interpretive criteria to determine and report the in vitro susceptibility of certain microorganisms to a drug 7or drugs74 2 and 7#e7 in subsection 7g77#b7-- 7,a7 by amending the matter preceding subparagraph 7,a7 to read as follows3 7#b7 with respect to approving an application under section #ehg;,b or granting a technology certification order under section #ehg;,d-- 2 and 7,b7 in subparagraph 7,a7-- 7i7 by striking device and inserting in vitro clinical test2 and 7ii7 by striking antimicrobial susceptibility testing device and inserting antimicrobial susceptibility in vitro clinical test4 #h4 ,combination products 7a7 ,in general ,section #ejc7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;g77 is amended-- 7#a7 in paragraph 7#a7-- 7,a7 in subparagraph 7,a71 by striking or biological product and inserting in vitro clinical test 7except for a product constituted of a device and an in vitro clinical test71 or biological product2 7,b7 in subparagraph 7,b71 by adding at the end the following3 ,for purposes of this ,act1 a product that constitutes a combination of a device and an in vitro clinical test is not a combination product within the meaning of this subsection and an in vitro clinical test that is offered as a separate product intended to inform the use of a drug1 biological product1 or device is not a combination product within the meaning of this subsection42 and 7,c7 in subparagraph 7,d77ii7-- 7i7 by inserting or in vitro clinical test after device2 and 7ii7 by inserting and in vitro clinical tests before shall2 7#b7 in paragraph 7#c71 by striking safety and effectiveness or substantial equivalence and inserting safety and effectiveness1 substantial equivalence1 or analytical validity and clinical validity before for the approved constituent part2 7#c7 in paragraph 7#d7-- 7,a7 in subparagraph 7,a71 by striking or #eac7;f77#b7 7submitted in accordance with paragraph 7#e77 and inserting #eac7;f77#b7 7submitted in accordance with paragraph 7#e771 #ehg;,b1 or #ehg;,d2 and 7,b7 in subparagraph 7,c71 by striking or #eae and inserting #eae1 or #ehg;,b1 or that is under an order under section #ehg;,d2 7#d7 in paragraph 7#e77;,a71 by striking or #eaj7k7 and inserting 1 #eaj7k71 #ehg;,b1 or #ehg;,d2 7#e7 in paragraph 7#g71 by striking or substantial equivalence and inserting 1 substantial equivalence1 or analytical validity and clinical validity2 7#f7 in paragraph 7#h71 by adding at the end the following3 7,i7 ,this paragraph shall not apply to a product constituted of a device and an in vitro clinical test4 2 and 7#g7 in paragraph 7#i7-- 7,a7 in subparagraph 7,c77i71 by striking or #ebj7;g7 and inserting #ebj7;g71 #ehg;,b1 or #ehg;,d2 and 7,b7 in subparagraph 7,d71 by striking or #ebj and inserting #ebj1 #ehg;,b1 or #ehg;,d4 7b7 ,classification of products ,section #efc of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#b7 is amended by adding at the end the following3 7d7 ,exemption ,this section shall not apply to a product constituted of only a device and an in vitro clinical test4 4 #i4 ,resources 7a7 ,findings ,congress finds that the fees authorized by this section will be dedicated to meeting the goals identified in the letters from the ,secretary of ,health and ,human ,services to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives1 as set forth in the ,congressional ,record4 7b7 ,establishment of user fee program 7#a7 ,development of user fees for in vitro clinical tests 7,a7 ,in general ,beginning not later than ,october #a1 #bjbe1 the ,secretary of ,health and ,human ,services 7in this section referred to as the ,secretary7 shall initiate the development of recommendations in accordance with this section to present to ,congress with respect to the goals1 and plans for meeting the goals1 for the process for the review of in vitro clinical test submissions and applications under subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act1 for the first #d fiscal years after fiscal year #bjbh and for the authorization of the ,in ,vitro ,clinical ,test ,user ,fee ,program for such fiscal years4 ,in developing such recommendations1 the ,secretary shall consult with-- 7i7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate2 7ii7 the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7iii7 scientific and academic experts2 7iv7 health care professionals2 7v7 representatives of patient and consumer advocacy groups2 and 7vi7 the regulated industry4 7,b7 ,prior public input ,prior to beginning negotiations with the regulated industry on the authorization of the ,in ,vitro ,clinical ,test ,user ,fee ,program1 as described in this section1 the ,secretary shall-- 7i7 publish a notice in the ,federal ,register requesting public input on the authorization of user fees2 7ii7 hold a public meeting at which the public may present its views on the authorization1 including specific suggestions for the recommendations submitted under subparagraph 7,e72 7iii7 provide a period of #cj days after the public meeting to obtain written comments from the public suggesting changes to the ,in ,vitro ,clinical ,test ,user ,fee ,program2 and 7iv7 publish any comments received under clause 7iii7 on the website of the ,food and ,drug ,administration4 7,c7 ,periodic consultation ,not less frequently than once every month during negotiations with the regulated industry1 the ,secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of the authorization of the ,in ,vitro ,clinical ,test ,user ,fee ,program and to solicit suggestions to be included in the recommendations transmitted to ,congress under subparagraph 7,f74 7,d7 ,updates to ,congress ,the ,secretary1 in consultation with regulated industry1 shall provide regular updates on negotiations on the reauthorization of the ,in ,vitro ,clinical ,test ,user ,fee ,program to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7,e7 ,public review of recommendations ,after negotiations with the regulated industry1 the ,secretary shall-- 7i7 present the recommendations developed under subparagraph 7,a7 to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives2 7ii7 publish such recommendations in the ,federal ,register2 7iii7 provide for a period of #cj days for the public to provide written comments on such recommendations2 7iv7 hold a meeting at which the public may present its views on such recommendations2 and 7v7 after consideration of such public views and comments1 revise such recommendations as necessary4 7,f7 ,transmittal of recommendations 7i7 ,in general ,not later than ,january #ae1 #bjbg1 the ,secretary shall transmit to ,congress the revised recommendations under subparagraph 7,a71 a summary of the views and comments received under such subparagraph1 and any changes made to the recommendations in response to such views and comments4 7ii7 ,recommendation requirements ,the recommendations transmitted under this subparagraph shall-- 7,i7 include the number of full-time equivalent employees per fiscal year that are agreed to be hired to carry out the goals included in such recommendations for each year of the #e-year period2 7,,ii7 provide that the amount of operating reserve balance in the user fee program established under this section is not more than the equivalent of #aj weeks of operating reserve2 7,,iii7 require the development of a strategic plan for any surplus within the operating reserve account above the #aj-week operating reserve within #b years of the establishment of the program2 7,,iv7 include an operating reserve adjustment such that1 if the ,secretary has an operating reserve balance in excess of #aj weeks of such operating reserves1 the ,secretary shall decrease such fee revenue and fees to provide for not more than #aj weeks of such operating reserves2 7,v7 if an adjustment is made as described in subclause 7,,iv71 provide the rationale for the amount of the decrease in fee revenue and fees shall be contained in the ,federal ,register2 and 7,,vi7 provide that the fees assessed and collected for the full-time equivalent employees at the ,center for ,devices and ,radiological ,health1 with respect to which the majority of time reporting data indicates are dedicated to the process for the review of in vitro clinical test submissions and applications under paragraph 7#e71 are not supported by the funds authorized to be collected and assessed under section #gch of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;j74 7,g7 ,publication of recommendations ,the ,secretary shall publish on the website of the ,food and ,drug ,administration the revised recommendations under subparagraph 7,f71 a summary of the recommendations1 views1 and comments received under subparagraphs 7,b71 7,c71 and 7,e71 and any changes made to the recommendations originally proposed by the ,secretary in response to such recommendations1 views1 and comments4 7,h7 ,minutes of negotiation meetings 7i7 ,public availability ,the ,secretary shall make publicly available1 on the website of the ,food and ,drug ,administration1 minutes of all negotiation meetings conducted under this subsection between the ,food and ,drug ,administration and the regulated industry not later than #cj days after such meeting4 7ii7 ,content ,the minutes described under clause 7i7 shall summarize any substantive proposal made by any party to the negotiations1 any significant controversies or differences of opinion during the negotiations1 and the resolution of any such controversy or difference of opinion4 7#b7 ,establishment of user fee program ,effective on ,october #a1 #bjbh1 provided that the ,secretary transmits the recommendations under paragraph 7#a77;,f71 the ,secretary is authorized to collect user fees relating to the review of in vitro clinical test submissions and applications submitted under subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act1 and any other activities or goals included in recommendations transmitted to ,congress pursuant to this subsection4 ,fees under such program shall be assessed and collected only if the requirements under paragraph 7#d7 are met4 7#c7 ,audit 7,a7 ,in general ,beginning #b years after first receiving a user fee applicable to submission of an in vitro clinical test application submitted under subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by this ,act1 the ,secretary shall1 on a biennial basis1 perform an audit of the costs of reviewing such applications and any other activities under such subchapter ,j included in recommendations transmitted to ,congress pursuant to this subsection4 ,such an audit shall compare the costs of reviewing such applications and other activities under such subchapter ,j to the amount of the user fee applicable to such applications and make any necessary adjustments as described in subparagraph 7,b74 7,b7 ,alteration of user fee ,the following adjustments shall apply with respect to audits performed under subparagraph 7,a73 7i7 ,if the audit performed #b years after first receiving a user fee applicable to submission of an in vitro clinical test application described under subparagraph 7,a7 indicates that the user fees collected for purposes of such subchapter ,j exceed #cc percent of the costs of reviewing such applications and carrying out activities included in recommendations transmitted to ,congress pursuant to this subsection1 the ,secretary shall alter the user fees applicable to applications submitted under such subchapter ,j such that the user fees do not exceed such percentage4 7ii7 ,if the audit performed #f years after first receiving a user fee applicable to submission of an in vitro clinical test application described under subparagraph 7,a7 indicates that the user fees collected for purposes of such subchapter ,j exceed #dj percent of the costs of reviewing such applications1 and carrying out activities included in recommendations transmitted to ,congress pursuant to this subsection1 the ,secretary shall alter the user fees applicable to applications submitted under such subchapter ,j such that the user fees do not exceed such percentage4 7iii7 ,if the audit performed #ab years after first receiving a user fee applicable to submission of an in vitro clinical test application described under subparagraph 7,a71 and any audit performed after such date1 indicates that the user fees collected for purposes of such subchapter ,j exceed #di percent of the costs of reviewing such applications1 and carrying out activities included in recommendations transmitted to ,congress pursuant to this subsection1 the ,secretary shall alter the user fees applicable to applications submitted under such subchapter ,j such that the user fees do not exceed such percentage4 7,c7 ,accounting standards ,the ,secretary shall perform an audit under subparagraph 7,a7 in conformance with the accounting principles1 standards1 and requirements prescribed by the ,comptroller ,general of the ,united ,states under section #ceaa of title #ca1 ,united ,states ,code1 to ensure the validity of any potential variability4 7,d7 ,implementation requirements ,in the event that the ,secretary fails to promulgate the regulations described in section #ehg;,b7a77#d71 #ehg;,d7j71 or #ehg,s7b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 by the applicable deadline for each such regulations as described in section #e7;a77#b77;,a77ii71 the ,secretary shall provide that the user fees applicable to applications submitted under subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 do not exceed #cj percent of the costs of reviewing such applications4 7#d7 ,conditions ,the user fee program described in this subsection shall take effect only if the ,food and ,drug ,administration issues a regulation related to the review requirements for in vitro diagnostic tests that would be subject to premarket review under section #ehg;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by section #c1 the review requirements for test categories eligible for technology certification under section #ehg;,d of such ,act1 as added by section #c1 and the parameters for the test categories that would be exempt from any review under subchapter ,j of chapter ,v of such ,act4 7#e7 ,user fee program definitions and resource requirements 7,a7 ,in general ,the term process for the review of in vitro clinical test submissions and applications means the following activities of the ,secretary with respect to the review of in vitro clinical test premarket and technology certification applications including supplements for such applications3 7i7 ,the activities necessary for the review of premarket applications1 premarket reports1 technology certification applications1 and supplements to such applications4 7ii7 ,actions related to submissions in connection with in vitro clinical test development1 the issuance of action letters that allow the marketing of in vitro clinical tests or which set forth in detail the specific deficiencies in such applications1 reports1 supplements1 or submissions and1 where appropriate1 the actions necessary to support the development of in vitro clinical tests4 7iii7 ,the inspection of manufacturing establishments and other facilities undertaken as part of the ,secretary's review of pending premarket applications1 technology certifications1 and supplements4 7iv7 ,monitoring of research conducted in connection with the review of such applications1 supplements1 and submissions4 7v7 ,review of in vitro clinical test applications subject to section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 and activities conducted in anticipation of the submission of such applications for investigational use under section #ehg,s of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by section #c74 7vi7 ,the development of guidance1 policy documents1 or regulations to improve the process for the review of premarket applications1 technology certification applications1 and supplements4 7vii7 ,the development of voluntary test methods1 consensus standards1 or mandatory performance standards in connection with the review of such applications1 supplements1 or submissions and related activities4 7viii7 ,the provision of technical assistance to in vitro clinical test developers in connection with the submission of such applications1 reports1 supplements1 or submissions4 7ix7 ,any activity undertaken in connection with the initial classification or reclassification of an in vitro clinical test in connection with any requirement for approval or eligibility for an exemption from premarket review of an in vitro clinical test4 7x7 ,any activity undertaken in connection with making a pathway determination of an in vitro clinical test1 including the identification1 establishment1 and implementation of mitigation measures4 7xi7 ,evaluation of postmarket studies required as a condition of an approval of a premarket application of an in vitro clinical test and ensuring such studies are conducted as required4 7xii7 ,any activity undertaken in connection with ensuring in vitro clinical tests offered under an exemption from premarket review pursuant to section #ehg;,c or #ehg;,g meet the criteria for such exemption and the applicable standard4 7xiii7 ,compiling1 developing1 and reviewing information on in vitro clinical tests necessary to identify issues with the ability of in vitro clinical tests to meet the applicable standard1 as applicable4 7,b7 ,resource requirements ,fees collected and assessed under this section shall be used for the process for the review of in vitro clinical test applications1 as described in subparagraph 7,a71 and shall-- 7i7 be subject to the limitation under section #gch7;g77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;j7g77#c771 in the same manner that fees collected and assessed under section #gcg7i77;,c7 of such ,act 7#ba ,u4,s4,c4 #cgi;i7#i77;,c77 are subject to such limitation2 7ii7 include travel expenses for officers and employees of the ,food and ,drug ,administration only if the ,secretary determines that such travel is directly related to an activity described in subparagraph 7,a72 and 7iii7 not be allocated to purposes described under section #gbb7;a7 of the ,consolidated ,appropriations ,act1 #bjah 7,public ,law #aae-ada74 7c7 ,reports 7#a7 ,performance report 7,a7 ,in general 7i7 ,general requirements ,beginning with fiscal year #bjbh1 for each fiscal year for which fees are collected under this section1 the ,secretary shall prepare and submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives annual reports concerning the progress of the ,food and ,drug ,administration in achieving the goals identified in the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f7 during such fiscal year and the future plans of the ,food and ,drug ,administration for meeting the goals4 7ii7 ,additional information ,beginning with fiscal year #bjbh1 the annual report under this subparagraph shall include the progress of the ,food and ,drug ,administration in achieving the goals1 and future plans for meeting the goals1 including-- 7,i7 the number of premarket applications filed under section #ehg;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act during the applicable fiscal year2 7,,ii7 the number of technology certification applications submitted under section #ehg;,d of the ,federal ,food1 ,drug1 and ,cosmetic ,act during the applicable fiscal year for each review division2 7,,iii7 the number of breakthrough designations under section #ehg;,i of the ,federal ,food1 ,drug1 and ,cosmetic ,act during the applicable fiscal year2 and 7,,iv7 the number of information requests requested by the ,secretary pursuant to section #ehg;,g7d7 of such ,act4 7iii7 ,real-time reporting 7,i7 ,in general ,not later than #cj calendar days after the end of the second quarter of fiscal year #bjbh1 and not later than #cj calendar days after the end of each quarter of each fiscal year thereafter1 the ,secretary shall post the data described in subclause 7,,ii7 on the website of the ,food and ,drug ,administration for such quarter and on a cumulative basis for such fiscal year1 and may remove duplicative data from the annual report under this subparagraph4 7,,ii7 ,data ,the ,secretary shall post the following data in accordance with subclause 7,i73 7aa7 ,the number and titles of draft and final regulations on topics related to the process for the review of in vitro clinical test submissions and applications1 and whether such regulations were required by statute or pursuant to the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7bb7 ,the number and titles of draft and final guidance on topics related to the process for the review of in vitro clinical test submissions and applications1 and whether such guidances were issued as required by statute or pursuant to the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7cc7 ,the number and titles of public meetings held on topics related to the process for the review of in vitro clinical tests1 and if such meetings were required by statute or pursuant to the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7iv7 ,rationale for ,,ivct user fee program changes ,beginning with fiscal year #bjbh1 the ,secretary shall include in the annual performance report under paragraph 7#a7-- 7,i7 data1 analysis1 and discussion of the changes in the number of individuals hired as agreed upon in the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f7 and the number of remaining vacancies1 the number of full-time equivalents funded by fees collected pursuant to this section1 and the number of full-time equivalents funded by budget authority at the ,food and ,drug ,administration by each division within the ,center for ,devices and ,radiological ,health1 the ,center for ,biologics ,evaluation and ,research1 the ,office of ,regulatory ,affairs1 and the ,office of the ,commissioner2 7,,ii7 data1 analysis1 and discussion of the changes in the fee revenue amounts and costs for the process for the review of in vitro clinical test submissions and applications1 including identifying-- 7aa7 drivers of such changes2 and 7bb7 changes in the average total cost per full-time equivalent in the in vitro clinical test review program2 7,,iii7 for each of the ,center for ,devices and ,radiological ,health1 the ,center for ,biologics ,evaluation and ,research1 the ,office of ,regulatory ,affairs1 and the ,office of the ,commissioner1 the number of employees for whom time reporting is required and the number of employees for whom time reporting is not required2 and 7,,iv7 data1 analysis1 and discussion of the changes in the average full-time equivalent hours required to complete review of each type of in vitro clinical test application4 7v7 ,analysis ,for each fiscal year1 the ,secretary shall include in the report under clause 7i7 an analysis of the following3 7,i7 ,the difference between the aggregate number of premarket applications filed under section #ehg;,b or section #ehg;,d of the ,federal ,food1 ,drug1 and ,cosmetic ,act and the aggregate number of major deficiency letters1 not approvable letters1 and denials for such applications issued by the agency1 accounting for-- 7aa7 the number of applications filed under each of sections #ehg;,b and #ehg;,d of the ,federal ,food1 ,drug1 and ,cosmetic ,act during one fiscal year for which a decision is not scheduled to be made until the following fiscal year2 and 7bb7 the aggregate number of applications under each of sections #ehg;,b and #ehg;,d of the ,federal ,food1 ,drug1 and ,cosmetic ,act for each fiscal year that did not meet the goals as identified by the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7,,ii7 ,relevant data to determine whether the ,center for ,devices and ,radiological ,health has met performance enhancement goals identified by the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7,,iii7 ,the most common causes and trends for external or other circumstances affecting the ability of the ,food and ,drug ,administration to meet review time and performance enhancement goals identified by the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f74 7,b7 ,publication ,with regard to information to be reported by the ,food and ,drug ,administration to industry on a quarterly and annual basis pursuant to recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f71 the ,secretary shall make such information publicly available on the website of the ,food and ,drug ,administration not later than #fj days after the end of each quarter or #abj days after the end of each fiscal year1 respectively1 to which such information applies4 7,c7 ,updates ,the ,secretary shall include in each report under subparagraph 7,a7 information on all previous cohorts for which the ,secretary has not given a complete response on all in vitro clinical test premarket applications and technology certification orders and supplements1 premarket1 and technology certification notifications in the cohort4 7#b7 ,corrective action report ,beginning with fiscal year #bjbi1 for each fiscal year for which fees are collected under this section1 the ,secretary shall prepare and submit a corrective action report to the ,committee on ,health1 ,education1 ,labor1 and ,pensions and the ,committee on ,appropriations of the ,senate and the ,committee on ,energy and ,commerce and the ,committee on ,appropriations of the ,house of ,representatives4 ,the report shall include the following information1 as applicable3 7,a7 ,goals met ,for each fiscal year1 if the ,secretary determines1 based on the analysis under paragraph 7#a77;,a77v71 that each of the goals identified by the recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f7 for the applicable fiscal year have been met1 the corrective action report shall include recommendations on ways in which the ,secretary can improve and streamline the in vitro clinical test premarket application and technology certification review process4 7,b7 ,goals missed ,for each of the goals identified by the letters described in recommendations transmitted to ,congress by the ,secretary pursuant to subsection 7b77#a77;,f7 for the applicable fiscal year that the ,secretary determines to not have been met1 the corrective action report shall include-- 7i7 a justification for such determination2 7ii7 a description of the types of circumstances1 in the aggregate1 under which applications or reports submitted under sections #ehg;,b and #ehg;,d of the ,federal ,food1 ,drug1 and ,cosmetic ,act missed the review goal times but were approved during the first cycle review1 as applicable2 7iii7 a summary and any trends with regard to the circumstances for which a review goal was missed2 and 7iv7 the performance enhancement goals that were not achieved during the previous fiscal year and a description of efforts the ,food and ,drug ,administration has put in place for the fiscal year in which the report is submitted to improve the ability of such agency to meet each such goal for the such fiscal year4 7#c7 ,fiscal report 7,a7 ,in general ,for fiscal years #bjbi and annually thereafter1 not later than #abj days after the end of each fiscal year during which fees are collected under this section1 the ,secretary shall prepare and submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives1 a report on the implementation of the authority for such fees during such fiscal year and the use1 by the ,food and ,drug ,administration1 of the fees collected during such fiscal year for which the report is made4 7,b7 ,contents ,such report shall include expenditures delineated by budget authority and user fee dollars related to administrative expenses and information technology infrastructure contracts and expenditures4 7,c7 ,operating reserve ,such report shall provide the amount of operating reserves of carryover user fees available each year1 and any planned allocations or obligations of such balance of operating reserves for the program4 7#d7 ,public availability ,the ,secretary shall make the reports required under paragraphs 7#a7 through 7#c7 available to the public on the website of the ,food and ,drug ,administration4 7#e7 ,enhanced communication 7,a7 ,communications with ,congress ,each fiscal year1 as applicable and requested1 representatives from the ,centers with expertise in the review of in vitro clinical tests shall meet with representatives from the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives to report on the contents described in the reports under this section4 7,b7 ,participation in congressional hearing ,each fiscal year1 as applicable and requested1 representatives from the ,food and ,drug ,administration shall participate in a public hearing before the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives1 to report on the contents described in the reports under this section4 ,such hearing shall occur not later than #abj days after the end of each fiscal year for which fees are collected under this section4 #aj4 ,authorization of appropriations ,for purposes of funding implementation of this ,act 7including the amendments made by this ,act71 including undertaking activities for the development of regulations and guidances1 hiring of necessary staff1 and the development of technology systems to implement this ,act 7including the amendments made by this ,act7 in a timely1 effective1 and efficient manner1 there is authorized to be appropriated #dhj1jjj1jjj1 to remain available through the end of fiscal year #bjbh4 #aa4 ,guidance on ,diagnostic ,innovation ,not later than ,january #a1 #bjbe1 the ,secretary shall issue guidance to assist developers of in vitro clinical tests intended to identify or diagnose rare diseases and in vitro clinical tests intended to address an unmet medical need4 ,such guidance shall include considerations for addressing barriers to developing sufficient data to demonstrate clinical validity for such tests1 such as challenges associated with data collection and obstacles to the timely generation of evidence4 #ab4 ,,gao report on unique considerations ,not later than #c years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report-- 7#a7 evaluating the unique considerations for hospital-based laboratories1 laboratories serving academic medical centers1 and other health care practitioners1 as appropriate1 in implementing this ,act1 including the amendments made by this ,act2 and 7#b7 including recommendations based on the findings of the report4 #ac4 ,assessments ,section #ahcd;,a7g7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciem-#a7;g77 is amended by adding at the end the following new paragraph3 7#c7 ,determinations with respect to in vitro clinical tests ,on or after the date that is #de days after the date of enactment of the ,,valid ,act of #bjbc1 for purposes of determining whether an in vitro clinical test 7as defined in section #bja7ss7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act7 is reasonable and necessary for the diagnosis or treatment of illness or injury 7under section #ahfb7;a77#a77;,a771 any assessment of the analytical validity or clinical validity of such test shall apply the definitions given such terms in subchapter ,j of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 4 #ad4 ,severability ,if any provision of this ,act is declared unconstitutional1 or the applicability of this ,act to any person or circumstance is held invalid1 the constitutionality of the remainder of this ,act and the applicability thereof to other persons and circumstances shall not be affected4